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ABSTRACT 
Parkinson's disease (PD) is a debilitating neurodegenerative movement 
disorder. It is characterized by the progressive loss of specific neurons in the 
brain, the dopaminergic neurons of the substantia nigra pars compacta of the 
midbrain. Increasing age is considered to be one of the strongest risk factors 
for PD. The symptoms of PD profoundly affect the quality of life of patients 
and their family members. 
The aetiology of PD is not completely understood. Several genes harbour 
mutations that contribute to developing PD. Little, however is known about 
the genetics of PD in the sub-Saharan African patients. African populations 
have greatly admixed ancestry with the greatest genetic diversity in the world. 
This diversity has important ramifications for genetic research. 
Sporadic or idiopathic cases of PD are the most recurrent in South Africa and 
Nigeria. Familial PD cases are relatively rare.  It is also possible that genetic 
mutations interact with environmental factors to cause PD onset and its 
progression.   
Several genes including PRKN, PINK1, PARK7, ATP13A2, SNCA, LRRK2, 
VPS35, EIF4G1, CHCHD2 and LRP10 have been associated with PD. The 
mutations in these genes provide new opportunities to understand the disease 
by suggesting biological pathways that could be involved in PD pathogenesis. 
The PD genes have been predominantly identified and studied in European, 
North American, North African and Asian populations. It is possible that the 
genetic information obtained from other populations may not be transferable 
to the sub-Saharan African populations. 
The present study focused on identifying pathogenic mutations in Black 
South African and Nigerian PD patients. This study is the first collaborative 
genetics study on PD between South Africa and Nigeria. This study 
hypothesized that novel disease-causing genes will be identified in Black 
South African and Nigerian PD patients. 
A total of 33 Black South African and 42 Nigerian PD patients were recruited 
and screened for genetic defects using various methods. The mean age at 
onset of PD in the South Africans and Nigerians was 48±8 and 65±10 years, 
respectively. Two South African patients had a family history of PD. 
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 This study evaluated the presence of exonic rearrangements such as 
multiplications or deletions of exons in the PD patients. A total of 42 Nigerian 
and 15 South African PD patients were studied for exonic rearrangement 
using a commercially available assay kit.  
The results revealed three Nigerian patients with exonic rearrangements: (1) 
Heterozygous deletion in PARK7 exon 1; (2) Heterozygous duplications in 
PINK1 exon 5 and PRKN exon 1; and (3) Two heterozygous duplications in 
PRKN exon 1 and 2 gene. 
The study also implemented targeted next-generation sequencing (NGS) to 
screen the 751 genes known to harbour pathogenic mutations in patients with 
neurological diseases using the AmpliSeqTM  Neurological Disease panel and 
the Ion Torrent sequencing platform. NGS is fast, scalable, reliable and could 
reveal putative pathogenic variants. 
Bcftools was used for assessing the data quality and to filter the variants. 
Sequence variants with mapping quality score > 100 and a minimum read 
depth > 40 were selected for follow-up. We used annovar utility software for 
the annotation. We removed variants with minor allele frequency > 0.01 in 
any of the frequency databases. We also assessed how often each variant was 
found in common among samples. Variants predicted to be deleterious were 
selected based on the prediction scores by MetaLR and MetaSVM as these 
two showed the best performance on curated data sets. We generated radar 
plots of these selected variants predicted to be deleterious to illustrate samples 
overall pathogenicity prediction. 
All 47 samples passed the quality control after sequencing. In summary, a 
total of 14,655 rare variants with a minor allele frequency of ≤0.01 were 
identified. Of which, 7,934 were intronic and 5,695 exonic. They included, 
198 UTR5, 341 UTR3, 32 frameshift, 3,175 synonymous and 2,448 missense 
variants.  
Altogether, 14,057 were single and 598 multiple variants comprising of 261 
insertions, 600 deletions and 13,794 substitutions. Altogether 60 variants 
linked to 44 genes were considered pathogenic based on MetaLR and 
MetaSVM scores. Altogether 41 of these genes were not previously 
associated with PD.  
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Seven novel mutations were identified in three known PD genes ATP13A2 
(S960R), PRKN (P153R and D245E) and PINK1 (S73L, S228F, S284Y and 
P305A). Finally, four novel variants were selected for Sanger sequencing, 
which confirmed the NGS results.  
In conclusion, the implementation of tNGS and the advanced bioinformatics 
tools led to identification of novel pathogenic mutations in the Black South 
African and Nigerian PD patients.  
Mutations were found in known PD genes and in genes not previously known 
to harbour mutations in PD patients. Further studies are required to ascertain 
the biological functions of these mutations. The results could also advance 
the discovery and the development of improved treatment approaches and 
drug interventions for PD. 
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OPSOMMING 
Parkinson se siekte (PS) is ‘n aftakelende neurodegeneratiewe 
bewegingskondisie. Dit word gekenmerk deur die  geleidelike afsterwing van 
spesifieke neurone in die brein, naamlik die dopaminergiese neurone van die 
substantia nigra pars compacta in die midbrein. Toenemende ouderdom 
word  beskou  as die belangrikste risikofactor vir PS. Die simptome van PS 
het ‘n diepgaande effek op die lewenskwaliteit van pasiënte en hul 
familielede. 
Die oorsaak van PS word nie ten volle vestaan nie. Verskeie gene bevat 
mutasies wat tot die ontwikkeling van PS kan bydra. Nietemin is daar min 
bekend oor die genetika van PS in Afrika suid van die Sahara.  Afrika-n 
bevolkingsgroepe het n komplekse herkoms en is van die mees genetiese 
uiteenlopende groepe in die wêreld. Hierdie diversiteit het belangrike 
implikasies vir genetika navorsing. 
Sporadiese oftenwel idiopatiese gevalle van PS word meestal in Suid Afrika 
en Nigerië gevind. Familiële PS gevalle is relatief skaars. Dit is ook moontlik 
dat daar interaksies tussen genetiese mutaties en omgewingsfaktore is wat 
bydra tot die ontstaan en vordering van PS.    
Verskeie gene, insluitend PRKN, PINK1, PARK7, ATP13A2, SNCA, LRRK2, 
VPS35, EIF4G1, CHCHD2 en LRP10 is geassosieer met PS. Die mutasies in 
hierdie gene bied nuwe geleenthede om die siekte beter te verstaan, deur 
relevante biologiese roetes uit te lig wat kan bydra tot PS. Die PS gene is 
hoofsaaklik geïdentifiseer en bestudeer in Europeese, Noord-Amerikaanse, 
Noord-Afrika en Asiatiese populasies. Dit is moontlik dat die genetiese 
inligting wat verkry is van hierdie populasies nie  van toepassing in  
bevolkingsgroepe van Afrika suid van die Sahara nie.  
Die huidige studie het beoog om patogeniese mutaties in Swart Suid-
Afrikaanse en Nigeriese  PS-pasiënte te identifiseer. Hierdie studie is die 
eerste gesamentlike PS-genetika studie tussen Suid-Afrika en Nigerië. Daar 
word voorgestel dat nuwe siekte-veroorsakende gene in hierdie pasiënte 
gevind sal word.  
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‘n Somtotaal van 33 Swart Suid-Afrikaanse en 42 Nigeriese PS pasiënte is 
bestudeer vir genetiese defekte deur middel van verskeie metodes. Die 
gemiddelde aanvangsouderdom van PS was onderskydelik 48±8 en 65±10 
jaar in die Suid-Afrikaners en Nigeriërs. Twee Suid-Afrikaanse pasiënte het 
‘n familie geskiedenis van PS. Hierdie studie het eers gesoek vir die 
teenwoordigheid van eksoniese herrangskikkings soos multiplikasies of 
delesies in PS-gene. A total van 42 Nigeriese en 12 Suid-Afrikaanse PS 
pasiënte is bestudeer vir eksoniese herrangskikkings met behulp van ‘n 
kommmersiële toetsstel. Die resultate dui op drie Nigeriese pasiënte met 
eksoniese herrangskikkings: (1) heterosigotiese delesie in PARK7 ekson 1; 
(2) heterosigotiese duplikasies in PINK1 ekson 5 en PRKN ekson 1; en (3) 
twee heterosigotiese duplikasies in PRKN eksone 1 en 2.  
Die studie het ook ‘n geteikende volgende-generasie volgordebepaling 
(VGV) benadering gebruik om te soek vir mutasies in 751 gene wat voorheen 
geassosieer is met neurologiese siektes, deur middel van die AmpliSeq™ 
Neurological Disease Panel as ook die Ion Torrent volgordebepalings-
platform. VGV is vinnig, opskaalbaar en betroubaar, en kan patogeniese 
variante ontdek. Vir die VGV deel van die studie is daar DNS monsters van 
33 Swart Suid-Afrikaanse en 14 Nigeriëse PS pasiënte gebruik.  
Bcftools is gebruik om die gehalte van die data te asseseer en om deur die 
variante te sif. Volgordevariante wat ‘n karteringsgehalte-telling > 100 en ‘n 
minimum leesdiepte > 40 het was geselekteer vir verdere studie. Ons het 
annovar sagteware gebruik vir die annotasie. Ons het variante met ‘n allel-
frekwensie > 0.01 in enige van die databasisse bewyder. Ons het gekyk na 
hoe gereeld elke variant in meer as een DNS monster voorgekom het. 
Patogeniese variante is gekies op grond van MetaLR en MetaSVM tellings, 
aangesien hierdie twee die beste gedoen het op saamgestelde datastelle. Ons 
het radarplotte genereer van die geselekteerde patogeniese variante om die 
algehele patogenesiteit-voorspelling uit te beeld.    
Al 47 DNS monsters wat gebruik is vir VGV het voldoen aan gehaltebeheer 
toetse na volgordebepaling. Ter opsomming, 14,655 rare variante is 
geïdentifiseer met n alleel-frekwensie van ≤0.01. Dit sluit in 32 
raamverskuiwing-, 3,175 sinonieme en 2,448 nie-sinonieme variante. 
Altesaam was daar 14,057 enkelbasis variante en 598 multibasis variante, 
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insluitende 261 insersies, 600 delesies en 13,794 substitusies. ‘n Totaal van 
60 variante in 44 verskillende gene was as patogenies aanskou na aanleiding 
van MetaLR en MetaSVM tellings. Sewe nuwe mutasies is geïdenfiseer in 
drie bekende PS gene, AP13A2 (S960R), PRKN (P153R en D245E) en PINK1 
(S73L, S228F, S284Y en P305A). Vier van die nuwe gene was gekies vir 
Sanger volgordebepaling, wat die VGV resultate bevestig het.  
Ter slotte, the soektog vir genetiese herrangskikkings en die implementering 
van VGV tesame met gevorderde bioinformatika hulpmiddels het gelei tot die 
identifisering van nuwe patogeniese mutasies in Swart Suid-Afrikaanse en 
Nigeriese PS pasiënte. 
Mutasies is gevind in beide bekende PS gene en in gene waarin PS mutasies 
nog nie voorheen beskryf is. Verdere studies word benodig om die biologiese 
funksies van hierdie mutasies vas te stel. Die resultate kan ook bydra tot die 
ontdekking en ontwikkeling van beter behandeling-benaderinge en 
medikasies vir PS.   
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OUTLINE OF THE DISSERTATION 
  
This dissertation provides information on a study that screened for pathogenic 
mutations in Nigerian and South African Parkinson’s disease patients over a 
three-year period. This dissertation is divided into five chapters: 
CHAPTER ONE lays the background to this study. Therein, Parkinson’s 
disease (PD) and its pathobiology are described. Current global prevalences 
of PD and the future projection of PD prevelance in sub-Saharan Africa (SSA) 
are elucidated. The genetic mutations identified in PD genes in the literature 
are listed, as well the mechanisms of pathogenicity of there mutations. The 
bioinformatics approach used in this study, to characterize mutations is 
explained. The principles of next-generation sequencing and other 
experimental procedures used in this study are explained. Chapter one further 
gives insight for the study rationale and objectives, by linking the facts that 
PD genetics is understudied in Black South African and Nigerian populations. 
CHAPTER TWO was submitted as a review article for publication. It covers 
the topic of PD in Nigeria. The study provides a comprehensive and critical 
review on all published studies on PD in Nigeria in a concise manner. It 
highlights the need for increased awareness among medical professionals in 
Africa about PD. It also highlights the need for genetic studies on PD in 
Nigeria. 
CHAPTER THREE is a study on copy number variation (CNV) detection 
in PD genes in 57 Black South African and Nigerian PD patients. Four 
putative CNVs were identified in three PD genes (PARK7, PINK1 and PRKN) 
in three patients. Probable mechanisms of these CNVs identified in PD are 
highlighted. Recommendations are made for further studies as there were 
several limitations in the current study. 
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CHAPTER FOUR was submitted as a research article for publication. It 
describes the implementation of next-generation sequencing to screen for 
pathogenic mutations in 47 Black South African and Nigerian PD patients 
using a commercially available panel of 751 genes associated with various 
neurological diseases. A total of 60 novel putative pathogenic mutations were 
identified. Known mutations in PD were not identified, suggesting that, 
unique mutations could be responsible for PD in SSA patients. 
Recommendations are made for further studies as there were several 
limitations in the current study. 
CHAPTER FIVE is the general discussion and final conclusions. Therein, 
the findings in the study are related with the current knowledge of PD 
genetics. Furthermore, the challenges and benefits of collaborations with 
South Africa and Nigeria to study PD genetics are emphasized.
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            CHAPTER ONE 
 
 
                               INTRODUCTION 
 
1.1     History of Parkinson’s disease 
Parkinson's disease (PD) is one of the neurological diseases that has no cure. It 
is a neurodegenerative condition that has been categorized under movement 
disorders. Studies have revealed that there was evidence of PD as far back as 
5000 years ago (Manyam, 1990). In the ancient Indian medicinal practices, they 
referred to it as “Kampavata” (Manyam, 1990). There was, however, no 
documented report that people were being cured of the ailment. A physician 
Galen described the ailment based on his observations as "shaking palsy" in AD 
175. It was not until 1817 that a detailed medical essay was published on the 
"shaking palsy" by a British physician James Parkinson, who originally 
described PD by carefully outlining the major motor signs (bradykinesia, rigidity 
and tremor) of the disease that are still today considered the hallmarks of PD 
(Lill and Klein, 2017). 
In his original famous essay on the shaking palsy, James Parkinson described the 
patients with the disease whom he had examined or observed on the street for 
his report (Parkinson, 1817 and Parkinson, 2002). He suggested that trauma and 
possibly inflammation as potential causes of PD.  
The interest to study the causes of PD continued with Paul Marie (1849-1933), 
a French anatomist, physiologist, sculptor and anatomical artist who was an 
assistant to Jean-Martin Charcot, and who in 1880 described the anatomical 
changes in PD patients (Figure 1.1). Dr. Leroux, one of Charcot scholars, also 
concluded that hereditary factors could be the cause of paralysis agitans (Lill and 
Klein, 2017). 
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1.2      Signs and Symptoms of PD 
1.2.1         Motor symptoms 
Motor symptoms are the most obvious first signs of PD and the symptoms are 
progressive. Because PD is neurodegenerative, patients usually go from being 
strong, independent and healthy individuals to being progressively, and 
persistently unable to move efficiently (Figure 1.2). The PD symptoms include:  
 Tremors:  resting tremor spreads throughout the whole arm, and stiff limbs,    
sometimes occurring in the lips, feet or tongue.   
 Bradykinesia:  Slow movements that progress to muscle stiffness. 
 Akinesia:  Muscle stiffness produced by muscle rigidity affecting mostly the 
legs and neck. When it affects the muscles of the face, it forms like a mask. 
 Leg discomfort: Burning sensations and cramp in the legs. 
 Balance: A progressive loss of coordination and posture balance, leading to 
risk of falls. 
 
 
 
 
Figure 1.1: Anatomical depiction of PD by Jean-Martin Charcot.  
Permission to use from BMJ Publishing Group Ltd. 
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1.2.2   Non-motors symptoms 
In addition to the predominant motor symptoms, Non-motor symptoms in PD 
also affect the brain and the peripheral nervous system. In about two decades 
before onset of PD motor symptoms, non-motor symptoms like constipation, 
sleep disorder and hyposmia (loss of smell sense) precede the onset of the main 
motor symptoms. The condition is described as prodromal PD. Some patients 
experience anxiety, anger, apathy, depression, hallucination and delusion as 
early signs of PD, or these symptoms occur throughout the course of the disease. 
These symptoms may be related to Braak’s theory of PD progression, which 
suggests that neurodegeneration starts in the enteric nervous system of the gut 
and in the medulla and olfactory bulb before reaching through dopaminergic 
(DA) neurons of the substantia nigra (Braak et al., 2003). This theory is 
supported by post-mortem studies that showed classical neurodegenerations in 
PD, related to non-motor symptoms and were thought to precede classical motor 
symptoms by several years (Hayes et al., 2010; Lees, 2010; Tibar et al., 2018).         
 
There are other non-motor symptoms evident in PD but they may present 
differently in patients. Low blood pressure, which can result in light-headedness 
and fainting. Temperature sensitivity increases in PD, perception of temperature 
can be affected, and may result in hot flashes and excessive sweating. Other signs 
described among PD patients are idiopathic rapid eye movement and sleep 
behaviour disorder (Chaudhuri et al., 2006, 2011, Tibar et al., 2018). 
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Figure 1.2: Typical motor signs of PD.  
From Monahan FD, Neighbors M: Phipps’ medical-surgical 
nursing: health and illness perspectives, edition 8, 
Philadelphia, 2007, Saunders, p 1446.) Permission from 
Saunders Publishing. 
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1.3      Diagnosis of PD 
 
1.3.1 Clinical diagnosis 
The diagnosis of PD is mainly clinical by using criteria of the UK PD society 
Brain Bank (UKPDSBBC) (Hughes et al., 1992). The patient must display 
bradykinesia plus any two of the three other cardinal symptoms (tremor, rigidity, 
postural instatbility). Often, PD patients do not have full set of symptoms 
described on the UKPDSBBC criteria, hence, taken into account these clinical 
manifestations will make the diagnostic process straightforward. The 
UKPDSBBC are reported to be accurate in over 90% of diagnosed cases 
clinically suspected to have PD (Dotchin et al., 2007).  The Hoehn and Yahr 
scale can be used to classify the severity of PD (Goetz et al., 2004). It has been 
shown to improve diagnotic accuracy in patients (Goetz et al., 2004). 
 
1.3.2 Neuroimaging examination 
The emergence of neuroimaging techniques has made it possible to use a single-
photon emission computed tomography (SPECT) along with a radio-labelled 
compound to study dopamine levels in the brain. The compound will bind to 
dopamine receptors and can be viewed using SPECT. This method allows the 
measurement of the amount of dopamine releasing neurons and can be compared 
with healthy individuals (Figure 1.6). Neuroimaging is a supportive technique 
that helps the clinicians to accurately diagnose PD.  
 
Figure 1.3: SPECT image showing dopamine levels in a healthy 
brain verus in a PD brain. Taken from  (Son et al., 2016), licenced by 
creative commons https://www.nature.com/articles/srep38070#rightslink 
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1.4   Aetiology of PD 
  
The neuropathological hallmarks of PD can be explained by the progressive loss 
of specific neurons in the brain, especially the dopaminergic neurons of the 
substantia nigra pars compacta  of the midbrain (Beal, 1992; Biskup et al., 2006; 
Chu and Kordower, 2007a; Levy et al., 2005 and (Li et al., 2014; Maiti et al., 
2017).  
 
Dopaminergic neurons are the main source of dopamine (DA) neurotransmitter 
in the central nervous system (CNS), with a prominent role in voluntary 
movement and behavioral processes (Shen and Cookson, 2004).  
 
 
 
Figure 1.4: Location of the substantia nigra and comparison between PD 
affected dopaminergic neurons and normal neurons during exocytosis.  
The figure shows the difference between the dopamine molecules released at the 
synaptic cleft during exocytosis in PD patients and healthy individuals. (A) The 
dopamine outflow is low at the synaptic cleft in the PD patients which is the 
hallmark of the disease. (B) Compared to healthy controls (left), nigrostriatal 
degeneration results in the depletion and ultimate loss of the neurotransmitter 
dopamine on synaptic terminals of striatal neurons (right). (C) The resulting 
motor symptoms, However, PD patients can experience non-motors symptoms 
these include olfactory dysfunction, sleep disturbances and depression. Taken 
from Bridi and Hirth 2018 licenced by Creative Commons. 
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Studies on DA are still relatively new to the field of monoamine transmitters in 
mammalian brain. Until the mid-1950s DA was considered as merely a precursor 
in the biosynthesis of the catecholamines. Later, physiologic and pharmacologic 
studies explored DA’s roles in the brain, and found that they regulate movements 
via two main pathways. Namely, the direct pathway that promotes voluntary 
movement and the indirect pathway that inhibits movement.  DA signalling from 
the substantia nigra is important for both pathways  (Luo and Huang, 2016; 
Purves et al., 2001).  
 
The discovery of profound depletion of DA in the striatum of PD patients was 
accompanied by poor motor control.  A normal movement occurs in non-PD 
individuals while a movement disorder is seen in PD patients due to the low 
levels of DA at the synapses (Figure 1.4).  Dopaminergic cell loss in excess of 
50% usually leads to the onset of PD symptoms (Cheng et al., 2010).  
 
Another important discovery in the understanding of PD pathophysiology was 
the discovery of the central role of cellular α-synuclein accumulation in genetic 
and sporadic forms of PD. Depositions of α-synuclein in the cytoplasm of the 
neurons in several brain regions, as well as the Lewy bodies were observed in 
the brain. The aggregated α-synuclein are found in dopaminergic brainstem 
neurons and in neurons in the olfactory system, but α-synuclein is also found in 
the limbic and neocortical brain regions as PD progresses (Poewe et al., 2017). 
This α-synuclein pathology is also shared by other PD-related conditions 
(synucleinopathies) with overlapping symptoms. The combined classical motor 
disturbances of PD are referred to as parkinsonism or parkinsonian syndrome 
which are also observable in other PD-related conditions like dementia with lewy 
body or multiple system atrophy. These conditions make it difficult to diagnose 
PD correctly in some patients due to sharing the common signs and symptoms 
of PD which confine their diagnoses.  
 
Furthermore, recent advances support the idea that a prion-like mechanism 
operates in PD. The propagation of α-synuclein pathology from one neuron to 
another plays an important role in the progressive worsening of symptoms and 
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the gradual involvement of additional brain and autonomic functions as the 
disease advances. The diversity in the molecular structure of α-synuclein 
aggregates, and consequently their capacity to interact with different ensembles 
of partner proteins and to propagate between different brain regions might 
explain why all PD patients do not follow the same disease course. These 
findings could also explain why other synucleinopathies (e.g., dementia with 
Lewy bodies and multiple system atrophy) take a different course to PD 
(Brundin and Melki, 2017). 
 
 
1.5          PD risk factors 
 
The aetiology of PD is not fully understood, but different studies have provided 
evidence that environmental, occupational and genetic factors are potential risk 
factors for developing PD (Ben-Shlomo, 1997). A number of risk factors are 
clearly evident in PD development. Lifestyle, including exposure to persistent 
organic pollutants, or shared genetic factors could contribute to PD in an 
individual.  
 
Environmental factors 
Environmental factors have been thoroughly studied as one of the leading causes 
of PD. Differences in PD incidence from one area to another have been 
recognized. The discovery of the effects of the toxin, 1-methyl 4-phenyl 1, 2, 3, 
6-tetrahydropyridine (MPTP) in parkinsonism in humans (Langston, 1985; 
Langston et al., 1983) supported the environmental hypothesis, that humans 
exposed to numerous pesticides and toxins could develop PD. MPTP is a prodrug 
to the neurotoxin MPP+, which causes permanent symptoms of PD by 
destroying DA neurons in the substantia nigra. It has been used to generate 
disease models in various animal studies (Langston, 2017). However, not 
everyone exposed to environmental toxins develops PD, although, the incidence 
of PD could be significantly greater in individuals exposed to certain 
environmental chemicals such as pesticides and fossil fuels (Brown et al., 2006).  
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Smoking cigarettes or drinking caffeine have been suggested to play protective 
roles against developing PD (Martyn and Gale, 2003), suggesting that 
environmental factors including personal lifestyles have complex roles in PD 
pathophysiology.  
Similarly, heavy metals toxicities such as lead poisoning were thought to be 
environmental toxins that can contribute to the development of PD (Chin-Chan 
et al., 2015). Other herbicides such as rotenone and paraquat have been 
extensively studied in PD animal models. These chemicals have similar 
mechanisms of actions as MPTP, by destroying the DA neurons in the brain 
(Langston, 2017).  
Gene-environment interactions in PD 
Interactions between genetic factors and environmental exposures could be 
major contributors to the aetiology of PD (Cannon and Greenamyre, 2013). 
Although, it is not completely understood how most of these interactions 
contribute to PD pathobiology in humans, such interactions have the potential to 
have a major impact on PD. Animal models have also highlighted the importance 
of genetic susceptibility to toxin exposure in PD. While many pesticides have 
limited evidence to link them to PD, paraquat and rotenone have been strongly 
linked to PD (Cannon and Greenamyre, 2013). Similarly, exposure to heavy 
metals such as iron, lead and manganese and their combinations are associated 
with an increased risk for developing PD, since they accumulate in the substantia 
nigra and contribute to oxidative stress (Chin-Chan et al., 2015).  
Absorption, distribution, metabolism, and excretion are key factors in how the 
human body deals with xenobiotic exposures (Cannon and Greenamyre, 2013). 
Genetic predisposition may affect toxin disposition in a number of ways relevant 
to PD, including increased toxin accumulation in sensitive brain regions and 
alterations in metabolism that produce more toxic species. There are indeed 
some data to support these predispositions (Cannon and Greenamyre, 2013). 
Polymorphisms in cytochrome P450s (CYP2D6) have received the most 
attention and have been reported as a risk factor for PD, with increased risk of 
~2–3-fold (Deng et al., 2004; Elbaz et al., 2004 Cannon and Greenamyre, 2013). 
 
Stellenbosch University  https://scholar.sun.ac.za
                                                                                                                                    
12 
 
Ageing 
Ageing comes with various changes in the physical and biochemical components 
of the body. PD generally affects the middle to late age of the population (45-80 
years), a small proportion of cases (~10%) present an onset earlier than 45 years 
of age. Its risks however, continue to increase in the elderly (80 and above) (de 
Lau et al 2006). Notably, increasing age is the strongest risk factor for the 
development of PD.  
 
The number of DA neurons consistently reduces as part of normal aging (Beal, 
1992; Biskup et al., 2006; Chu and Kordower, 2007a; Levy et al., 2005). The 
progression of PD increases exponentially with age (Collier et al., 2017; de Lau 
and Breteler, 2006a; Ross et al., 2000). 
 
Gender 
Studies have shown that males are more likely to have PD than females. Recent 
meta-analysis data indicated that PD is twice as common in men as in women 
(Miller and Cronin-Golomb, 2010). The studies suggested that this may be 
because males have greater exposure to other risk factors such as toxins or head 
trauma and other occupational hazards (Poewe et al 2017).  
Similarly, it has been speculated that oestrogen may have neuro-protective 
effects, of which it might reduce the risk of developing PD in females. 
Menopausal women therefore, might be at risk for developing PD. 
Genetic factors 
Generally, PD occurs as a sporadic disorder. Prior to 1997, it was not known that 
the aetiology of PD could be linked to genetic factors. However, in the last two 
decades, it has been postulated that mutations in genes can lead to PD. In most 
people, it is not a single genetic mutation that causes PD, but there are several 
genetic changes that increase the risk for PD. This is likely true for sporadic 
cases of PD.  
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However, first-degree family members of affected patients have a 2-3 fold 
increased risk to develop the disease compared to subjects in the general 
population or controls (Savica et al., 2016; Sveinbjörnsdottir et al., 2000). In 
familial forms of PD, mutations in several genes have been reported (Table 1.1). 
Cell-based models are proving to be extremely valuable tools for figuring out 
what these genes and their proteins do and how PD-linked mutations have altered 
their functions (Moore et al., 2005). 
 
Presently, about 34 genes have been directly implicated in the aetiology of PD 
(Table 1.1), of which five genes [Alpha-synuclein (SNCA),  Leucine-rich repeat 
kinase 2,  (LRRK2),  Parkin RBR E3 Ubiquitin Protein ligase (PRKN), PTEN-
induced kinase 1 (PINK1) and  Protein deglycase DJ-1 (PARK7)], have been 
strongly linked to and have been replicated in a Mendelian form of PD. SNCA 
and LRRK2 have been classified as autosomal dominant (AD) genes whereas 
PRKN, PINK1 and PARK7 have been classified as autosomal recessive (AR) 
genes. 
 
Physiologically, some of these genes regulate normal functioning of the DA 
pathways. SNCA promotes exocytosis and it can play a part in endocytosis at 
the synaptic transmissions (Logan et al 2017). LRRK2 regulates phosphorylation 
of endophilin A postsynaptically and the release of clathrin coated endocytic 
vesicles (Lin and Farrer, 2014). Parkin is involved in ubiquitination and 
proteasomal function (Arkinson and Walden 2018). PINK1 and PARK7 regulate 
maintenance of mitochondria (Jain et al., 2005;  Lin and Farrer, 2014).  
 
PINK1 and Parkin cooperate in several processes that are associated with the 
mitochondrial functions (Scott et al 2017). Parkin is recruited to the 
mitochondrial surface and activated by PINK1, to exert its E3 ubiquitin protein 
ligase function (Mouton-Liger et al 2017). This binding is required to mediate 
autophagosome formation on the damaged mitochondrion, leading to 
mitophagy. Parkin is also involved in the maintenance of mitochondrial levels 
of PD-linked mitochondrial enzyme HSD17B10, possibly by promoting its 
import through the TOM complex (Mouton-Liger et al 2017).   
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PINK1 and Parkin can also control localized translation of several mRNAs for 
nuclear-encoded subunits of respiratory chain complexes. PINK1 and Parkin 
also control the formation of mitochondria-derived vesicles, leading to the 
specific degradation of damaged mitochondrial content (Mouton-Liger et al 
2017). Parkin also regulates the process of mitochondrial biogenesis by 
promoting the proteasomal degradation of the PGC-1α transcriptional repressor 
PARIS, in a PINK1-dependent manner (Mouton-Liger et al 2017). 
 
The functions of these proteins share similar pathways that make genetic studies 
of PD interesting  
 
The G2019S mutation in LRRK2 appears to be the most common known 
mutation underlying PD (including the apparently sporadic form), with 
frequencies as high as 6% in the European patients diagnosed of PD and 41% in 
North African Arabs patients (Lesage et al., 2006). 
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               Table 1.1: A list of genes that are associated with PD and parkinsonism 
Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
ARSB AR PD Contains mutation 
recently replicated 
in a large cohort PD 
study  
Lof mutation (Q887X 
stopgain) identified 
(Jansen et al., 
2017) 
ATP7B AD Parkinsonism Contains mutations 
associated with 
parkinsonism 
Identification of 
mutation H1069Q (as 
either homo-or 
heterozygous) have 
strong association with a 
variety of parkinsonism 
including PD in 
European populations 
(Montes et al., 
2014; 
Oczkowska et 
al., 2014; Sechi 
et al., 2007) 
ATP13A2 AR PD and 
Parkinsonism 
Contains mutations 
considered as non-
PD but robustly 
associated with 
parkinsonism. 
Pathogenic 
mutations were 
associated with 
complex 
phenotype with 
parkinsonism, 
spasticity, and 
dementia. 
(Ramirez et 
al., 2006) 
CHCHD2 AD PD Contains mutations 
robustly associated 
with PD 
Missense 
mutations (T61I, 
R145Q) and exon 
skipping were 
identified in 
familiar PD  
(Funayama et 
al., 2015) 
DCTN1 AD Parkinsonism Contains mutations 
considered as non-
PD but robustly 
associated with 
parkinsonism. 
Heterozygous 
mutation, (F52L), 
segregates with 
parkinsonism in a 
family. 
(Araki et al., 
2014) 
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
DNAJC13 AD PD and 
Parkinsonism 
Contains mutations 
considered as non-
PD but robustly 
associated with 
parkinsonism. 
Mutation in 
receptor-mediated 
endocytosis 
8/RME-8 (N855S) 
was found to 
segregate with 
disease. Screening 
of cases and 
controls identified 
four additional 
patients with the 
mutation, of which 
two had familial 
parkinsonism. 
(Vilariño-
Güell et al., 
2011)  
DNAJC6 AR PD Contains mutations 
robustly associated 
with PD 
Different 
homozygous 
mutations 
segregating with 
PD in a family 
were identified. 
One of the 
mutation was 
flanked by long 
runs of 
homozygosity 
within highest 
linkage peaks. 
(Olgiati et al., 
2016) 
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
EIF4G1 AD PD Contains mutations 
robustly associated 
with PD 
A missense 
mutation 
(R1205H) found 
by genome -wide 
linkage analysis 
and disease 
cosegregation 
analysis in a large 
French family with 
ADPD. 
(Chartier-Harlin et 
al., 2011; Dhungel 
et al., 2015; Lesage 
et al., 2012; Tucci et 
al., 2012a) 
FBXO7 AR PD Contains variants 
reported as PD risk 
factors 
A homozygous 
truncating 
mutation (R498X) 
was identified in 
familial PD 
(Conedera et al., 
2016; Di Fonzo et 
al., 2009)  
GBA AR PD Contains variants 
reported as PD risk 
factors 
Multiple rare 
variants of 
intermediate-effect 
strength identified 
associated with PD 
and a gene 
expression study 
in GBA mutant 
fibroblast. 
(Sanchez-Martinez 
et al., 2016; 
Sidransky et al., 
2009) 
GIGYF2 AD PD Contains mutations 
reported as PD risk 
factors 
A total of seven 
different missense 
mutations resulting 
in single amino 
acid substitutions 
were present in 12 
unrelated PD 
index patients 
(4.8%) and not in 
controls. 
(Lautier et al., 2008) 
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
GPATCH
2L 
 
AR PD Contains mutation 
recently replicated 
in a large cohort PD 
study  
Lof mutation (R362X 
stopgain) identified 
(Jansen et al., 2017) 
GRN AR PD Contains variants 
reported as PD risk 
factors 
A single 
nucleotide 
polymorphism 
(rs5848) was 
studied in PD and 
was considered to 
be a risk factor in 
PD patients. 
(Chang et al., 2013) 
HTRA2 AD PD Contains mutations 
robustly associated 
with PD 
G399S mutation 
was identified and 
homozygotes for 
this allele 
developed PD. 
(Gulsuner et al., 
2014) 
LRP10 AD PD Contains mutations 
robustly associated 
with familial 
autosomal dominant 
PD cases 
Five mutations including 
(N517del, R533L P699S) 
that were replicated and 
studied for mechanisms 
in cell-based assays 
 
 
   (Quadri et al.,  
2018) 
 
 
LRRK2 AD PD Contains mutations 
robustly associated 
with PD 
Six confirmed 
point mutations: 
R1441G, R1441C, 
N1437H, Y1699C, 
G2019S, I2020T 
were earlier 
identified in 
familiar PD. 
(Paisán-Ruíz et al., 
2004; Zimprich et 
al., 2004) 
MAPT AR PD-dementia Contains variants 
reported as PD risk 
factors 
Five SNPs were 
significantly 
associated with PD 
(Tobin et al., 2008; 
Wang et al., 2016) 
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
PARK7 AR PD Contains mutations 
robustly associated 
with PD 
Mutations 
(deletion of 
14.082bp and 
L166P) were 
identified in PD 
patients. 
(Bonifati et al., 
2003) 
PINK1 AR PD Contains mutations 
robustly associated 
with PD 
More than 20 
mutations, point 
mutations, 
INDELs, and exon 
rearrangements 
were identified in 
PD. 
(Valente et al., 
2004) 
PLA2G6 AR PD Contains mutations 
reported as PD risk 
factors 
PLA2G6 
mutations 
identified in 
levodopa-
responsive 
dystonia-
parkinsonism and 
segregation of 
R632W with 
disease. 
(Lu et al., 2012; 
Paisan-Ruiz et al., 
2009; Sina et al., 
2009) 
POLG1 AR Parkinsonism Contains mutations 
robustly associated 
with parkinsonism 
Heterozygous 
mutation 
(Y955C) was first 
identified in 
progressive 
external 
ophthalmoplegias. 
Subsequently,27 
mutations in 14 
probands with a 
variety 
(Stewart et al., 2009; 
Van Goethem et al., 
2001; Wong et al., 
2008a) 
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
of parkinsonism 
have been reported 
PRKN AR PD Contains mutations 
robustly associated 
with PD 
Pathogenic 
mutations, point 
mutations, 
INDELs, and exon 
rearrangements 
have been 
implicated in PD. 
(Brüggemann and 
Klein, 1993; Kitada 
et al., 1998) 
PTPRH 
 
AR PD Contains mutation 
recently replicated 
in a large cohort PD 
study  
Lof mutation (90-2insT 
stopgain) identified 
(Jansen et al., 2017) 
SLC30A1
0 
AR Parkinsonism Contains mutations 
confirmed with 
association and 
functional studies 
Identification 
of homozygous 
c.507delG and F167S 
mutations in 
parkinsonism in Dutch 
and italian families.  
(Quadri et al., 2012) 
SNCA AD PD Contains mutations 
robustly associated 
with PD 
Three rare 
mutations: A53E, 
A30P, E46K and 
duplications and 
triplications of the 
SNCA gene were 
first identified in 
PD. 
(Polymeropoulos et 
al., 1997; Singleton 
et al., 2003) 
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
SPG11   Contains mutations 
considered as non-
PD but robustly 
associated with 
parkinsonism. 
Two mutations, 
c.3664insT and 
c.6331insG, found 
in a patient with 
spastic paraplegia 
and early onset 
parkinsonism. 
(Guidubaldi et 
al., 2011) 
SYNJ1 AR Parkinsonism Contains mutations 
reported as 
parkinsonism risk 
factors 
Patients with early 
onset 
parkinsonism had 
mutations: R258Q 
and S1422R  
(Quadri et al., 
2013) 
TMEM23
0 
AD PD Contains mutations 
reported as PD risk 
factors 
Pathogenic 
mutations; 
(R141L, Y92C, 
R171C, I125M, 
and M64T) 
cosegregated with 
PD in a family.  
Mutations 
influenced gene 
expression. 
(Deng et al., 
2016) 
UHRF1BP1L AR PD Contains mutation 
recently replicated 
in a large cohort PD 
study 
Lof mutation (K1376X 
stopgain) identified 
(Jansen et al., 
2017)  
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Gene Inheritance 
pattern 
Associated with 
PD/Parkinsonism  
Comment Findings Study reference 
VPS13C AR PD Contains variants 
reported as 
parkinsonism risk 
factors 
Mutations 
(G1389R, 
Q1593K) 
associated with a 
distinct form of 
early-onset 
parkinsonism 
characterized by 
rapid and severe 
disease 
progression and 
early cognitive 
decline; 
resembling diffuse 
Lewy body 
disease. 
(Lesage et al., 
2016) 
VPS35 AD PD Contains mutations 
robustly associated 
with PD 
Pathogenic 
mutations 
(D620N,R524W,L
774M,I241M,M57
I) identified in 
family members 
with PD. 
(Dhungel et 
al., 2015; 
Mohan and 
Mellick, 
2017; 
Vilariño-
Güell et al., 
2011; 
Zimprich et 
al., 2011) 
  Single neuclotides Polymorphism (SNP), Insertion and Deletion (INDELs), Lof (loss of function), Autosomal recessive (AR), Autosomal dominant (AD)
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Understanding the genetic causes of PD is reshaping the knowledge about PD 
pathology and how it progresses. However, some genes still lack strong 
evidences to associate them to PD pathology. These include PARK3, UCHL1 
(PARK5), GIGYF2 (PARK11), HTRA2 (PARK13) and PLA2G6 (PARK14). The 
genetics of PD is complex because there are overlapping mutations in these 
genes in PD and other diseases such as Alzheimer’s disease, dementia and Lewy 
body disease. To date, there are only five genes that have been robustly linked 
to PD (Table 1.2 and Appendix I for the list of mutations catalogued in these 
genes). These will be elaborated on in the section below. 
 
                  Table 1.2: Loci and genes strongly associated with, and replicated in inherited PD  
Locus Gene 
symbol 
Chromosome Mode of 
inheritance 
Age at 
onset 
PARK1 SNCA            4q Autosomal 
dominant 
            ~45 
PARK2 PRKN 6p Autosomal 
recessive 
30-60 
PARK6 PINK1 1p36 Autosomal 
recessive 
36-60 
PARK7 DJ-1 1p36 Autosomal 
recessive 
27-40 
PARK8 LRRK2 12p Autosomal 
dominant 
45-57 
 
SNCA 
The study by Polymeropoulos et al 1997 was the first study that showed a 
mutation in the α-synuclein and it was discovered before the identification of α-
synuclein in the Lewy Bodies (Spillantini et al., 1997) in PD. A missense 
mutation (A53T) in α-synuclein (encoded by SNCA gene) was identified in a 
classical positional cloning (Polymeropoulos et al 1997). Thus, the discovery of 
α-synuclein accumulation in Lewy bodies in PD in 1997 (Spillantini et al., 1997).  
 
The two landmark studies were the first to show the effects of genetic component 
in SNCA gene in association with PD. However, more missense mutations in 
SNCA (A30P, E46K, H50Q, and A53E) were later identified in other studies that 
confirmed the causative role of α-synuclein in PD (Wang et al., 2016, 2017).  
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Mutations identified in the gene in the patients have high penetrance and were 
associated with early-onset PD within the age 40s or 50s with typical motor 
symptoms and a good response to L-dopa treatment. 
 
A recent report described another missense mutation, G51D that was associated 
with parkinsonism pyramidal syndrome in a French family (Lesage et al., 2013). 
 
Three missense mutations (A53E, A30P, E46K), as well as duplications and 
triplications in the SNCA gene have been associated with autosomal dominant 
PD (Krüger et al., 1998; Polymeropoulos et al., 1997; Singleton et al., 2003).  α 
-synuclein is mostly expressed at the presynaptic space in the CNS.  SNCA 
aggregates to form fibrils deposits due to its hydrophobic non-amyloid beta 
component domain and progresses to form the Lewy bodies that are involved in 
the pathology of PD. The oligomeric forms of α-synuclein fibrils deposits are 
cytotoxic. Overexpression of α-synuclein in in vitro studies increased the 
formation of α-synuclein protofibrils (Conway et al., 2000; Fredenburg et al., 
2007). In a study that used toxin that specifically targeted and damaged 
mitochondria in rodents and in cell culture experiments showed the involvement 
of α-synuclein aggregates in PD (Betarbet et al., 2000; Fornai et al., 2005).  
 
The accumulation of unfolded proteins produced by SNCA was linked to the 
ubiquitin proteasome pathway leading to mitochondrial dysfunction and 
neuronal cell death (Tanaka et al., 2001). Majorly, protein aggregation and 
mitochondrial dysfunction were identified to be interwoven and were considered 
as the causes of PD in human brain studies. Many studies found α-synuclein 
accumulation in the substantia nigra and striatum of PD patients (Devi et al., 
2008). 
 
PRKN 
Parkin (encoded by PRKN) plays a role in the ubiquitin pathways involving the 
E1-activating enzyme, an E2-conjugating enzyme, and an E3 ligase. It which has 
E3 ubiquitin ligase function and is involved in the proteasome-mediated 
degradation, and during autophagy.  
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Ubiquitin signalling plays a central role in protein quality control. Parkin can 
trigger proteasome-independent ubiquitination, it also has roles in mediating 
transcriptional regulation, protein trafficking and neuroprotective signalling 
(Fallon et al., 2006).  
 
Parkin facilitates the polyubiquitination reaction so that the process of 
proteasomal degradation will enable the clearing of proteins that normally 
aggregate in the brain and in the mitochondria.  
 
The loss of E3 ligase activity causes accumulation of toxic protein aggregates 
leading to autosomal-recessive juvenile parkinsonism (Dawson, 2006). The role 
of parkin is, therefore, essential by protecting cells against further damage. 
Mutations in the PRKN gene predispose cell to damage by compromising the 
processes of protein degradation.   
 
PINK1 
PINK1 mutations cause autosomal recessive early onset PD (Valente et al., 
2004). PINK1 gene encodes a mitochondrial serine/threonine-protein kinase. It 
protects cells from stress-induced mitochondrial dysfunction in different regions 
of the mitochondrial membrane  (Gandhi et al., 2006; Pridgeon et al., 2007).  
 
This protein is found in cells throughout the body. PINK1 also plays crucial roles 
in mitophagy, a selective degradation of mitochondria by autophagy. Studies 
have shown in in vitro cell-based assays that mutations in this gene can lead to 
mitochondrial dysfunction, leading to abnormalities in mitochondrial 
morphology, resulting to a decreased membrane potential, and increased reactive 
oxygen species (ROS) production, sensitive to apoptosis (Wood-Kaczmar et al., 
2008). Wang and colleagues found that PINK1 overexpression restored normal 
mitochondrial morphology that reduced ROS production indicating that PINK1 
is important in the maintainance of mitochondrial morphology and to protect the 
neurons damages cause by ROS in mice brain (Wang et al., 2011). A study also 
showed that embryonic fibroblasts derived from PINK1 knockout (KO) mice 
had low mitochondrial membrane potential, decreased cellular ATP levels and 
declines mitochondrial respiratory activity (Amo et al., 2011). 
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PARK7 
Mutations in PARK7 gene can cause autosomal recessive early onset 
parkinsonism (Bonifati et al., 2003). PARK7 is crucial in many tissues and 
organs, including the brain. PARK7 has antioxidant and transcription modulation 
properties. One of the protein's functions may be to help protect cells, 
particularly brain cells, from oxidative stress. PARK7 is localized in the cytosol 
and can also be found in the nucleus and mitochondria (Zhang et al., 2005).  
When there is oxidative stress, PARK7 will translocate to the mitochondria 
where it will gain a neuroprotective abilities. The translocation of PARK7 is 
facilitated by the oxidation of cysteine 106 to cysteine-sulfinic acid which is vital 
for PARK7 in its function in the mitochondria (Blackinton et al., 2009; Canet-
Avilés et al., 2004). When PARK7 was silenced in neuronal cells, there was 
increased cell death that was linked to stress and inhibition of the proteasome  
(Taira et al., 2004; Yokota et al., 2003).  Mitochondrial complex I dysfunction 
is the leading mechanism implicated in PD associated with in PARK7 mutations. 
 
LRRK2 
LRRK2 mutations have been associated with both familial and sporadic forms of 
PD (Klein and Schlossmacher, 2006; Paisan-Ruiz et al., 2009; Zimprich et al., 
2004). The LRRK2 gene encodes serine/threonine kinase containing mitogen-
activated protein kinase kinase kinase (MAP3K), a Roc domain with 
Ras/GTPase, a WD40-repeat domain and leucine-rich repeats (Biskup and West, 
2009; Gandhi et al., 2009; Mata et al., 2006). LRRK2 mutations is responsible 
for the neurotoxicity  caused by an increase in LRRK2 kinase activity suggesting 
a toxic gain of function (Gloeckner et al., 2006; Greggio et al., 2006). 
Overexpression of LRRK2 leads to apoptotic neuronal cell death and 
mitochondrial dysfunction (Iaccarino et al., 2007).   
 
The most common mutation in LRRK2 is G2019S, it causes defects in 
mitochondrial morphology and functions, resulting to an increased production 
of ROS in the neurons. LRRK2 interacts with Dynamin like protein 1 (DLP1) in 
neurons leads this interaction leads to translocation of DLP1 from the cytosol 
into the mitochondria (Niu et al., 2012).  
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Similarly, ATP13A2 gene can be classified as a known PD gene, although the 
gene is not largely implicated in PD pathology, but pathogenic mutations in 
ATP13A2 show that this gene is associated with parkinsonism and including PD. 
ATP13A2 gene is involved in autophagy. Mutations in ATP13A2 can decrease 
the ability of lysosomes to degrade proteins and mediate clearance of 
autophagosomes hence leading to aggregation of α-synuclein in neurons (Dehay 
et al., 2012; Yang and Xu, 2014).  
  
ATP13A2 encodes a lysosomal transmembrane protein that belongs to the 5P-
type ATPase subfamily. Its activities are localized in the lysosome, but when 
mutations are involved in PD, the activities of this gene are localize to the 
endoplasmic reticulum. ATP13A2 is highly expressed in the brain especially in 
the cytosol of the dopaminergic neurons suggesting a brain-specific function. 
Studies showed that ATP13A2 expression levels in the substantia nigra were 
reduced in post-mortem tissue samples of patients with sporadic PD compared 
to controls without PD.  
 
ATP13A2 can also facilitate the transmembrane transport of manganese, zinc, 
iron and cadmium that cause neurodegeneration. Elevated levels of manganese 
and zinc have been found in serum and cerebrospinal fluid of PD patients.  
Exposure to these metals is a significant environmental risk. ATP13A2 protects 
cells from toxicity by regulating the homeostasis of manganese and zinc 
(Rentschler et al., 2012; Yang and Xu, 2014). In summary, mitochondria are 
involved in autophagy in the cells (Rentschler et al., 2012). The differentiated 
cells like the neurons depend on active membrane transport systems that also 
require mitochondria to function. Hence, the survival of these neurons when they 
are stressed or damaged depends on the autophagy (Tooze and Schiavo, 2008). 
Autophagy impairments caused by mutations have been implicated in PD. 
 
In 2011, Zimprich and colleagues identified a mutation in vacuolar protein 
sorting 35 homolog gene (VPS35, encoding vacuolar protein sorting 35) in a 
family with inherited PD. This mutation was found in every affected individual 
in the family and segregates with late-onset PD in a Mendelian autosomal 
dominant manner (Hernandez et al 2016). VPS35 protein alters the trafficking 
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of cathepsin D, a protein that is implicated in the degradation of α-synuclein. 
VPS35 is linked to the other autosomal dominant PD genes SNCA and LRRK2 
through endosomes and vesicular trafficking and underscores the importance of 
studying these pathways in health and disease (Hernandez et al 2016).  
 
Beta glucocerebrosidase (GBA) is a gene long associated with the autosomal 
recessive lysosomal storage disorder, Gaucher’s disease. Aharon-Peretz and 
colleagues were able to show that a single mutation in GBA gene increased the 
risk for PD. The function of GBA is well established as an integral enzyme 
required for the breakdown of glucocerebroside to ceramide. Multiple studies 
have shown that glucocerebrosidase activity is lower in patients carrying GBA 
mutations and in sporadic PD cases, suggesting a broader role for GBA in 
pathogenesis (Hernandez et al., 2016; Schapira, 2015). 
 
 
1.6     Biological processes associated with PD 
 
There are various biological processes contribute to the pathophysiology of PD. 
The roles of environmental toxins and brain trauma in PD pathophysiology have 
been described earlier, PD-linked genetic mutations have specific pathways by 
which they interact and lead to PD onset. Mitochondrial dysfunction, calcium 
imbalance and oxidative stress are the leading biological processes implicated in 
PD pathology.  
 
1.6.1         Oxidative stress 
Oxidative stress is associated with PD as a consequence of mitochondrial 
dysfunction in the brain tissue. This theory was supported by the identification 
of mutations in the PARK7 gene that resulted in cellular oxidative stress. PARK7 
has antioxidant effects but the mutated form had reduced gene expression 
(Guzman et al., 2010; Poewe et al., 2017). 
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It is the process of oxidative phosphorylation in the mitochondria that generates 
ROS and intracellular oxidative stress.  The mitochondrial complex I and 
complex III are the main sites of ROS production in mitochondria. Superoxide 
radical is produced when there is a transfer of single electron to oxygen in the 
respiratory chain. Constant stress perturbation in the dopaminergic neurons 
causes neurodegeneration.  
The mitochondrial complex I activity in the post-mortem substantia nigra of 
patients with idiopathic PD has been studied (Parker et al., 2008; Schapira et al., 
1989). Oxidative damage to the catalytic subunits of complex I had a correlation 
between increased protein oxidation and reduction in electron transfer ability in 
PD patients. 
 
1.6.2   Mitochondrial dysfunction 
Both sporadic and inherited forms of PD share biochemical, pathological and 
clinical features. Mitochondrial dysfunction is a major point of emphasis in the 
study of both forms of PD (Grünewald et al., 2018; Keane et al., 2011). 
Mitochondrial complex I deficiency was described in a study in 1989 when 
Schapira and colleagues studied the brains of PD patients  (Schapira et al., 1989).  
The primary function of the mitochondria in a cell is to produce adenosine 
triphosphate (ATP) through the process of respiration and oxidative 
phosphorylation. This process serves as a source of energy in a cell. When there 
is joining of redox and phosphorylation reactions in the inner membrane of 
mitochondria, ATP will be synthesised. ATP can be formed when the electron 
transport chain transfers electrons via the complexes I-IV and nicotinamide 
adenine dinucleotide (NADH) or flavin adenine dinucleotide (FADH2). This 
will lead to the formation of a proton gradient in the inner mitochondrial 
membrane. Proton influx from the mitochondrial accumulates in the 
intermembrane space which then creates an electrochemical gradient. This 
electrochemical gradient is the driver for the synthesis of ATP from adenosine 
diphosphate (ADP) by ATP synthase. 
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1.6.3   Calcium imbalance 
Calcium regulates the functions of mitochondria and endoplasmic reticulum. 
Calcium influxes in the neurons come through the L-type calcium channels or 
by the activation of N-methyl-D-aspartate (NMDA) receptors.  Calcium binding 
proteins and the metabotropic glutamate receptors govern the regulations of 
calcium presence in the intracellular space (Figure 1.5).  Increased levels of 
calcium in the neuron increase dopamine metabolism in the substantia nigra pars 
compacta DA neurons. Also by shifting the levels of calcium influx through the 
L-type calcium channels in the substantia nigra dopaminergic neurons, a basal 
mitochondrial oxidant stress was induced and implicated in aging and cell death 
(Mosharov et al., 2009). 
Calcium is transported by a calcium uniporter inside the cell across the plasma 
membrane to the mitochondria. The mitochondrial membrane pores then allow 
the communication with the endoplasmic reticulum and mitochondria directly 
(Rizzuto et al., 2000).  Mitochondrial sodium/calcium exchanger and high 
conductance ion channels like the mitochondrial permeability transition pore 
regulates the efflux of calcium from mitochondria (Rizzuto et al., 2000). 
Mitochondrial permeability transition pore has two conductance states, when it 
is low, it is reversible and involved in calcium handling, when it is high, it is 
irreversible and leads to mitochondrial swelling and leakage of molecules like 
cytochrome C that triggers apoptosis in cell (Gogvadze et al., 2006). 
 
1.6.4    Neuroinflammation 
The term neuroinflammation is gaining overwhelming support in the 
understanding of PD pathophysiology. It is explained as a self‐propelling cycle 
of inflammatory process involving the brain immune cells (microglia and 
astrocytes) that drives the progressive neurodegeneration.  Moreover, increasing 
evidence suggests that early‐life occurrence of inflammation in the brain, as a 
result of either brain injury or exposure to infectious agents, may play a role in 
the pathogenesis of PD (Hirsch and Hunot, 2009).  
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Neuroinflammation usually leads to a cascade of events that assault the neurons 
(Figure 1.5). During neuroinflammation there is microglial activation, 
astrogliosis, and lymphocytic infiltrations (Hirsch and Hunot, 2009).  
These inflammatory cells drive the processes. The release of inflammatory 
cytokines during neuroinflammation, will amplify the inflammatory response by 
activating and recruiting other cells to the brain lesion, by activating the 
microglia, the neurons will be damaged.   
This process is being mediated by releasing various toxic substances including 
the inflammatory cytokines such as IL-1b, TNF-a, IL-6, NO, PGE, and 
superoxide. 
 
1.6.5    Other 
In addition, PD symptoms could be amplified in the presence of stress also. Risk 
factors such as cholesterol intake, dairy products, alcohol, body mass index, 
caffeine and cigarettes have been investigated in PD but there is little evidence 
to support their roles in PD pathobiology (Abbas et al., 2018). Since the 
prevalence of PD is different from one country to another, environmental factors 
and diet might be responsible (Chaudhuri et al., 1997). Low levels of vitamin B 
folate have also been linked to severe PD symptoms in mouse studies, suggesting 
that people with low levels of vitamin B folate could be predisposed to the 
disease.  
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Figure 2.5 Molecular mechanisms involved in PD, the figure shows major 
interactions between molecular pathways that are implicated in the 
pathogenesis of PD. Taken from (Poewe et al., 2017) Permission from Springer 
Nature 
 
 
1.7        Treatment of PD 
 
The discovery that DA loss in the SNPc will cause extrapyramidal PD 
symptoms, provided the basis for development of treatment. In the 1960s the 
drug L-dopa was first administered to treat the symptoms and has since become 
the first-line of drug to treat PD.  Similarly, excellent response to L-dopa is a 
supportive criteria for diagnosing PD with the UKPDSBBC (Hughes et al., 
1992), and can also be used to correctly diagnose PD as only PD patients will 
respond quickly to L-dopa intake. L-dopa structure is closely similar to DA 
structure (Figure 1.6). It has a carboxylic acid group that makes it polar and can 
cross the blood-brain barrier where DOPA decarboxylase enzymes can convert 
L-dopa to DA. This occurs both in the peripheral circulation and in the CNS.  
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DA synthesis occurs from a rate limiting step from the conversion of the amino 
acid tyrosine, which when tyrosine gets into the neurons get converted to L-dopa 
by the enzyme tyrosine hydroxylase. Subsequently, the conversion continues by 
the L-aromatic amino acid decarboxylase. This enzyme is most active so that 
even in a healthy individual the level of DA is negligible in the brain. Following 
the release of DA, it can be degraded to dihydroxyphenylacetic acid (DOPAC) 
and homovanillic acid (HVA) by the monoamine oxidase (MAO) and catechol-
O-methyl transferase (COMT), respectively. DOPAC and HVA are the major 
metabolites of DA. The roles of MAO and COMT in degrading DA to DOPAC 
and HVA, respectively, make them major sites for drug actions in the treatment 
of PD.  
                          A)                 B) 
  
                        
Figure 1.6: Structures of (A) DA neurotransmitter and (B) L-dopa, a DA 
receptor agonist. 
There is currently no drug that can prevent, reverse, or halt the progression of 
the disease. PD, like other neurodegenerative diseases has complex pathogenesis 
so patients show a wide range of symptoms which makes its treatment difficult. 
Currently, drug treatments of PD are based on symptomatic management. When 
PD symptoms progress, the other non-dopaminergic neurons will be involved, 
so the drugs that target the dopamine pathways might not be appropriate to treat 
other non-motor symptoms that arise at later stages of the disease (Burn, 2013). 
The medications to treat the motor symptoms of PD act on a complex neurologic 
interaction in the striatum that coordinates movement.  
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A combination of L-dopa and carbidopa can be administered as the first line 
treatment to aid movement deficit in PD (Figure 1.7 and Appendix II for classes 
of drugs approved by the FDA and used for treating PD). Levodopa can cross 
the blood brain barrier where it is converted into dopamine, whereas carbidopa 
inhibits dopamine decarboxylase in the central nervous system to prevent 
dopamine degradation. Tolcapone can also be administered along with levodopa 
and carbidopa, it is a selective inhibitor of COMT at the peripheral tissues and 
central nervous system, so that it prevents the degradation of levodopa. A 
dopamine agonist, bromocriptine is given to patients to directly stimulate 
dopamine receptors. In addition, MAO type B inhibitors selegiline administered 
once daily, can inhibit MAO-B to ensure that dopamine has a longer lasting 
effect in the brain (Connolly and Lang, 2014). Also, amantadine (100 mg) has 
been useful in treating gait dysfunction and dyskinesia in PD (Connolly and 
Lang, 2014)  
Certain treatments are recommended to treat the non-motor symptoms in PD. 
Clozapine is effective for hallucinations and psychiatric disturbances, and 
recently a new drug nuplazid was approved by the FDA to treat psychosis in PD 
patients. Some other classes of drugs have been tried in PD patients such as the 
anti-cholinesterase which is effective for treating dementia (Figure 1.7 and 
Appendix II). Antidepressants and pramipexole are typically administered to 
treat depression (Connolly and Lang, 2014). Anticholinergic medications also 
help to regulate muscle movement.  
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Figure 1.7: Classes of drugs that can activate or inhibit receptors at neuron 
sites to alleviate PD symptoms. BBB: Blood Brain Barrier; DAT: Dopamine 
transporter: COMT: catechol-O-methyl transferase; DOPAC: 
dihydroxyphenylacetic acid, L-DOPA: levodopa; TH: Tyrosine; D2R and D1R: 
Dopamine receptors 1 and 2; AADC: Aromatic L-amino acid decarboxylase and 
MAO: monoamine oxidase. Taken from (Poewe et al., 2017), Permission from 
Springer Nature. 
 
However, these drugs do not cure PD nor can they reverse neuronal loss. 
Besides, each drug has serious adverse effects that might be unbearable for the 
patients, hence the more reason to investigate better drug treatments for PD. The 
symptomatic approach to treat PD has been limited. Still, the drugs and other 
existing therapies have been used to improve a patient's quality of life. Surgical 
therapy including deep brain stimulation has also been considered to improve 
dopamine levels in the brain. In some instances, making lifestyle and dietary 
changes, and employing physical and speech therapy has been recommended to 
PD patients and has proven to be beneficial. 
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1.8        Incidence and Prevalence of PD 
  
PD occurs globally across all ethnic groups and geographical regions. PD 
incidence increases with age (Figure 1.8). It is generally accepted that the 
prevalence of the disease ranges from 1-2% among individuals over the age of 
60 years (Olanow et al., 2009; von Campenhausen et al., 2005) and affects 4% 
of the people above 80 years (de Lau and Breteler, 2006a).  
The exact global figures for PD prevalence are not available, though it is 
estimated that 9-10 million people worldwide have PD, and the incidence is 
predominant in Europe and North America. The incidence of the disease varies 
in different reports. The global incidence of PD ranges from 5 to >35 new cases 
per 100,000 yearly (Poewe et al., 2017). 
Similarly, an incidence rate of 15.4–27.6/100,000 and 6.1–17.4/100,000 in the 
door to door and record-based studies was reported in Europe (Abbas et al., 
2018). The incidence in Asian studies was lower at 1.5–17/100,000 compared to 
9–22/100,000 and 11–13/100,000 in studies from Europe and North American 
studies respectively (Abbas et al., 2018). A meta-analysis of European studies 
reported PD incidence of 11–19/100,000. In addition, the median incidence was 
14/100,000  cases under the age of 65 years, while at the age group of 70 years 
or older the median incidence was higher at 160/100,000 (Abbas et al., 2018).  
 
Incidence studies may be affected by misdiagnosis of PD, especially among the 
most elderly. Likewise, cases of no or poor diagnosis of PD in patients are likely 
to occur especially in an area where expert neurologists are scarce, and if the 
patients fail to visit the hospital at the onset of the disease. It is plausible to expect 
higher incidence rates of PD in the urban areas than in the rural areas due to the 
lack of neurologists in the rural areas. Also patients in rural areas have limited 
access to quality health services. High levels of pollutants and environmental 
toxins in urban cities due to the industrialization could contribute to higher 
prevalence in these areas. 
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Figure 1.8: PD incidence increases with age the incidence rate is higher in 
age 60 years and above. Permission from centre for disease control and 
prevention  https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5853a1.htm 
    
A number of epidemiological studies have been conducted across the globe to 
ascertain the disease burden and the possible risk factors. A study that carried 
out a meta-analysis of data of PD from 1985-2010 observed an increase in PD 
prevalence globally. The study reported prevalence data as a number of PD cases 
per 100,000 individuals. Table 1.3 provides summaries of prevalence studies of 
PD from (1985-2010) by age, sex and geographic location. 
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Table 2.3: A summary of incidence studies of PD by age, sex and geographic location 
Age 
group 
Crude 
incidence of 
PD Number of 
cases/100,000 
Incidence of PD by geographical location (N/100,000) 
 
       Asia                   SA                       N.A/ Euro /AUS 
 Incidence of PD  by sex 
(N/100,000) 
 
 
Female           Male 
40-49 41 - - - 45 36 
50-59 107 88 228 113 41 134 
55-64 173 - - - 150 233 
60-69 428 376 637 540 392 389 
65-74 425 - - - 610 706 
70-79 1087 646 2180 1602 813 932 
>80 1903 148 6095 2953 1517 2,101 
Table 2.3 was modified from  (Pringsheim et al., 2014). (SA)- South America, (N.A)-North America, (Euro)-Europe, (AUS)-Australia. 
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Crude prevalence studies by geographic location indicated that PD occurrence 
was relatively high in South America, North America, Europe, Australia and 
Asia (Pringsheim et al., 2014). Also, males between the age of 50–59 years had 
a significantly higher in prevalence of PD of 134/100,000 as compared to 
females, who had a prevalence of PD of 41/ 100,000 (Pringsheim et al., 2014), 
suggesting that males are more often affected by PD than females. 
 
1.8.1 PD prevalence studies in sub-Saharan African countries 
Prevalence studies on PD in sub-Saharan Africa (SSA) are sparse. Studies from 
1982-2006, found only 7 reported cases of PD/100,000 in Ethiopia  (Tekle-
Haimanot et al., 1990), 10/100,000 in Nigeria (Osuntokun et al., 1987), 
20/100000 in Togo (Balogou et al., 2001) and 20/1000 patients in Tanzania  
(Dotchin et al., 2008a).  Still, it is difficult to compare data on prevalence of PD 
in Africa with other continents.  
A study in Tanzania demonstrated that the prevalence of PD in that country is 
predicted to increase by an alarming 184% by the year 2025 (Dotchin et al., 
2012), surpassing the corresponding 92% increase projected for Canada and the 
USA (Bach et al., 2011).  
In Nigeria, age-adjusted PD prevalence rates range from 10 to 67 per 100,000 
for community-based studies (Osuntokun et al., 1987; Schoenberg et al., 1988), 
whereas hospital-based studies report rates of 4.1 to 59.4/ 1000 of all 
neurological consultations (Ekenze et al., 2010a; Okubadejo et al., 2010a). It was 
reported in 2014 that roughly 90,000 Nigerians suffer from PD.  Epidemiological 
studies in South Africa are also limited. The prevalence rate for PD from one 
hospital-based study was ~5/1000 in South African population (Cosnett and Bill, 
1988) and 5.3/1000 among South Africans (White, Mixed ancestry, Black and 
Indian) in a cross sectional study (Cosnett and Bill, 1988). Although, broad 
prevalence studies on PD in SSA are sparse, the aforementioned evidence is 
contrary to the view that PD is a disease associated with ethnicity or that it occurs 
predominantly in the Western countries.   
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The population in SSA is growing more rapidly and also ageing more rapidly. 
The prevalence of PD in SSA is set to increase significantly. A recent study 
projected that SSA populations will increase significantly in age (Figure 1.9).  
 
This has important implications for PD studies in SSA, especially in the rapidly 
increasing population countries like South Africa and Nigeria. Similarly, 
because PD could indirectly affect the socio-economic growth of a particular 
country by increasing disabilities among the middle-aged and old-aged people 
and will ultimately reduce their workforce ability. In Africa, based on the theory 
that increasing industrialization and environmental toxins could predispose 
people to PD, and since South Africa and Nigeria probably are the two most 
industrialized countries in the SSA with a large workforce, it is likely that PD 
prevalence will increase drastically.  
 
 
Figure 1.9: Population aged 60-79 years and 80 years or over in SSA, 1990-
2050. United Nations, Department of Economic and Social Affairs. Population 
Division (2015). World Population Prospects: The 2015 Revision. 
http://www.un.org/en/development/desa/population/publications/pdf/popfacts/
PopFacts_2016-1.pdf  Reprinted with the permission of the United Nations." 
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1.9 Analysis tools for studying genetic diseases 
 
1.9.1 Next-generation sequencing platforms 
 
Next-Generation Sequencing (NGS) technique is an emerging tool that provides 
a way to explore the genetic basis of various diseases including movement 
disorders such as PD and has resulted in the discovery of a number of disease-
causing genetic variants. NGS is a rapid, robust, and cost-effective high 
throughput parallel sequencing.  Utilization of NGS to identify specific changes 
in DNA by rapidly and simultaneously sequencing multiple gene targets within 
multiple samples is making sequencing studies much better. Conventional 
methods of sequencing like the Sanger sequencing are not efficient for a large-
scale rapid sequencing study. The cost of buying the reagents required to 
sequence a hundred samples using Sanger method might be too expensive for 
this type of study. Hence NGS was chosen for this study. In contrast to the 
whole-genome sequencing, a targeted DNA panel is designed to capture and 
amplify a specific area of interest in the genome.  
 
The key to a targeted sequencing is to amplify genomic regions of interest using 
PCR and specific sets of pooled primers. Before now, the tasks of designing such 
primers and optimizing PCR conditions were labour-intensive and time-
consuming. Targeted NGS (tNGS) gene-panel tests have also given the field of 
genomics an edge in identifying causative genes and variants, providing a faster 
pipeline with a high diagnostic yield in clinical settings. For heterogeneous 
disorders like PD, tNGS provides higher coverage for known disease-associated 
genes and can be flexible in including suspected genes in the targeted library 
based on patient phenotype.  
 
Each sequencing platform however has advantages and disadvantages (Table 
1.4). When considering a large-scale sequencing study with accuracy, an NGS 
approach will be most suitable.  Generally, Illumina instruments are used more 
widely than any other NGS technology, but such broad use of a single 
technology may introduce systemic bias, especially in variant identification 
(Chakravorty et al 2017). 
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Table 1.4:  Comparison between the different sequencing platforms. 
 
Platform 
 
Ion Torrent 
sequencing 
 
Pacific Bio 
 
Pyro-
sequencing  
 
Illumina 
Sequenci
ng by 
ligation 
(SOLiD) 
  
Sanger 
sequencing 
 
Insert size 
 
250 bp 
 
2900 bp 
 
700 bp 
 
700 bp 
 
50 bp 
 
400 bp 
Accuracy (%)  
99.4 
 
99 
 
99.9 
 
99.2 
 
99.9 
 
99.9 
Error rate 
(%) 
1.17 12.86 N/A 0.80 N/A 0.5 
Average reads 
per run 
>5 million <1million 
 
~1 million >100 
million 
>100 
million 
N/A 
Duration  
2 hours 
 
2 hours 
 
24 hours 
 
~2 days 
 
~1 week 
 
3 hours 
 
Advantages 
 
Fast & less 
expensive 
 
Longest 
read length 
 
 
Long read 
size, fast 
 
Potential 
for high 
sequence 
yield 
 
Low cost 
per base 
 
Most 
acurate. 
Useful for 
many 
applications 
Disadvantages Homo-
polymer 
errors 
Low yield 
at high 
accuracy. 
 
Expensive 
equipment 
Expensive  
 
Homo-poly 
mer errors 
N/A 
 
 
Longer 
duration 
than other 
platforms 
Expensive 
and 
impractical 
for larger-
scale 
sequencing 
projects 
      Table 1.4 was modified from the (Quail et al 2012) study.  N/A-Not applicable.
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An Ion Torrent sequencing with a customized Ion AmpliSeq™ designed panel 
has been used to effectively study sporadic cases of PD and was shown to be a 
powerful method to screen for mutations in PD patients (Gorostidi et al 2016). 
In this study a customized panel of genes was available to screen for mutations 
in genes that are mostly linked to neurological diseases in people.  
In the current study, the Ion AmpliSeq™ Neurological Research Panel (Thermo 
Fisher Scientific) was used for targeted next-generation sequencing (tNGS), it is 
a commercially available panel for the screening of 751 genes, including 17 of 
the 34 known PD genes. The panel  produces an average base coverage of 165X, 
97% reads on target and 99.4% average gene coverage (www.ampliseq.com). 
Only 10 ng of DNA is needed to generate mutational profiles.  
 
1.9.1.1 Next-Generation Sequencing on Ion Torrent Personal Genomic 
Machine 
 
Ion Torrent library construction includes DNA fragmentation, hybridization of 
primer sequences, ligation of adapters, and library purification. Sequence 
template preparation can be performed manually or by use of an OneTouch™ 
Machine (Life Technologies). Template preparation is carried out using an 
emulsion PCR and enrichment system on Ion Spheres™ Particles (ISPs). The 
ISPs have covalently linked complementary adapter sequences on their surfaces 
to facilitate amplification on the particles.  
 
Enriched particles are primed for sequencing by annealing a sequencing primer 
and are then loaded into the wells of an Ion Chip (Figure 1.10). The Ion sphere 
particles with the amplified library can be loaded on the Ion torrent Chip 540 for 
bidirectional sequencing of amplicons on the Ion S5 Personal Genomic Machine 
(PGM). The sequencer combines semiconductor-sequencing technology with 
basic biochemistry to directly translate chemical information into digital data. 
This eliminates the need for expensive optics, lasers, and complex sequencing 
chemistries with fluorescently labelled nucleotides.  
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Normally, there is a release of a proton when a nucleotide is incorporated by the 
polymerase in the DNA molecule, and the process will lead to a change in pH. 
The semiconductor sequencing chip contains million copies of the amplified 
barcoded beads. The Ion PGM depending on the chip used, can generate to 
5.5 million reads, with an output reaching 2 Gb, a reading length up to 400 bases, 
and a run time between 2 to 7 hour.  
 
The Ion PGM sequencer successively flow-in one nucleotide after another in the 
chip. To show that one nucleotide complements the sequence of the DNA 
molecule in a micro-well and has been incorporated, hydrogen ions will be 
released. The release of hydrogen ions makes a change in pH in the solution that 
can be detected by the ion sensor (Figure 1.10). But if there are two identical 
bases on the DNA strand, the voltage will be doubled, and the chip will record 
two identical bases being called. If a nucleotide does not match in a well, no 
voltage change is recorded and no base will be called. After, standard file formats 
for the analysis are produced.  
  
 
 
Figure 1.10: Ion Torrent library preparation and sequencing 
principle in a single well in a sequencing chip. The dNTP is incorporated 
complementary to the nucleotide to start a reaction that leads to the base 
calling. Permission from Springer Nature. 
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1.9.1.2           Base Calling and Map reading 
 
The binary alignment mapping (BAM) containing raw reads can be generated 
after sequencing. Base calling and mapping of the raw reads with the hg19 
reference sequence can be carried out on Ion Torrent Suite™ Software 5.2.  The 
beginning steps of the Torrent Suite™ Software 5.2 analysis pipeline are 
described in Figure 1:11.  
 
 
 
Figure 1.11: The Torrent Mapping Alignment Program (TMAP). It is a 
sequence alignment software program optimized specifically for Ion Torrent™ 
data. TMAP contains several mapping algorithms and is recommended for the 
Ion Torrent suite software 5.10. Taken from http://129.130.90.13/ion-
docs/GUID-D13D3B43-FB55-43FD-ADE0-5EC4170FB49C.html Permission 
from Thermo Fisher Scientific 
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1.9.1.3  Steps involved in the Ion Torrent sequencing 
 
Ion Torrent sequencing requires the following steps (Figure 1.11) 
 The sequencing instrument generates Data (DAT) files of electrical signals' 
raw traces. 
 The signal-processing step converts the raw traces into a single number per 
flow per well. 
 The BaseCaller converts the file information of each well into a sequence of 
bases and writes the sequence into an unaligned BAM file. 
 The BAM file is passed to TMAP for alignment.  
 
The signal-processing steps also mark several types of low-quality reads. These 
include polyclonal reads which are reads with two template beads instead of one, 
reads with high signal processing residual indicating an ambiguous signal value 
and reads that do not contain a valid library. The BaseCaller module also 
performs read filtering and read trimming. 
 
1.9.2        Variant Calling and Annotation 
 
Ion Reporter™ Software 5.4 is used to annotate variants. The software includes 
a set of bioinformatics tools for the data analysis, annotation, and translating of 
sequencing data. Specialized custom analysis and workflow plug-ins are applied 
for complex sequencing results. To achieve confidence in the NGS sequencing 
data, certain criteria are looked for in the data (Table 1.5). The American 
College of Medical. Genetics and Genomics and the US Centers for Disease 
Control and Prevention proposed guidelines for NGS studies and bioinformatics 
pipelines to produce quality genomic studies. These guidelines address test 
validation, quality control, proficiency testing, and reference materials. Quality 
metrics such as QUAL scores, depth, coverage uniformity, mapping quality, and 
GC bias should be considered in an NGS study (Chakravorty et al 2017). 
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A comprehensive annotation of coding and noncoding regions and accurate 
variant classifications are  crucial in NGS studies. When genome annotation 
pipelines have classified variants that are discovered in sequencing, it is 
necessary to understand each variant identified based on their functions. In 
addition, variants in other structural domains of genes can also be important for 
gene function and have regulatory roles in expression. 
             
    Table 1.5: Benchmarks used to evaluate sequencing quality in tNGS.   
Indicator  Description  
Number of mapped 
reads  
Total number of reads mapped 
to the reference.  
Number of reads on 
target  
Total number of reads mapped 
to any targeted region of the 
reference.  
Target base coverage  A base that is covered by 
multiple target regions counted 
once per sequencing read.  
Bases in target regions  The total number of bases in all 
specified target regions of the 
reference.  
Percent of reads on 
target  
The percentage of reads 
mapped to any targeted region 
relative to all reads mapped to 
the reference.  
Total aligned base 
reads  
The total number of bases 
covered by reads aligned to the 
reference.  
Total base reads on 
target  
The total number of target 
bases covered by any number 
of aligned reads.  
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Indicator  Description  
Average base 
coverage depth  
The average number of reads 
of all targeted reference bases.  
Uniformity of base 
coverage  
The percentage of bases in all 
targeted regions covered by at 
least 0.2x the average base 
coverage depth.  
Average base read 
depth  
The average number of reads 
of all targeted reference bases 
that were read at least one time.  
Number of amplicons  The number of amplicons 
specified in the target regions 
file.  
Uniformity of 
amplicon coverage  
The percentage of bases in all 
targeted regions covered by at 
least 0.2x the average base read 
depth.  
Amplicons with no 
strand bias  
The percentage of all amplicons 
that did not show a bias towards 
forward or reverse strand read 
alignments.  
Amplicons reading 
end-to-end  
The percentage of all 
amplicons that were considered 
to have a sufficient proportion 
of assigned reads (70%) that 
covered the whole amplicon 
target from end-to-end.  
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 Table 1.6: Types of variants according to the functional annotation. 
Annotation Description 
Frameshift 
insertion 
A insertion of one or more 
nucleotides that causes a 
frameshift in protein coding 
sequence. 
Frameshift 
deletion 
A deletion of one or more 
nucleotides that causes a 
frameshift in protein coding 
sequence. 
Frameshift 
block 
substitution 
A block substitution of one or 
more nucleotides that causes a 
frameshift in protein coding 
sequence 
Stopgain A nonsynonymous SNV, 
frameshift insertion/deletion, 
nonframeshift 
insertion/deletion or block 
substitution that leads to the 
immediate creation of a stop 
codon at the variant site. For 
frameshift mutations, the 
creation of stop codon 
downstream of the variant will 
not be counted as a stop gain. 
Stoploss A nonsynonymous SNV, 
frameshift insertion/deletion, 
nonframeshift 
insertion/deletion or block 
substitution that leads to the 
immediate elimination of a 
stop codon at the variant site 
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  Source: http://annovar.openbioinformatics.org/en/latest/user-guide/gene/ 
 
 
 
 
 
 
 
Nonframeshift insertion A insertion of 3 or multiples of 
3 nucleotides that do not cause 
frameshift in protein coding 
sequence 
Nonframeshift deletion A deletion of 3 or multiples of 
3 nucleotides that do not cause 
frameshift in protein coding 
sequence 
Nonframeshift block 
substitution 
A block substitution of one or 
more nucleotides that do not 
cause frameshift in protein 
coding sequence 
Nonsynonymous SNV A single nucleotide change 
that cause an amino acid 
change 
Synonymous SNV A single nucleotide change 
that does not cause an amino 
acid change 
Unknown Unknown function (due to 
various errors in the gene 
structure definition in the 
database file) 
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1.9.3   In silico pathogenicity tools 
The impact of variants identified in a genetic study can be determined by 
computational approaches, or in silico testing. The purpose is to predict and 
possibly interpret functionally, the roles of a variant in a disease pathology. It is 
essential to understand how a gene that harbours a particular variant is relevant 
to a particular disease. Various in silico tools using different implementations 
and combinations of features have now been developed (Appendix III). These 
in silico tools are generally based on: The analyses of sequence conservation at 
the position of a missense substitution, which is measured from a protein 
multiple sequence alignment. The severity of a missense substitution with 
respect to the observed range of variation at its position in an alignment, and 
structural features of the wild-type and variant proteins are determined (Bryony 
et al 2013). 
 
Widely used in silico tools for annotations of variants.  
 SIFT (Sorting Intolerant From Tolerant): is an algorithm which predicts 
whether an amino acid substitution will affect protein function based on 
sequence homology and the physical properties of amino acids.  A SIFT score 
of less than 0.05 is predicted to be deleterious. A substitution with a score greater 
than or equal to 0.05 is predicted to be tolerated (www.sift.jcvi.org/). 
 PolyPhen2: is a tool that predicts possible impact of an amino acid 
substitution on the structure and function of a human protein using physical and 
comparative considerations.  Structural features such as amino acid atomic 
contacts and solvent accessibility are also assessed and empirically determined 
cut-offs used to predict if the substitution is probably damaging, possibly 
damaging or ‘benign’ (www.genetics.bwh.harvard.edu/pph2/). 
 Grantham score: is a prediction of the effect of substitutions between amino 
acids based on chemical properties, including polarity and molecular volume, 
characterised into classes of increasing chemical dissimilarity: conservative (0-
50), moderately conservative (51-100), moderately radical (101-150), or radical 
(≥151). 
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 Combined Annotation Dependent Depletion (CADD): is a tool for scoring 
the deleteriousness of single nucleotide variants as well as insertion/deletion 
variants in the human genome. CADD can quantitatively prioritize functional, 
deleterious, and disease causal variants across a wide range of functional 
categories, effect sizes and genetic architectures and can be used to prioritize 
causal variation in both research and clinical settings. C-scores strongly correlate 
with allelic diversity, pathogenicity of both coding and non-coding variants, and 
experimentally measured regulatory effects, and also highly rank causal variants 
within individual genome sequence (www.cadd.gs.washington.edu/). 
 LRT score: The likelihood ratio test (LRT) is a statistical test of the goodness-
of-fit between two models. A relatively more complex model is compared to a 
simpler model to see if it fits a particular dataset significantly better. If so, the 
additional parameters of the more complex model are often used in subsequent 
analyses. The LRT is only valid if used to compare hierarchically nested models 
(www.evomics.org/resources/likelihood-ratio-test/). 
 MutationTaster score: is a web-based application to evaluate DNA sequence 
variants for their disease-causing potential. The software performs a battery of 
in silico tests including amino acid substitutions, conservation of amino acid, 
loss of function, effects on slicing and other regulatory region, to estimate the 
impact of the variant on the gene product/protein. Tests are performed on both, 
protein and DNA level (www.mutationtaster.org/).  
MutationAssessor: predicts the functional impact of amino-acid substitutions in 
proteins. The functional impact is assessed based on evolutionary conservation 
of the affected amino acid in protein homologs. The method has been validated 
on a large set (60k) of disease associated Online Mendelian Inheritance in Man 
(OMIM) and polymorphic variants (www.mutationassessor.org). 
 FATHMM score: is capable of predicting the functional effects of protein 
missense mutations by combining sequence conservation within hidden Markov 
models representing the alignment of homologous sequences and conserved 
protein domains, with "pathogenicity weights" representing the overall tolerance 
of the protein/domain to mutations (www.fathmm.biocompute.org.uk/).  
 
Stellenbosch University  https://scholar.sun.ac.za
                                                                                                                                    
53 
 
1.9.4   High Resolution Melt (HRM) Test 
 
High Resolution Melting (HRM) can be used to screen for genetic variants. 
HRM is a cost effective, simple and fast method for DNA analysis. HRM 
analysis is based on DNA melting (dissociation) that is observed at the 
denaturing stage of a PCR. HRM can detect small sequence variations just by 
direct melting of the DNA double strands. HRM is a post-PCR method. The 
region of interest within the DNA sequence is first amplified using PCR and 
specific oligonucleotides. An intercalating dye (SYTO9) is added to the reaction 
and as the amplicons were being produced, the dye is incorporated. The dye 
fluoresces only in the presence of double-stranded DNA. 
The amplicons can be heated from 50°C to 95°C applying holds at a time-
interval. When the temperature is increasing, at a certain melting temperature the 
sample DNA will start to denature, leading to a separation of the DNA strands 
to a double stranded DNA. The melting temperature depends on the sequence 
context of the DNA fragments. If a DNA fragment is rich in high GC content, it 
will melt at higher temperature than a DNA fragment rich in high AT content.  
At a point where the DNA fragment has been separated into a double strand, 
fluorescence is released, and it is plotted showing the level of fluorescence vs 
the temperature, generating a melting curve. This HRM melting curve can show 
the differences, even if a single base is changed in the DNA sample sequence. 
The melting curves generated after HRM analysis are plotted with fluorescence 
on the Y axis and temperature on the X axis (Figure 1.12 and Figure 1.13). 
The limitation of HRM analysis is that it will not determine the sequence change 
present in the DNA fragment. It merely indicates that the DNA sequence is likely 
to be different with different melting profiles. Sanger sequencing is required to 
confirm that and to identify the sequence change responsible for the difference 
in melting profiles. 
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Figure 1.12: Example of a HRM standardized graph. The temperature 
usually is set at a range of 55–95oC. There is a correlation between the 
fluorescence and temperature, allowing identification of variation 
between different wild type samples and mutant samples respectively. 
Taken from (Serban et al 2014). Permission by BMJ Publishing Group 
Ltd. 
 
 
 
 
Figure 1.13: Example of a HRM difference graph. This graph is used 
when a particular genotype is identified and used as a reference/baseline 
for the other DNA samples. The position of each sample relative to the 
reference is plotted against the temperature thereby showing differences 
between various samples. Taken from (Serban et al 2014). Permission by 
BMJ Publishing Group Ltd. 
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1.9.5  Detection of Copy number Variations (CNVs) 
1.9.51   Mechanisms CNVs 
 
Changes in the structure of chromosomes occur by two general mechanisms, 
homologous recombination (HR) and nonhomologous recombination. HR is 
used in repair of DNA breaks and gaps. There will be no change in structure if a 
damaged sequence is repaired using homologous sequence in the same 
chromosomal position in the sister chromosome or homologue, but repair might 
utilize homologous sequences in different chromosomal positions. This is called 
non-allelic and could change the structure of the chromosome. The correct 
choice of recombination partner prevents chromosomal structural change. 
 
Non-allelic homologous recombination (NAHR) occurs if a recombination 
repair event utilizies a direct repeat as homology, resulting to products that are 
reciprocally duplicated and deleted for sequence between the repeats. These 
might segregate from each other at the next cell division, thus changing the copy 
number in both daughter cells (Hastings et al., 2009), (Figure 1.14). 
 
The best studied mechanism of HR is double-strand break (DSB)-induced 
recombination. The HR-double-strand break repair mechanisms occurs at the 
break, where 5′ ends are resected to leave 3′ overhanging tails. These catalyze 
the invasion by one or both ends into homologous sequence forming a D-loop. 
The 3′ end then primes DNA synthesis that extends and past the position of the 
original break (Hastings et al., 2009). The second end is incorporated into the D-
loop by annealing, and is also extended. Following ligation, which forms a 
double Holliday junction, the junctions are resolved by endonuclease. The 
overall effect will be either a non-crossover or a crossover, depending upon 
whether the two junctions are resolved in the same or different orientations 
(Hastings et al., 2009), (Figure 1.14).  
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Similarly, the presence of microhomology at a site of nonhomologous 
recombination has been regarded as the signature of nonhomologous end joining 
(NHEJ). The NHEJ is like DSB, NHEJ rejoins DSB ends accurately or leads to 
small 1-4 bp deletions, and also in some cases to insertion of free DNA (Hastings 
et al 2009; La Cognata et al 2017). It is likely that NHEJ contributes to some 
chromosomal rearrangements by joining nonhomologous sequences. 
 
The Fork stalling and template switching (FoSTeS) mechanism is proposed to 
occur in cells under stress. A free single-stranded lagging template might acquire 
secondary structures, which could block the progress of the replicating fork. The 
3′ ends then become free from their templates and might then align to other free 
single-stranded-template sequence on another replicating fork that shares 
microhomology, resulting to rearrangement such as duplication, deletion, 
inversion or translocation depending on the position of the other replicating fork 
(Hastings et al 2009; La Cognata et al 2017). Fork stalling can be caused by other 
situations, such as lesions in the template strand or shortage of deoxynucleotide 
triphosphates (Hastings et al 2009; La Cognata et al 2017), (Figure 1.14). 
 
 
 
Figure 1.14: Schematic illustration of the three most common events 
causing genomic rearrangements. A. NAHR generates CNVs when genomic 
segments with high sequence similarity (direct low-copy repeats sequences, 
green arrows) recombine. This recombination can generate a duplication of the 
similar locus (red arrow) on one chromosome, while removing the copy from the 
other.  
Stellenbosch University  https://scholar.sun.ac.za
                                                                                                                                    
57 
 
B. Double stranded breaks (DBS) in DNA sequence recruit NHEJ-associated 
proteins to repair and ligate DNA strands together. First, end-repair protein 
replaces lost nucleotides on the double-strand break and DNA ligase associates 
broken DNA fragments together. If fragments from different chromosomes 
ligate together, duplications or deletions of sequence can occur. C. After the 
original stalling of the replication fork (black line), the lagging strand disengages 
and anneals to a second fork (blue line), followed by extension of the now 
‘primed’ second fork and DNA synthesis. After the fork disengages, the tethered 
original fork with its lagging strand (black and blue lines) could invade a third 
fork (green line). Serial replication fork disengaging and lagging strand invasion 
could occur several times (e.g., FoSTeS × 2, FoSTeS × 3, etc.) before resumption 
of replication on the original template. It should be noted that the CNVs created 
through FoSTeS are difficult to be distinguished from those generated by 
microhomology- mediated breakpoint-induced repair (MMBIR), a mechanism 
of end-joining that relies on small-scale homology of DNA sequence at the ends 
of DSBs. Taken from (La Cognata et al 2017) licenced under creative common 
(http://creativecommons.org/licenses/by/4.0/) 
 
Mainly, these mechanisms contribute to the deletions and duplications of 
chromosomal segments and could affect about 12% of human genome leading 
to changes in the levels of expression of genes, a redundancy in sequence, so that 
some copies are free to evolve new or modified functions or patterns of 
expression, while other copies maintain the original function.  
This likelihood allow reassorting of exons between different genes by 
translocation, insertion or deletion, so that proteins might acquire new domains, 
and hence new or modified activities  (Frith and Khan, 2018; La Cognata et al., 
2017). 
  
1.9.5.2 Multiplex Ligation-Dependent Probe Amplification (MLPA) 
MLPA is a multiplex PCR method, it is simple and robust and can be used for 
identifying chromosomal DNA copy number changes in many targets. MLPA 
requires a thermocycler and capillary electrophoresis apparatus. MLPA 
experiment can simultaneously be carried out in about 96 samples and provide 
the results within 24 hours. 
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Amplification of a probe is dependent on a ligation process, which can only 
occur if target sequence is present in the DNA sample. Two adjacent probes are 
designed that contain forward and reverse primer sequence respectively for a 
short sequence of target DNA (Figure 1:15). In addition, one of the two probes 
contain a stuffer sequence the length of which can be varied. The probes are 
hybridized to the target DNA and subsequently ligated. Only if ligation occurred, 
a functional PCR product is produced, so that amplification only happens if 
target sequence is present in the DNA sample. The amount of PCR product is 
proportional to the amount of target sequence present in the sample, making the 
technique suitable for quantitative measurements. 
 
The importation and pre-processing of MLPA raw data utilizes an automated 
workflow suitable for genetic profile analysis, that begin with raw sequencer 
chromatogram files or pre-processed peak tables. The multiple probe mixes can 
then be combined for each probe mix, the MLPA setup can be entered initially 
in the software including the dye setup, this strategy for automated name and 
information parsing, and selection of the size standard used. Peaks on the 
samples are assigned automatically to known probes based upon the size 
information provided in the probe mix definitions (Applied Biosystems and 
Beckman MLPA manual). 
 
The MLPA (PO51 and PO52) kit detects CNVs in PD genes 
(https://www.mlpa.com). It consists of two different kits, each with a separate 
probe mix. These probe mixes contain oligonucleotides for ligation to the exons 
of genes known to cause PD, as well as reference probes. The SALSA MLPA 
P051 (MRC Holland, Netherlands) is designed to amplify exons of SNCA, 
LRRK2, PRKN, PINK1, PARK7 and ATP13A2. SALSA MLPA P052 (MRC 
Holland, Netherlands) amplifies exons of PRKN, UCHL1, GCH1, CAV1 and 
LRRK2. The genes included on the SALSA MLPA P051 kit are genes with 
previously reported CNVs in PD patients.  
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The raw data are analysed using the Coffalyser.Net software, version 131211 
(http://coffalyser.software.informer.com/download/). The fragment analysis and 
comparative analysis can be done using the Coffalyser software. The software 
displays peak signals and size markers for the electropherogram analyses to be 
differentiated (Figure 1:15). Raw data files (ABI files, .fsa format) are exported 
in Coffalyser where analyses can be done, the process requires some 
standardization methods as described in the Coffalyser manual. 
 
The analysis results have different ranges of values that can be interpreted as 
heterozygous or homozygous deletions or duplications.  MLPA peak detection 
can vary in height. The following guidelines are used for the interpretation of 
results: 
 
 Peak height values between 0.7 and 1.3 are considered to represent results of 
samples without a deletion or exonic rearrangements 
 Values between 0.3 and 0.6 indicate a heterozygous deletion 
 Values between 1.4 and 1.6 indicate a heterozygous duplication 
 Values higher than or equal to 1.7 indicate a triplication 
 Absence of a peak indicates either a possible point mutation at that probe 
recognition site or a homozygous deletion (ratio 0.0). 
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Figure: 1:15: Description of the MLPA processes showing 
hybridization of probes and capillary electrophoresis signal 
peaks. Permission from Applied Maths NV, a bioMérieux 
company Sint-Martens-Latem, Belgium. 
https://download.appliedmaths.com/sites/default/files/img/lpa1.j
pg 
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1.10         Study Rationale 
The challenges of a genetic PD study in SSA are enormous. Many SSA PD 
patients do not have access to quality health services. The majority are thought 
to be undiagnosed and untreated, leading to poor health outcomes. Increasing 
interests to study the genetics and epidemiology of PD in SSA are advancing and 
increasing the rates of correct diagnosis. The number of people with PD are set 
to increase in the SSA. The contributions of genetics to the study of PD in SSA 
could enhance our understanding of the disease mechanisms. Hence, in this 
study, a number of different techniques were used, including NGS, MLPA and 
HRM. The principles of these techniques used in the present study were 
discussed in section 1.9.  
 
1.10.1          Diversity of SSA population 
The DNA in the human genome are constantly changing and this process allows 
humans to evolve and adapt. The little changes that occur in the genome of an 
individual contribute largely to the observable phenotypes and may have an 
impact on disease pathogenesis or responses to treatments. It has been 
established that mankind evolved from Africa thousands of years ago, and as the 
earth changed, people began to migrate to all directions. Studies have shown that 
African ancestry populations are greatly admixed (Figure 1.16). Many factors 
contributed to this genetic diversity in Africa, which includes migrations, 
intermarriages, and a genetic bottleneck that has occurred in some environments 
in the past. African populations have the greatest genomic diversity in the world, 
and this diversity has important ramifications for genomic research (Rotimi et al 
2007). Even among the African populations, the haplotype blocks differ. The 
functional effects of a genetic variant could have major consequences relating to 
the pharmacogenomics studies of treatments. The causes of drug treatment 
idiosyncrasy in people have been the central focus of the pharmacogenomics 
studies that depend mostly on the understanding of genetics of individuals.  
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The observed genetic diversities in Africans warrant further investigations. This 
is necessary and could potentially explain PD mechanisms in them. Furthermore, 
the implications of the genetic diversity might lead to the development of 
specific medications that will be suitable for a particular group of people.  
 
 
 
Figure 1.16: Haplotype differences across different ethnicities in  a 1000 
Genomes Project. African populations have a highest level of haplotype blocks 
compared to other populations. Taken from Rotimi et al 2018. Permission from 
Oxford University Press. 
 
Nearly all diseases have ethnic variations in occurrence. It can be said that racial 
groups are constantly undergoing evolutionary change. Polymorphic genetic 
markers may be linked to certain groups of people, depending also on geographic 
locations. Genetic variations such as single nucleotide polymorphisms (SNPs), 
CNVs, multiple nucleotide variations (MNVs), INDELs, RNA splice site 
mutations and large genomic rearrangements are often studied as genetic causes 
of a disease.  
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These genetic factors are inheritable and could affect the functionality of a gene. 
To understand the genetics of PD in SSA, especially in admixed populations of 
Black origin, the aforementioned genetic markers should be considered. 
Common variants discovered in PD so far are mostly single nucleotide variations 
(SNVs), small deletions (less than 20 bp), CNVs and MNVs. Rarely had PD 
been associated with any form of chromosome defects in patients.   
The mutations in PD-causing genes have been predominantly identified and 
studied in European, North American, North African and Asian populations. 
Most of these mutations identified in PD and were replicated are considered for 
genetic testing in a clinical setting. It is possible that the information from other 
populations may not be transferable to the SSA populations. 
 
1.10.2 Limited genetic studies on Black South African and Nigerian 
patients with PD 
Little is known about the genetics of Black South African and Nigerian PD 
patients. There are several challenges with genetic studies of PD in SSA. These 
include relatively small sample sizes, partly because PD patients are reluctant to 
go to the neurological clinic to aid their diagnoses and treatments. They try to 
avoid stigmatization because people still believe that PD is a mysterious disease 
created by some divination. The lack of genetic studies is also due to lack of 
funding and resources for genetic studies in SSA countries.  
In SSA, little is known about the genetics of PD. One study screened for 
pathogenic mutations in LRRK2 in Ghanaian PD patients (Cilia et al 2012) and 
found no mutations, similarly, another study looked at PRKN mutations in 
Zambian PD patients (Yonova-Doing et al 2012), and found exon 2 and 4 
deletions; and another study that screened for PINK1 mutations in a Sudanese 
PD family (Cazeneuve et al 2009) found a homozygous variant in PINK1 gene 
that segregated with PD in the family. 
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The previous genetic studies in South African and Nigerian PD patients (Table 
1.7) suggested that the genetic causes of PD in SSA might be unique. Although, 
sporadic and familial cases of PD exist in both in South Africa and Nigeria, more 
studies are needed to investigate the interplay of genetics and the environmental 
factors in PD in both countries. The projection that there will be an increase in 
the prevalence of this disorder worldwide, including SSA countries, means that 
comprehensive genetic studies are urgently needed.  
. The first study described the results of 57 Nigerian PD patients screened for 
pathogenic mutations in the known PD genes (Okubadejo et al., 2008).  
 The second study utilized Human Genome Diversity Cell Line Panel for 
screening coding variants in the EIF4G1 gene in Nigerian controls (Cann et al., 
2002; Tucci et al., 2012).  
 
Pathogenic mutations were found in three Black South African PD patients, all 
with mutations in the PRKN gene (Blanckenberg et al., 2013). However, 
mutations in the SNCA, LRRK2, VPS35, EIF4G1 or CHCHD2, leading to PD 
with an autosomal dominant inheritance or in PINK1, PARK7, or ATP13A2, 
associated with PD with autosomal recessive inheritance were not identified. 
 
Similarly, some other genes like those that control the functions of the brain are 
yet to be associated with causative PD mutations in the Black South African or 
Nigerian patients. It is likely that some of the genes that have not been studied 
have important roles in PD.  
 
Consequently, this project was intended to identify novel disease-causing genes 
and novel disease-causing mutations in the PD genes in the South African and 
Nigerian PD patients. By collaborating with expert neurologists in Nigeria and 
South Africa, well characterized PD patients were identified and recruited for a 
comprehensive genetic study. High-throughput NGS techniques were 
considered as the best tools for sequencing. 
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Table 1.7: A summary of genetic studies in Black South Africans and Nigerians PD patients. 
Autosomal 
dominant 
genes 
Country No.of  
Patient
s 
Screened 
(Methods) 
Result Reference 
LRRK2 Nigeria 57 Exons 31 and 41   No mutation (Okubadejo et 
al., 2008a) 
 SNCA South 
Africa 
12 
 
All 6 exons +A30P 
mutation (Exon 
dosage-MLPA) 
No mutation (Keyser et al., 
2010a) 
VPS35 South 
Africa  
18 D620N mutation 
(CASP assay) 
No mutation (Blanckenberg 
et al., 2014a) 
EIF4G1 South 
Africa  
Nigeria 
18 
26 
R1205H mutation 
(CASP assay) 
Exons 8 and 22 
qRT-PCR 
No mutation 
No mutation 
(Blanckenberg  
et al., 2014a) 
(Tucci et al.,  
2012b) 
 
 
 
 
Autosomal 
recessive 
genes 
 
Country No.of  
Patient
s 
Screened 
(Methods) 
Result Reference 
DJ-1 South 
Africa 
12 Exons 1,3,5&7   
(Exon dosage-
MLPA) 
No mutation (Keyser et al., 
2010a) 
 
 
PRKN 
 
 
Nigeria
  
 
 
   
 57 
 
 
All 12 exons 
 
 
No mutation 
 
(Okubadejo et 
al., 2008a) 
PRKN South 
Africa 
17 All 12 exons (SSCP 
and HRM) 
Duplication 
and deletion 
of exon 2 
and exon 9, 
respectively 
in two 
affected 
siblings.  
(Bardien et al., 
2009) 
 
 
(Haylett et al., 
2012a) 
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Heterozygou
s G430D  
mutaton and 
deleten of 
exon 4 in 
another 
probad 
PRKN South 
Africa 
21 All 12 exons 
MLPA assay and 
qRT-PCR  
A single 
heterozygous 
exon 4 
deletion in 
PRKN found 
in one 
proband 
(van der 
Merwe et al., 
2016) 
PINK 1 South 
Afica 
12 All 8 exons (Exon 
dosage-MLPA) 
No mutation (Keyser et al., 
2010a) 
PINK 1 South 
Afica 
18 All 8 exons (Exon 
dosage-MLPA) 
No mutation (Keyser et al., 
2010b) 
 
HRM, high resolution melt; MLPA, multiplex ligation-dependent probe amplification. SSCP, 
single-strand conformation polymorphism, KASP assay, Competitive Allele Specific PCR.  
qRT-PCR, quantitative reverse transcriptase PCR. Table 1.7 was modified from Blanckenberg et al., 2013 with permission. 
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1.11   Goal of the present study 
This study hypothesized that by using targeted NGS sequencing strategies to 
screen Black South African and Nigerian PD patients, novel pathogenic 
mutations in genes could be identified.  
The significance of the study is that identifying novel pathogenic mutations in 
genes in these patients will improve our understanding of PD pathobiology 
specifically on how the mutations in genes affect the SSA PD patients. 
1.12      Aims and Objectives 
The present study aimed to identify new mutations in known genes and 
putative deleterious variants in other non-PD genes in the Black South African 
and Nigerian PD patients 
Hence, this study had the following objectives: 
 Perform a literature search and compile a review of all studies on PD in 
Nigeria 
 Recruit Black South African and Nigerian PD patients and controls over a 
three year period for genetic studies 
 Record relevant demographic, clinical and genetic data of PD patients in a 
REDCap database 
 Screen for exonic rearrangements in candidate genes using MLPA 
 Set up and optimise Ion Ampliseq targeted resequencing panel for mutation 
screening of the patients 
 Screen for sequence changes in Black South African and Nigerian PD 
patients using a panel of 751 genes  
 Validate selected novel variants predicted to be deleterious using Sanger 
sequencing techniques 
 Screen for selected novel variants predicted to be deleterious frequency 
using High resolution melt assay 
 Protein structures and modelling for functional prediction of selected novel 
variants predicted to be deleterious 
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 Figure 1.17: An overview of the study framework.   
A total of 33 Black South African and 42 Nigerian PD patients 
were recruited over a two–year period at the Obafemi Awolowo 
University Ile-Ife and Tygerberg Academic Hospital, Cape Town, 
South Africa. Extractions of the genomic DNA were carried out 
in the Division of Molecular Biology and Human Genetics at 
Stellenbosch University. Copy number variation assays (samples 
from 15 South African and 42 Nigerian patients) and the tNGS 
(samples from 33 South African and 14 Nigerian patients) were 
performed at the Central Analytical Facilities, Stellenbosch 
University. Data analysis and further studies were also 
performed at the Division of Molecular Biology and Human 
Genetics at Stellenbosch University 
 
             
 
 
Recruitment of study 
participants in South Africa 
and Nigeria 
  
DNA extraction and storage.   
Concentrations & quality 
check 
 
Library 
preparations and 
Multiplexing PCR 
Targeted next generation 
sequencing (tNGS) on 
personal genome machine 
 
 tNGS variant annotations and 
analysis 
 MLPA copy number variations 
analysis 
Exonic 
rearrangements in 
candidate genes 
using MLPA 
 
 Verification of variants in PD 
genes using Sanger sequencing 
technique. 
 Screening for the frequencies of 
the variant in the Black controls 
samples using HRM. 
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CHAPTER TWO 
 
PARKINSON’S DISEASE IN NIGERIA: A REVIEW OF PUBLISHED 
STUDIES AND RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 
The following chapter consists a review manuscript submitted to the 
Parkinsonism and Related Disorder Journal, and it is currently under 
considerations for publication.  
 
My contributions to this chapter were: 
 I conceptualised the idea to write a review article on the previous studies on PD 
in Nigeria to highlight the important findings from the previous studies on PD in 
the most populated country in Africa, currently understudied for PD. The review 
also highlighted the challenges of studying PD in Nigeria, which has important 
implications for the present study.   
 I did the literature search of related published articles and retrieved the 
information used for this review  
 I prepared the tables and figures  
 I drafted the manuscript. 
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2.1                                                    Abstract 
 
Parkinson’s disease (PD) affects 1-2% of individuals above 60 years amounting 
to over 7 million people worldwide. Thus, PD has become an important 
contributor to the neurological disease burden. Nigeria is the most populous 
country in Africa, and alarmingly, approximately 9.1 million Nigerians are 
above 60 years and are therefore at risk for developing PD.  We carried out a 
critical review of published literature on PD in Nigeria to summarize the findings 
and to evaluate gaps in knowledge. Seven electronic databases were searched for 
studies published in English before 18th July 2018. Search terms were 
[“Parkinson’s disease” OR “Parkinson disease” OR “parkinsonian disorders” 
OR “Parkinsonism”] AND “Nigeria”. A total of 44 articles (including eight 
reviews) published since 1969 were identified and reviewed. Amongst the 
original research articles, most (23) were on PD symptoms or prevalence. There 
were only two studies on genetics and two on environmental factors. The 
estimated crude prevalence of PD in Nigeria was lower (10 to 249/100 000) 
compared to studies published in Europe (65.6 to 12 500/100 000). Our findings 
suggest that PD is under-diagnosed in Nigeria. Possible environmental risk 
factors identified include blacksmithing and well-water contaminated with trace 
metals. Given the rising numbers of the ageing population in Nigeria, more 
studies to evaluate the prevalence and causes of PD in this country are urgently 
needed. To this end, more funding, resources and a workforce of well-trained 
neurologists and scientists are essential to manage the impending health burden 
of PD and related disorders in this country.   
 
Keywords: Parkinson’s disease; Parkinsonism; Nigeria; prevalence; 
symptoms; risk factors 
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2.2                                          Introduction 
 
Worldwide, approximately 2% of people above the age of 60 and 4% above the 
age of 80 years are affected with Parkinson disease (PD) (de Lau and Breteler, 
2006b) but the prevalence varies widely according to geographic region. In Sub-
Saharan Africa (SSA), the prevalence of this condition differs depending on the 
study cited and ranges from 10 to 235/100 000 in urban populations, (Lekoubou 
et al., 2014a) compared to the crude prevalence in Europe which ranges from 
65.6/100 000 to 12 500/100 000 (von Campenhausen et al., 2005b). Although 
studies conducted in rural areas in SSA are limited, a door-to-door study in rural 
Tanzania found a crude prevalence rate of 20/ 100 000, and notably, 78% of the 
patients were previously undiagnosed (Dotchin et al., 2008b). Based on findings 
from a systematic review, the prevalence of PD varied from 0.4 to 0.7% of 
neurological admissions/consultations in hospital-based studies in seven SSA 
countries (Lekoubou et al., 2014a). Over the past 26 years, the burden of 
neurological disorders including PD has increased substantially, making PD one 
of the leading causes of disability and mortality worldwide (Dorsey et al., 2018). 
To improve health-care planning and health outcomes of people with PD in 
Nigeria, we must understand not only the number and distribution of people with 
PD but also how these disorders affect population health. 
 
There is a common misconception that there are few aged individuals (defined 
here as people aged 60 years and over) in SSA. However, it should be noted that 
the small increase in the proportion of the aged individuals in SSA masks a large 
increase in the actual number i.e. the number of people aged 60 and over is 
predicted to almost double from over 34 million in 2005 to over 67 million in 
2030 (Council, 2006; Victoria et al., 2006). Notably, the number of people aged 
60 years is currently rising more rapidly in this region than in developed 
countries and this trend is set to continue in the future (Velkoff and Kowal, 
2007). 
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Consequently, the number of PD cases is expected to increase significantly 
especially in the most populous SSA countries such as Nigeria, Ethiopia, 
Democratic Republic of Congo, Tanzania, South Africa and Kenya (World 
population review, 2018). Nigeria, the seventh most populous country in the 
world, with an estimated 182 million people in 2015 (Chapin, 1991.), is a multi-
ethnic country inhabited by over 500 ethnic groups (Supplementary Figure 
2.1). It has a history of slave trade, inter-border trading, intermarriage and cross-
border migrations from neighboring countries making Nigerians a 
heterogeneous group of people (Chapin, 1991). In 2005, Nigeria was ranked 
among the top 30 countries internationally on the basis of its population aged 60 
years and older (Victoria et al., 2006). According to data from the World Bank, 
approximately 2,75% of Nigerians, corresponding to 5.25 million people, are ≥ 
65 years (World Bank, 2015) and these could potentially be considered to be at 
risk for developing late-onset PD. Also, increasing industrialization in Nigeria 
without a proper way of handling the effects of industrialization is currently 
contributing to the environmental degradation mostly caused by carbon emission 
and other toxicities (Theodore, 2006). The effects of these environmental 
hazards may be linked to the causes of sporadic forms of PD in Nigeria. 
 
If these predicted trends are realized, then the management and care of patients 
with PD in Nigeria need urgent attention. It has been noted that current problems 
to proper care of patients in low-resource settings include lack of access to 
sustainable, affordable drug treatment and medical supervision (Dotchin and 
Walker, 2012; Mokaya et al., 2016). Also, the need to raise awareness of PD 
within the general population and that PD is a condition and not part of general 
ageing has been highlighted. It has also been suggested that minimal consensus 
management guidelines for PD should be established to improve the consistency 
and quality of care to patients in SSA (Williams et al., 2018a). 
 
With this information as a backdrop, we summarized all published studies on PD 
in Nigeria, and provide recommendations for future studies. Our goal is to 
highlight not only the research that has been done but also the lack or paucity of 
studies on this impending health burden in Nigeria.  
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It should be noted however that the importance of the implications of this review 
is not limited to Nigeria but include all SSA countries.  
 
 
2.3.                                             Methods 
 
We searched seven electronic databases (PubMed, HubMed, BioMedSearch, 
Ovid, Web of Science®, Scopus and Google Scholar) for articles on PD in 
Nigeria published on or before 18th July 2018. Search terms were [“Parkinson’s 
disease” OR “Parkinson disease” OR “parkinsonian disorders” OR 
“Parkinsonism”] AND “Nigeria”. Articles selected to be potentially relevant 
were downloaded to a reference manager, Zotero (“Zotero | Your personal 
research assistant,” 2018). The full text of relevant articles was obtained, and the 
contents critically evaluated in this review. Exclusion criteria include studies that 
were not published in English and studies that were not done on Nigerian PD 
patients or controls. Also, we did not consider articles that did not undergo a 
formal peer-review process. 
 
 
2.4.                             Overview of retrieved articles 
A total of 3 496 items were identified in the seven databases searched, and of 
these 405 were selected for consideration. After duplicates, conference abstracts 
and non-human studies were removed, 46 articles were considered to be 
potentially relevant (Figure 2.1; Supplementary Table 2.1). The full texts of 
these articles were retrieved, read and evaluated for content resulting in 44 
articles being included in the review. For the two that were excluded; one was 
not on Nigerian PD patients, and the other was a letter to the editor of a journal. 
Among the 44 relevant articles, 10 studies investigated prevalence of PD in 
Nigeria, 13 reported on symptoms and signs  in Nigerian PD patients (one study 
reported on prevalence and on symptoms (Femi et al., 2012), two were genetic 
reports on PD in Nigerian individuals, two reported on environmental risks 
factors for PD in Nigeria, seven reported on other diseases mimicking the clinical 
features of PD, three studied biochemical or pathological findings and eight were 
review articles (Supplementary Figure 2.2).  
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Of the 44 articles, 40 (90.9%) articles had either a Nigerian as the first or the last 
author, and four articles had only non-Nigerian authors. Therefore, most of the 
studies published on PD in Nigeria were led by Nigerian investigators. 
 
 
2.5.                                   Prevalence of PD in Nigeria 
 
A total of 10 publications involved estimation of the number of PD patients in 
Nigeria (Table 2.1). Four different study designs were used and included five 
neurological hospital admissions studies, two neurological out-patient, one 
hospital-based and one community-based study (Schoenberg et al (Schoenberg 
et al., 1988) re-analyzed the same data set as Osuntokun et al (Osuntokun et al., 
1987), which was a community-based study, but included only the 3 412 
participants aged over 39 years). We calculated crude prevalence ratios of PD 
cases per 100 000 in each study and this ranged from 10 to 249 (Table 2.1). 
When compared with global PD prevalence per geographic location which 
ranged from 41 to 2 953 (Pringsheim et al., 2014b),  we found that PD prevalence 
is low in Nigeria.  
 
The five neurological hospital admission studies were carried out in four 
different locations in Nigeria, and ranged in size from 781 to 9 600 (Chapp-
Jumbo et al., 2004; Ekenze et al., 2010b; Osuntokun, 1971; Owolabi et al., 2010; 
Talabi, 2003). The number of PD cases in these studies varied from 0.4% to 
2.2%. The estimated crude prevalence of PD was from 32 to 165/100 000, with 
the lowest estimate from the Niger Delta area  (Chapp-Jumbo EN., 2004) and 
the highest from Enugu in South East Nigeria (Ekenze et al., 2010b). 
 
Two studies analyzed neurological out-patient populations, one in Lagos in 
Southwest Nigeria and the other in Kano in Northwest Nigeria (Femi et al., 2012; 
Okubadejo et al., 2010b). The number of PD patients among patients with 
neurological disorders varied between the two sites with the Kano study 
reporting an over four-fold greater number of PD patients (20/1 360 for Lagos 
vs 80/1 153 for Kano). The reason for this difference is not clear.   
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It is, however, plausible to speculate that exposure to environmental hazards 
such as herbicides and pesticides might be a possible reason for this difference. 
Similarly, we could not rule out hereditary PD as one of the reasons for the 
increased PD prevalence in the Kano study. Marriages among related individuals 
are more frequent in Northwest Nigeria than Southwest, and this might 
contribute to the increased frequency of Parkinson’s Disease. (Theodore, 2006). 
These two study sites are known to be the most populous places in Nigeria. In 
addition, Kano is situated in the Northwest Nigeria where blacksmithing and 
commercial farming are some of the major occupations of the people living in 
the rural and urban communities, whereas Lagos is more urbanized, and the 
majority of the people living there are not farmers or involved in blacksmithing.   
 
The hospital-based study investigated the prevalence of PD among all 8 026 
hospital admissions, 1 220 of which were neurological admissions (Dada, 1970), 
and identified 20 PD patients. The crude prevalence estimate from this study was 
249/100 000. 
 
The community-based study was a door-to-door survey using simple 
questionnaires and clinical evaluations of nearly 20 000 individuals. The study 
identified a total of 699 individuals with neurological conditions, but only two 
of them had PD (Osuntokun et al., 1987). The crude prevalence estimates for PD 
from this study was 10/100 000 (Osuntokun et al., 1987) without age-adjustment 
and 59/100 000 (Schoenberg et al., 1988) when considering only the older 
population.  
 
In summary, the estimated number of people with PD in Nigeria is low; the 
reason might be due to under-diagnosis or misdiagnosis of PD. There was 
evidence of regional variation in the prevalence of PD in Nigeria but the reasons 
for this are currently not known.  The variation may also be linked to the lack of 
expert neurologists in some areas in Nigeria that can correctly diagnose PD. 
Also, the lack of adequately informed and trained non-specialists in rural regions 
is a factor leading to under- and misdiagnosis of PD in SSA. Not all of the 
epidemiological studies reported on PD in Nigeria described the diagnostic 
criteria they used (Osuntokun et al., 1987).  
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It is noteworthy that there were five neurological hospital admissions studies, 
two neurological out-patient, one hospital-based and one community-based 
study reviewed in the present study, each with different limitations that could 
affect the overall estimates of PD prevalence. 
 
 
2.6                            Clinical profile of PD in Nigeria  
 
Our literature search identified a total of 13 studies cataloguing the symptoms 
and signs of Nigerian PD patients (Table 2.2). In addition, seven Nigerian 
studies (Adebayo et al., 2013; N.U. et al., 2011; Odeku and Adeloye, 1973; 
Osuntokun et al., 1972; Owolabi, 2013; Ugoya et al., 2011) reported patients 
with similar symptoms and signs of PD in other disorders including progressive 
supranuclear palsy (Owolabi, 2013), drug induced Parkinsonism (Ugoya et al., 
2011), typhoid fever (Osuntokun et al., 1972), Lewy body dementia (Adebayo 
et al., 2013), ischemic cerebrovascular disease (Osuntokun et al., 1969), cranial 
meningiomas (Odeku and Adeloye, 1973), and essential tremor (Osuntokun et 
al., 1987). It is important to note that PD symptoms vary widely from patient to 
patient. One of the Nigerian studies demonstrated clearly the difficulties in 
diagnosing PD patients stating that “none of the patients had received a definite 
diagnosis of PD prior to specialist consultation, instead the patient’s referral 
letter stated ‘neurological disorder’ or `neurological symptoms’ (Okubadejo et 
al., 2010). 
 
2.6.1 Preclinical symptoms of PD 
 
Preclinical symptoms of PD precede the onset of the characteristic motor 
features of PD, and include olfactory dysfunction, sleep disturbances, 
depression, anxiety, apathy and constipation (Table 2.2). Although, these 
conditions are not a definite indication to develop PD, cataloguing the presence 
of these preclinical symptoms in patients is helpful when actual PD is to be 
diagnosed. There were no published studies that described preclinical symptoms 
of PD in Nigeria. 
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2.6.2      Motor symptoms of PD 
 
Cardinal motor symptoms of PD are rigidity, resting tremor, gait abnormalities 
and bradykinesia, which have been reported extensively also in Nigerian PD 
patients (Table 2.2) (Femi et al., 2012). These signs are required for PD 
diagnosis. 
 
One Nigerian study reported that frequent falls with sustained injuries were 
about three times more common in PD patients than controls, and that the risk 
for falls increased with increasing age and disease severity (Farombi et al., 
2016).  
 
2.6.3  Non-motor symptoms of PD 
 
Non-motor symptoms (NMS), which include cognitive disorders, visual 
dysfunction related to object and face perception, autonomic impairment, and 
mood disorders, are seen very frequently in PD patients, and were also reported 
in many Nigerian PD patients (Akinyemi et al., 2008; Ojagbemi, 2013; 
Ojagbemi et al., 2013; Ojo et al., 2012; Okubadejo and Danesi, 2017; Okunoye, 
2015; Okunoye and Asekomeh, 2013; Owolabi et al., 2016, 2014) (Table 2). 
Neurobehavioral disorders can occur in PD patients at any stage of the disease, 
whereas psychotic symptoms occur more commonly during treatment with 
dopamine agonists. About 90% of PD patients will have at least one 
neuropsychiatric symptom during the course of the disease (Chaudhuri et al., 
2011). Neuropsychiatric symptoms such as depression, visual hallucinations, 
delusion, aggression and apathy have also been reported in Nigerian PD patients 
(Table 2.2) (Ojagbemi, 2013; Okunoye and Asekomeh, 2013).   
 
NMS greatly impact the quality of life of PD patients and their caregivers 
(Aarsland et al., 2009; Ojagbemi, 2013). In addition, NMS vary significantly 
from patient to patient.  For example, several Nigerian PD patients had 
respiratory impairments related to difficulties in breathing, while others had 
cardiovascular dysfunction or gastrointestinal disorders (Okubadejo and Danesi, 
2017; Owolabi et al., 2016, 2014).  
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In summary, psychiatric symptoms, gastrointestinal disorders and 
cardiovascular autonomic dysfunction were the most common NMS observed in 
Nigerian PD patients (Ojagbemi et al., 2013; Okubadejo and Danesi, 2017; 
Osuntokun and Bademosi, 1979; Owolabi et al., 2014).  
 
 
 2.7       Biochemical and pathological findings in Nigerian PD patients 
 
Findings from biochemical and pathological studies can provide clues to disease 
mechanisms. Only three biochemical or pathological studies were identified in 
our search. One study compared the melanized nigral neuronal count between 
neurologically normal Nigerians (n=23) and normal British (n=7) individuals as 
this has been postulated to have a link to PD (Muthane et al., 2006). The results 
of the study showed no significant differences in the number of melanized 
neurons between the two groups (Muthane et al., 2006).   Another group studied  
brains (n=94) of neurologically normal Nigerians and found Lewy bodies in four 
male individuals (Jendroska et al., 1994), suggesting that incidental Lewy body 
disease is at least as frequent in Nigeria as in industrialized nations. Furthermore, 
a study investigating the level of homocysteine in plasma samples of 40 Nigerian 
PD patients and 40 age- and sex-matched healthy controls identified increased 
levels of homocysteine in nine (22.5%) patients known to be on long-term 
regimen of levodopa (Ojo et al., 2011). This corroborates the hypothesis that 
homocysteine levels are significantly increased in levodopa-treated PD patients 
compared to controls. Also, elevated levels of homocysteine are an emerging 
risk factor for neurological disorders such as stroke, dementia and Alzheimer’s 
disease (Seshadri et al., 2002). It is possible that further studies on biochemical 
and pathological findings in Nigerian PD patients could provide unique insights 
into differences in disease mechanisms between Africans and non-Africans.  
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2.8                 Environmental risk factors for PD in Nigeria 
 
Regional variation in the incidence of a disease could suggest that there are 
environmental risk factors contributing to the disease and that long-term 
exposure to these agents may accelerate the disease process. For example, the 
use of pesticides that inhibit mitochondrial functions has been associated with 
PD in the United States (Tanner et al., 2011). Some early reports showed five 
times higher prevalence of PD in the USA than in Nigeria, and suggested that 
environmental risk factors could account for this difference in prevalence 
(Schoenberg et al., 1988). Furthermore, in Nigerian studies, prevalence of PD 
varied from one environment (region) to another (Table 2.1). Although these 
discrepancies may be due to methodological differences between the studies, it 
is worthwhile to investigate whether dietary and lifestyle factors such as 
neurotoxins in certain diets may account for regional variations in the prevalence 
of PD. One such example is the possible link identified in Guam and New 
Caledonia between an atypical Parkinsonism phenotype and Annonaceae’s 
consumption (Caparros-Lefebvre and Steele, 2005). 
 
Our literature search identified two studies carried out in Nigeria investigating 
the role of environmental risk factors for PD. In a multi-center case-control 
study, trace metals identified in well-water were associated with PD (Ogunrin et 
al., 2012). Also, xenobiotics thought to be associated with PD were studied in 
Nigerian PD patients but their use was not associated with the disorder (Igbokwe 
et al., 1993). In one study, blacksmithing,  which is a common occupation in 
Nigeria, mostly among the people from the Northern part of the country (e.g. 
Kano state), was found to be associated with PD (Akinyemi, 2012; Falope et al., 
1992). As well-water is one of the main sources of water supply in Nigeria, it is 
plausible that environmental factors such as trace metal contamination in well-
water as well as blacksmithing may contribute to development of PD but further 
studies are needed to confirm this.    
 
Nigeria is perceived as a homogeneous group of people. It should be noted, 
however, that each region in the country has different tribes that make the 
country quite diverse in terms of culture, language and ancestral origin 
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(Supplementary Figure 2.1). Also, other factors such as vegetation, climate, 
topography, lifestyle, diets and the socioeconomic factors differ extensively 
across different regions of the country; all of these could contribute to the 
prevalence of PD. For example, people living in South-Western Nigeria are more 
likely to be exposed to industrial-derived toxins, whereas people living in the 
oil-rich Southern region could be more exposed to toxic chemicals and aquatic 
foods contaminations due to oil-spillages. 
 
 
                  2.9             Genetic studies on PD in Nigeria 
 
Approximately 5-10% of PD patients have a monogenic form of PD, which is 
due to highly penetrant, rare pathogenic mutations (Lill, 2016). The genetics of 
PD is complex as common genetic variants may act in concert with 
environmental factors. Genome-wide association studies have identified 26 PD 
risk loci, (Lill, 2016) but none of these loci have been studied in Nigerian PD 
patients. Familial PD cases in Nigeria have been mentioned (Table 2.1), but to 
date no genetic causes have been identified in these patients.  Currently, only 
one genetic study on Nigerian PD patients has been published (Okubadejo et al., 
2008) (Table 2.3). The study analyzed mutations in LRRK2, PRKN and ATXN3 
in 57 Nigerian PD patients who showed cardinal signs of PD such as tremor, 
rigidity, bradykinesia and gait abnormality, of which nine patients presented 
with at least one first-degree relative with a history of tremors. No pathogenic 
mutations in the genes commonly known to cause PD in European, North 
American or North African populations were found (Okubadejo et al., 2008).  
 
Interestingly, the study identified two heterozygous variants (p.A46T, and 
p.R334H in PRKN) of unknown pathogenicity in two PD patients from different 
ethnic groups in Nigeria (Okubadejo et al., 2008).   
 
Notably, the fact that nine of the PD cases presented with a first-degree relative 
with a history of tremor, indicates that an autosomal dominant mode of 
inheritance is possible in these families.  
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The study did not rule out the possibility of mutations in any of the known 
autosomal dominant PD genes such as SNCA and GBA.  
 
In another study, Tucci et al (Tucci et al., 2012) screened 26 Yoruba (Nigerian) 
individuals from the Human Genome Diversity Cell Line panel to estimate the 
frequency and diversity of coding variants in the EIF4G1 gene (Tucci et al., 
2012).  No pathogenic mutations were identified.  
 
The limitations of these genetic studies are the small sample sizes and the fact 
that only and few PD genes were screened. In conclusion, further genetic studies 
on the Nigerian population are warranted since the frequency of certain 
pathogenic mutations have been shown to differ widely between different 
population groups. For example, the frequency of the G2019S mutation in the 
LRRK2 gene varies from approximately 40% in North African Arabs, to roughly 
28% in Ashkenazi Jews and to only 3% in Caucasian populations from southern 
Europe (Healy et al., 2008). To date, no Black PD patient has been found to 
harbor the G2019S mutation (Blanckenberg et al., 2013; Williams et al., 2018) 
further providing support for the striking differences observed in the genetic 
etiology between various ethnicities.  
 
 2.10                        Implications and recommendations 
 
It is important that PD patients are diagnosed early and accurately as 
epidemiological studies and other clinical studies on PD in Nigeria are dependent 
on this. Primary care physicians play an important role in this regard. There are 
a number of differential diagnoses including essential tremor, vascular 
parkinsonism, normal pressure hydrocephalous, brain tumors, multiple system 
atrophy, supranuclear palsy, and Huntington’s disease, and an initial brain 
computed tomography (CT) scan should be performed to exclude the major 
causes of secondary Parkinsonism.  
If the history obtained however suggests rarer causes, where possible, 
appropriate biochemical or genetic tests should be requested. Also, in a SSA 
setting the management of PD should have a multidisciplinary approach as well 
as integration into the primary health care systems of each country.  
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The team members could include neurologists, nurses, physiotherapists, 
occupational therapists, speech therapists, neuroscientists, neuropathologists, 
neuro-geneticists, social workers as well as community health workers. 
Furthermore, strategies and support services e.g. telemedicine, where patients 
can be diagnosed and treated remotely via telecommunication technology, 
should be established to facilitate diagnosis of patients in rural settings. In 
addition, educational courses focused on non-specialist physicians, nurses and 
community health officers on the diagnosis and management of 
neurodegenerative disorders, should be provided as well as country-wide PD 
awareness campaigns to educate the general public about PD. This may help to 
alleviate issues of stigmatization, victimization or abandonment experienced by 
PD patients and their families within their communities. It is also critical to 
investigate family history of the disorder in PD patients. A positive family 
history and a young age-at-onset (below 40 years) are both strong indicators of 
a genetic component underlying the disease in an individual. 
 
Treatment for PD needs to be more accessible and affordable to Nigerian 
patients. It would be important to conduct surveys on the availability and 
affordability of anti-parkinsonian medications in SSA countries, similar to the 
study conducted in Kenya (Mokaya et al., 2016). Anti-parkinsonian drugs should 
be available and covered under the National Health Insurance Scheme, and the 
Federal Ministry of Health, policy makers, and politicians need to take action 
and remove the barriers and obstacles that limit broader availability of these 
drugs.   
 
In 2012, The International Parkinson and Movement Disorder Society 
established a Task Force on Africa, and its main mission is assisting with 
diagnosis of PD in Africa, together with ensuring affordable and sustainable 
treatment. 
(http://www.movementdisorders.org/MDS/Regional-Sections/Task-Force-on-
Africa.htm) 
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Additional studies on the prevalence of PD are needed to determine the extent 
of the problem in Nigeria. Problems with the existing prevalence studies include 
the fact that there were only two door-to-door studies (regarded as the most 
accurate method for determining prevalence), and that most studies were 
hospital-based. Since not every individual is taken to a hospital for diagnosis, 
the true prevalence of PD in the country cannot be ascertained. Worldwide trends 
indicate rapidly growing numbers of PD cases (Bach et al., 2011)  and it is 
anticipated that this is also true for Nigeria but more studies are required to 
confirm this. More studies are also needed on the genetic causes of PD in Nigeria 
since this population is likely to harbor novel mutations. It is possible that future 
treatments might be based on the genetic etiology identified in overseas 
populations, which may not be transferable to Nigerian populations. 
Furthermore, more studies on clinical manifestations of PD in Nigerian PD 
patients are required, since this might identify clinical symptoms unique to this 
population. Also, neuroimaging using at least CT, and if available magnetic 
resonance imaging, can often help in differential diagnosis to exclude other 
causes of Parkinsonism  (Tripathi et al., 2018). 
 
 
2.7                                 Study limitations 
 
The limitations of this review include restricting the search to only English 
articles. It is also possible that even though our search was performed using 
seven different search engines, some relevant articles were missed because they 
did not contain the key words used here.  
 
 
2.8                                       Conclusion 
This review summarizes all the published human studies on PD in Nigeria. It can 
be concluded that, although 44 studies have been published since 1969, much 
more research is still needed.  Also, the comparability of the existing studies is 
limited, due to differences in study designs. There was little information on 
neuroimaging to aid differential diagnosis of PD and there were very few genetic 
studies on PD in Nigeria.  
Stellenbosch University  https://scholar.sun.ac.za
                                                                                                                                    
86 
 
It should be noted that Nigeria comprises many different ethnic groups and 
geographic regions, and this should be taken into account when analyzing 
epidemiological, genetic, biochemical and pathological findings on PD.  
 
We believe that primary care physicians have an important role in the timeous 
diagnosis of patients. They need to be aware of prodromal PD and its symptoms, 
including depression, constipation, hyposmia, and sleep disturbances, which 
could occur 10-20 years prior to the typical PD signs, as well as non-motor 
features.  Similarly, they need to document the family history, other concomitant 
diseases, occupational records and history of exposure to environmental hazards 
for patients as this information may strengthen future etiological studies and the 
management of PD in Nigeria. 
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Table 2.1: Summary on PD prevalence studies in Nigeria 
Study 
year 
Study 
site 
Geographic 
region in 
Nigeria 
Study design Total 
hospital/co
mmunity 
population 
Number of 
patients with 
neurological 
disorders 
Number (%) 
of PD patients 
Family 
history 
of PD 
patients 
Age at onset 
for PD (mean 
+/-SD; years) 
Crude 
prevalence 
ratio 
cases/100 000 
Study 
reference 
 
Neurological admission studies 
1970 Univers
ity of 
Ibadan 
 
South West Analysis of 
neurological 
admissions during 
1957 – 1969 
220 000 9 600 90 (0.9) 1 N/A 47 (Osuntoku
n, 1971) 
2003 Univers
ity of 
Ibadan 
South West Analysis of 
neurological 
admissions during 
Jan 1998 – Dec 
2000 
26 355 781 4 (0.5) N/A N/A 75 (Talabi, 
2003) 
2004 Univers
ity of 
Port 
Harcour
t 
South South Analysis of 
neurological 
admissions during 
April 1993 – March 
2003 
92 544 1 393 30 (2.2) N/A N/A 32 (Chapp-
Jumbo 
EN., 
2004) 
2010 Univers
ity of 
Nigeria 
Teachin
g 
Hospital 
Enugu 
South East Analysis of 
neurological 
admissions during 
Jan  2003 – Dec 
2007 
8 440 1 249 14 (1.1) N/A N/A 165 (Ekenze et 
al., 2010) 
2010 Aminu 
Kano 
Teachin
g 
Hospital 
North West Analysis of 
neurological 
admissions during 
Jan 2005 – July 
2007 
6 282 980 4 (0.4) N/A N/A 63 (Owolabi 
et al., 
2010) 
 
Neurological out-patient studies 
2010 Lagos 
State 
Univers
ity 
South West Analysis of 
neurological 
outpatient clinic 
N/A 1 360 20 (1.5) 1 61.5 ±10 N/A (Okubadej
o et al., 
2010) 
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Teachin
g 
Hospital 
during Jan 2005 – 
Dec 2006 
2012 Two 
Tertiary 
Health 
Facilitie
s in 
Kano 
North West Analysis of 
neurological out-
patient clinic during 
June 2007 – June 
2011 
N/A 1 153 (96 with 
parkinsonism) 
80 (6.9) 3 58.2±6.72 N/A (Femi et 
al., 2012) 
 
Hospital based studies 
1970 Lagos 
State 
Univers
ity 
Teachin
g 
Hospital 
South West Analysis of hospital 
admissions during 
1962-1967 
8 026 1 220 20 (1.6) N/A N/A 249 (Dada, 
1970) 
 
Community based studies  
1987* Igbo-
Ora 
South West Community 
surveys used 
questionnaire and 
simple clinical 
evaluation in 1982 
18 954 699 2 (1.4) N/A N/A 10 (Osuntoku
n et al., 
1987) 
1988* Igbo-
Ora 
South West Community 
surveys used 
questionnaire and 
simple clinical 
evaluation in 1982 
3 412 N/A 2 (0.05) N/A >39 59 (Schoenbe
rg et al., 
1988) 
 
 N/A, not available Community-based door-to-door survey. Both studies used the same primary data from Nigeria.  
Schoenberg et al analyzed data from individuals > 39 years old. *Crude prevalence ratio is given as the number of PD cases/100 000 individuals. 
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           Table 2.2:  Symptoms and signs of PD identified in Nigerian patients 
Category Symptom or sign Brief description Reported in 
Nigerian PD 
patients 
Study reference 
Preclinical 
symptoms 
Olfactory problems Loss of smell No  
 Gastrointestinal 
disorders 
Indigestion and 
abdominal pain 
No  
 Sleep disorder Episode sleep No  
 Mood disorder Lack of motivation No  
 Orthostatic 
hypotension 
Low blood pressure 
when standing up 
No  
Primary 
motor 
symptoms 
Resting tremor Slight tremor in the 
hand or foot on one 
side of the body 
Yes (Osuntokun, 1971), 
(Akinyemi et al., 
2008), (Okubadejo et 
al., 2008), (Femi et al., 
2012), (Okunoye, 
2015) 
 Bradykinesia Difficulty with 
repetitive movements 
Yes (Osuntokun, 1971), 
(Okubadejo et al., 
2008), (Femi et al., 
2012), (Okunoye, 
2015), (Osuntokun and 
Bademosi, 1979) 
 Rigidity Stiffness and 
inflexibility of the 
limbs, neck and trunk 
Yes (Osuntokun, 1971), 
(Akinyemi et al., 
2008), (Okubadejo et 
al., 2008), (Femi et al., 
2012), (Okunoye, 
2015) 
 Postural instability Tendency to be 
unstable when standing 
upright 
Yes (Osuntokun, 1971), 
(Akinyemi et al., 
2008), (Okubadejo et 
al., 2008), (Femi et al., 
2012), (Okunoye, 
2015) 
Secondary 
motor 
symptoms 
Freezing of gait Hesitating before 
stepping and 
exaggerated first step 
Yes (Osuntokun, 1971), 
(Femi et al., 2012), 
(Okunoye, 2015) 
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 Micrographia Shrinkage in 
handwriting 
Yes (Femi et al., 2012), 
(Okunoye, 2015) 
 Mask-like 
expression 
Decreased unconscious 
facial movements 
No  
 Akathisia Unwanted 
accelerations 
No  
 Falls Falling due to 
instability 
Yes (Farombi et al., 2016) 
 Speech problem Drooling and excess 
saliva 
Yes (Osuntokun, 1971), 
(Femi et al., 2012), 
(Okunoye, 2015), 
(Osuntokun and 
Bademosi, 1979) 
Non-motor 
symptoms 
Cognitive disorders Delusion, 
hallucination, 
depression, anxiety, 
apathy and irritability,  
Yes (Osuntokun, 1971), 
(Ojagbemi, 2013), 
(Okunoye and 
Asekomeh, 2013), 
(Osuntokun and 
Bademosi, 1979) 
  Difficulty remembering 
events 
Yes (Ojagbemi, 2013), 
(Okunoye, 2015) 
 Poor vision Sight problem No   
 Autonomic 
dysfunction 
Cardiovascular 
disorders 
Yes (Osuntokun, 1971), 
(Okubadejo and 
Danesi, 2017) 
 Obesity or weight 
loss 
Excessive weight gain 
or weight loss 
No   
 Pulmonary 
problems 
Reduced vital capacity Yes (Owolabi et al., 2016) 
 Sexual dysfunction Low libido No   
 Mood disorder Persistent low mood Yes (Akinyemi et al., 2008) 
 Sweating Excessive night 
sweating 
No   
 Gastrointestinal 
disorders 
Indigestion and 
abdominal pain 
Yes (Owolabi et al., 2014) 
     
               For more information (http://www.pdf.org/en/symptoms). 
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        Table 2.3: Genetic studies on Nigerian PD patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene analyzed Number of 
patients 
Number of 
controls 
Method Findings Study 
reference 
Parkin (PRKN) 57 51 Sanger sequencing of 
all exons and 
exon/intron boundaries 
No 
pathogenic 
mutations 
found 
(Okubadejo 
et al., 2008) 
Ataxin 3 
(ATXN3) 
57 51 Screen for repeat 
expansions 
No 
pathogenic 
mutations 
found 
(Okubadejo 
et al., 2008) 
Leucine-rich 
repeat kinase 
(LRRK2) 
57 51 Sanger sequencing of 
exons 31 and 41 
No 
pathogenic 
mutations 
found 
(Okubadejo 
et al., 2008) 
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Figure 2.1: Flow diagram of literature search strategy and results. 
Several electronic databases were searched as described in the methods. 
See Table S2.1 for full listing of the 46 articles. 
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Supplementary Figure 2.1: Map of Nigeria demonstrating significant ethnic 
diversity of different regions of the country. Permission from Stratfor 
Worldview (www.stratfor.com) a geopolitical intelligence platform. 
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Supplementary Figure 2.2: Distribution of topics covered in the 36 original 
studies on PD in Nigeria and used in this review. One study reported on both 
prevalence and symptoms and is included here in both categories. There were 
eight review articles which are not included in this figure.
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               CHAPTER THREE 
    
 
 
        COPY NUMBER VARIATION ANALYSIS ON 57 BLACK SOUTH 
AFRICAN AND NIGERIAN PARKINSON’S DISEASE PATIENTS 
(UNPUBLISHED DATA) 
 
 
3.1    Background 
 
Parkinson’s disease (PD) is a movement disorder that can be either inherited or 
sporadic. Patients can have genetic defects such as substitutions, deletions or 
duplications in the PD genes. Frequently identified mutations in the known PD 
genes are single base substitutions that lead to the conversion of one amino acid 
to another. Also, small deletions or insertions have been identified in PD patients 
and are catalogued in the PD mutation database (https://www.molgen.vib-
ua.be/PDMutDB). Most of these mutations are in the PRKN, SNCA, LRRK2, 
PINK1 and PARK7 genes.  
 
The term copy number variation (CNV) refers to structural changes such as large 
deletions or duplications in the chromosome and in a gene.  Studies have shown 
that in CNVs the rearrangement lengths may vary between 50 and 20000 bases 
(Frith and Khan 2018). Genomic rearrangements such as multiplications of one 
or more exons or deletions of exons have been previously reported in the PD 
genes (Djarmati et al., 2004; Morais et al., 2016; Olgiati et al., 2015; Pankratz et 
al., 2009). It is, therefore, plausible that CNVs may predispose an individual to 
developing PD.  
 
These genomic rearrangements are usually not detectable with routine mutation 
screening techniques such as HRM or Sanger sequencing. Similarly, despite that 
NGS offers a simultaneous testing of thousands of loci with high reproducibility, 
high resolution, and scalability to detect mutations in genes, one of the 
limitations described in the NGS studies in Chapter 1, is the inability to 
accurately detect large deletions and duplications in a DNA sample.  
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Genomic rearrangements such as deletions or duplications can produce a 
completely different phenotype or lead to a loss of function of a gene (Gamazon 
and Stranger 2015); hence people affected by CNV in PD could have varied 
expressions that may impact PD manifestations at any stage. 
 
There are different types of genomic rearrangements. The frequently observed 
exonic rearrangements (details in Chapter 1) are non-tandem duplications of 
the same strand, non-tandem duplications of the opposite strand, non-tandem 
double duplication, inversion next to deletion, inversion and tandem 
multiplication (Frith and Khan 2018). 
 
There are few techniques that can detect CNVs in different diseases. The 
methods for studying structural variations are difficult, time-consuming and 
sometimes yield low quality outputs. Some of the popular techniques used 
include fluorescence in situ hybridization (FISH), comparative genomic 
hybridization (CGH) and genome-wide SNP arrays (Feuk et al 2006). In 
addition, MLPA assay is a widely used technique for screening of CNVs. The 
MLPA technique represents a reliable method for a large-scale and cost-effective 
gene dosage screening. It is efficient and can be used to analyse several CNVs 
in a single reaction. In a single MLPA reaction, up to 45 different probes can be 
amplified simultaneously, allowing for the detection of an aberrant copy number 
of up to 45 genomic sequences including small intragenic rearrangements 
(Djarmati et al 2007). 
 
The principle of MLPA is based on the simultaneous amplification of the 
hybridized probes. Each probe is designed to amplify a given exon of a gene. 
The principles of MLPA and the analyses underlying CNVs have been discussed 
in Chapter 1 of this thesis. The control probes located in different chromosomal 
regions are also added to the same reaction for relative quantification during the 
analysis. The specific MLPA assay kits for studying CNVs in PD causative 
genes are available commercially (SALSA MLPA Kit P051/P052 MRC 
Holland; www.mrc-holland.com).  
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  Table 3.1:   List of specific probes included in the SALSA PO51and PO52 probemix 
Gene SALSA PO51 probemix SALSA PO52 
probemix 
SNCA Exons 1,2,3,4,5,6 and 
A30P mutation 
 
N/A 
PRKN 
/Parkin 
Exons 
1,2,3,4,5,6,7,8,9,10,11,12  
Exons 
2,3,4,5,6,7,8,9,10,11,12  
PINK1 Exons 1,2,3,4,5,6,7,8 N/A 
PARK7 Exons 1,2,3,4,5,6,7 
 
N/A 
LRRK2 G2019S mutation Exons 
1,2,10,15,27,41,49 and 
G2019S  mutation 
ATP13A2 Exons 2 and 9 14 and 27 
Further details available on MLPA website (https://www.mlpa.com) and  
MRC Holland website (www.mrc-holland.com). 
 
 
The P051 and P052 probe mixes were designed to analyse aberrant CNVs in the 
PD genes SNCA, PARK1, PRKN, UCHL1, PINK1, PARK7, LRRK2, GCH1 and 
ATP13A2.  The probe mixes are designed in such a way that the P051 probe mix 
contains the probes that can screen each exon in PARK7, ATP13A2, PINK1and 
PRKN genes. It also contains a probe for screening each exon in the SNCA gene, 
as well as a probe specific for the SNCA A30P mutation. In addition, it contains 
a probe that will generate a signal when the LRRK2 G2019S mutation is present 
(Table 3.1). 
 
Whole exon insertions or deletions are common in the PRKN gene in PD 
patients. These mutations have been identified in autosomal recessive and 
sporadic forms of the disease. CNV rearrangements involving PRKN exons 
account for 50–60% of all pathogenic exon dosage abnormalities in PD (Kim et 
al. 2012). Whole-gene multiplications (duplications or triplications) have been 
identified mostly in SNCA in PD patients.  
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The whole gene multiplications of SNCA led to the over-expression of the α-
synuclein and protein deposits were found in large quantities in the brains of PD 
patients. It was found that individuals with duplications have a classical PD 
phenotype, whereas those with triplications have earlier onset and faster disease 
progression (Wang et al. 2013; Keyser et al. 2010; Sekine et al. 2010; Kojovic 
et al. 2012; Darvish et al. 2013; Olgiati et al. 2015). CNVs have also been 
reported in PINK1 (Cognata et al 2017) and PARK7 genes. PARK7 is the third 
most common gene that is frequently associated with pathogenic CNVs in PD 
genes, and responsible for early-onset PD (Bonifati et al. 2003; van Duijn et al. 
2001). Limited information exists on pathogenic CNVs in LRRK2 or ATP13A2 
genes.  
The aim of the study 
This study was designed to identify possible CNVs in 57 Black South African 
and Nigerian PD patients. This study used the commercially available MLPA 
assay kit for PD (SALSA MLPA Kit P051), which comprises 31 exons of the 
four known PD genes (SNCA, PARK7, PINK1, and PRKN) for the exon dosage 
analysis A subset of the same patients were also screened for mutations in genes 
using tNGS and described in Chapter 4 of this study. 
Study rationale 
Studies on CNVs in PD patients in the SSA are limited. To date one previous 
study on the CNVs in Black South African PD patients described only one Black 
PD patient with an heterozygous deletion in PRKN exon 4 (Mahne et al 2016). 
In another study by Haylett et al., only two Black South African patients were 
found to harbour mutations in the PRKN gene (Haylett et al 2012). Equally, the 
number of studies on CNV assays in the Nigerian PD patients is limited. One 
previous CNV study on Nigerian PD patients did not identify any CNV 
mutations (Okubadejo et al 2008).   
 
It is important to understand the roles of CNVs in the PD pathogenesis in SSA. 
The rationale for the present study was that comprehensive genetic studies on 
Black PD patients from SSA are limited.  
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There is need to use modern techniques and resources to screen a large cohort of 
patients from this region to ascertain the spectrum of mutations in genes in PD 
patients. Similarly, CNVs are thought to be a rare cause of PD in the SSA PD 
patients.  
 
3.2.    Methods 
 
 
3.2.1.        Study participants 
 
In this study we used DNA samples from 15 Black South African and 42 
Nigerian PD patients (Supplementary Table 3.1). The South African patients 
were recruited at the Neurology Clinic the Tygerberg Academic Hospital, Cape 
Town, South Africa and the Nigerian PD patients at the Neurology Clinic the 
Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria. The 
patients gave written informed consent before participating in the study and 
ethical committee approvals were obtained from both centres. This study was 
approved by the Health Research Ethics Committee of Stellenbosch University 
(HREC S16/08/151), and the Obafemi Awolowo University Teaching Hospital’s 
Ethics and Research Committee (ERC/2015/08/15). The patients fulfilled the 
diagnostic criteria by the UK Parkinson’s Disease Society Brain Bank clinical 
diagnostic for PD. Patients’ baseline demographic data were obtained. Venous 
blood (20 ml) was collected into two EDTA tubes (10 ml each) for genomic 
DNA extraction. 
Genomic DNA extractions were performed using the Nucleo Spin Blood XL kit 
(Macherey-Nagel Duren, Germany). The protocol provided by the manufacturer 
was followed.  
The quality and concentrations of the DNA samples were determined using 
Nanodrop®.  DNA samples were prepared according to the instructions by the 
manufacturer of the MLPA kits (MRC Holland SALSA MLPA Kit P051). The 
DNA samples included a total of 57 PD patients, three healthy individuals 
(negative reference controls), no-DNA control, and one PD patient (positive 
reference) previously tested for exon rearrangements and found to have a 
deletion in exons 3 and 4 of the PRKN gene. 
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3.2.2.   MLPA assay 
 
The experiments were performed according to the manufacturer’s instruction. 
The MLPA assay was performed in three steps. The first step was the DNA 
denaturation. On the first day, briefly, 5 μl of the DNA samples (10 ng/μl) were 
pipetted into 0.2 ml tubes.  The DNA samples were denatured in a thermocycler 
at 98°C for 5 minutes. The samples were cooled down at room temperature.  
The DNA samples were hybridized to the SALSA MLPA Kit P051 probe mix 
by adding to each sample an aliquot of 1.5 μl of probe mix and 1.5 μl of the 
MLPA buffer. The samples were incubated at 95°C for 1 min, and finally 
hybridized at 60°C for 16 to 24 hours. 
On the second day, the hybridised probes were ligated. The thermocycler 
temperature was reduced to 54°C, while the samples were still in the 
thermocycler, 32 μl of Ligase-65 mix were added to each reaction tube, kept at 
54°C for 15 min, and finally heated at 98°C for 5 min to inactivate the ligase 
enzymes.  
Thereafter, the samples were cooled down at room temperature for the PCR 
amplification of the ligated probes. To each reaction mixture, 10 μl of the 
polymerase master mix were added and immediately transferred into a 
thermocycler and the PCR was started (33 cycles at 95°C for 30 seconds, 60°C 
for 30 seconds, 72°C for 60 seconds, and a final 20-minute step at 72°C) The 
reaction was paused at 15°C.  
 
The final reaction products were electrophoresed using an ABI 3100 DNA 
analyzer (Applied Biosystems) with Liz 500 size standard 0 (Thermo Scientific, 
Waltham, Massachusetts, USA) and Gene Mapper software v3.0 (Applied 
Biosystems) at the Central Analytical Facilities of Stellenbosch University. 
 
The data were uploaded on the Coffalyser. Net software (v14072.1958, MRC-
Holland, Netherlands) for the copy number analysis. The Coffalyser.Net 
software provides quality scores for each reaction.  
 
Stellenbosch University  https://scholar.sun.ac.za
                                                                                                                                    
103 
 
Coffalyser.Net starts with raw data analysis (baseline correction, and peak 
identification) and extensive quality control (e.g. DNA quantity used; complete 
DNA denaturation, degree of sloping) and interpretation of the control fragments 
that are included in the SALSA MLPA PO51 probe mix. We determined the 
final probe ratios by comparing the relative probe peak in the DNA sample of 
interest to all reference samples. Reference DNA samples are expected to have 
a normal copy number for both the reference and target probes. 
 
 
3.2.3.          Analysis 
 
The MLPA assay was performed on the 57 samples in one reaction according to 
the experimental procedures. The data were visually analysed to identify peak 
signal sloping in the eletropherogram graphs. The samples that showed peak 
signal sloping were repeated. The raw data files (.fsa) were analysed using 
Coffalyser.Net software. The software required that the fragment MLPA 
reaction scores (FMRS) for each sample be above the threshold support for a 
comparative analysis. The score is based on: 
 
 Signal intensity of the median probe fragment 
 Maximum probe signal intensity 
 Baseline intensity of probe dye 
 Signal drop of internal run of probe fragments in combination with signal 
widening 
 Percentage of unused primers 
 Probes to peak noise percentage 
 DNA concentration check 
 DNA denaturation check 
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Hence, only the data with FMRS percentage quality scores of 60–100% were 
included in the comparative analyses between the samples and the references.  
We corrected errors related to sloping by setting the major outlier ratio filter for 
low and high peaks at 0.4 and 2.0 respectively to eliminate false negative or false 
positive results. The pre-ratios and the final ratios generated for the patient 
samples were compared with the mean values of the corresponding negative 
reference samples. The typical value for a normal copy number is 1.0.  A possible 
locus rearrangement such as deletion or multiplication with the ratio value of 0.5 
or 1.5, respectively. As described in the MLPA manual (https://www.mlpa.com) 
the ranges of the final ratio values for a heterozygous deletion of one allele copy 
is 0.33 to 0.62 (mean 0.52), while the range is 1.27 to 1.41 (mean 1.33) for 
heterozygous duplications (three allele copies), and 1.76 to 2.0 (mean 1.92) for 
triplications (four allele copies) (https://www.mlpa.com). 
 
3.3.          Results and Discussion 
 
In this study, we detected heterozygous deletions in the PRKN exons 3 and 4 in 
the sample which was used as a positive control and previously found to contain 
these deletions in the Mahne et al 2016 study on a Black South African PD 
patient. This result proved that the MLPA was working in our laboratory. The 
analysis of the 57 PD patients for CNV revealed three Nigerian patients with 
exonic rearrangements. A decrease or increase in the copy number ratio was 
observed in those three patients. The variations in the ratios indicated possible 
exonic rearrangements in their DNA (Table 3.2). Sample 13.039 had a 
heterozygous deletion in PARK7 exon 1. Sample 13.253 had two heterozygous 
duplications in PINK1 exon 5 and in PRKN exon 1. The third sample 13.334, 
had two heterozygous duplications in PRKN exons 1 and 2 (Table 3.2). In each 
case, the signal peaks in the electropherogram were compared with the reference 
peaks and showed that variation occurred in the copy number (Figure 3.1). 
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  Table 3.2:   Summary of copy number variations identified in this study 
          
Sample 
          
Ethnicity  
CNV 
identified 
Probe 
length 
(bp) 
CNV 
ratio 
13.039 Yoruba PARK7 exon 
1 deletion 
350 0.5 
13.253         Yoruba PINK1 exon 
5 duplication 
143 1.5 
13.253         Yoruba PRKN exon 1 
duplication 
237 1.5 
13.334 Yoruba PRKN exon 1 
duplication 
237 
 
1.5 
 
13.334 Yoruba 
 
PRKN exon 2 
duplication 
287 
 
1.5 
 
See Figure 3.1: For electropherogram results. 
 
The study of CNV mutations is important for the understanding of the 
pathogenesis of PD. MLPA SALSA PO51 probe mix used in this study could 
analyse most of the exons of the four known PD genes. 
 
The positive reference used in this study was a Black South African PD patient 
with deletions in PRKN exon 3 and 4 and had PD AAO of 50 years with no 
family history (Figure 3.1). 
 
There are three major mechanisms accountable for genomic rearrangements 
which have been described in Chapter 1: NAHR, NHEJ, and FoSTeS. These 
three mechanisms are involved in pathogenic genomic rearrangements (Gu et al 
2008 and Morais et al 2016). NAHR generates CNVs when genomic segments 
with high sequence similarity recombine. The double stranded breaks in DNA 
sequence recruit NHEJ-associated proteins to repair and ligate DNA strands 
together so that if fragments from different chromosomes ligate together, 
duplications or deletions of sequence can occur. The FoSTeS serial replication 
represents a fork disengaging and lagging strand invasion occurring several 
times during DNA replication processes (La Cognata et al 2017). The CNV 
aberrations could affect the overall functions of a gene, either by damaging or 
reducing the effects of a gene. They could also cause an overexpression of a gene 
if the CNV is a tandem repeat (multiplications). The types of CNVs identified in 
this study were in these categories. 
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The chromosomal regions mostly affected by the CNV are the subtelomeric 
regions and contain an abundance of segmental duplications. They are more 
susceptible to non-allelic homologous recombination and are potential regions 
for genomic instability generating CNVs (Gu et al., 2008; Sharp et al., 2006) . 
These loci containing many genes including the known PD genes are located in 
the distal chromosome regions, and are susceptible to high recombination rates  
 
PARK2 spans approximately 1.38 Mb and encodes the protein parkin. The 456-
amino acid protein harbors four major functional domains corresponding to its 
function as an E3 ubiquitin ligase (Figure 3.2). Its role in the ubiquitin-
proteasome system and mitochondrial maintenance has been described in 
Chapter 1. Dysregulation of mtDNA homeostasis is a key process in the 
pathogenesis of neuronal loss in PD (Pinto et al., 2018).  
A study of a complete spectrum of mtDNA changes, including deletions, 
duplications and point mutations in PRKN in single neurons from the 
dopaminergic substantia nigra in PD patients and controls showed changes in 
mtDNA copy number relating to a compensatory mechanism to the accumulated 
deletions in PRKN gene   (Dölle et al., 2016). The study suggested that 
dysregulation of mtDNA homeostasis is a key process in the pathogenesis of 
neuronal loss in Parkinson disease. They excluded patients with known 
monogenic causes of PD to ensure that their sample was homogenous and 
representative for sporadic PD. They ensured that no monogenic mutations were 
identified in the PD patients in the known PD genes. It is important to relate 
recent findings in PD genetics research in literature. Considering also, that, the 
patients studied here are sporadic cases. However, discussing the Dolle et al 
2016 findings in the present study might not be applicable if the CNVs identified 
in PRKN gene in the patient are causative or inherited. 
The PRKN exons 1 and 2 where duplications were identified in this study are 
part of the PRKN coding region and are being expressed during transcription 
(Figure 3.2).   
Mutations in PRKN gene have been associated with an early-onset PD (Morais 
et al 2016). 
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Parkin mutations are most frequent, explaining 50% of the cases with a clinical 
diagnosis of familial Parkinson's disease compatible with recessive inheritance 
and onset <45 years, and 15% of the sporadic cases with onset <45 years 
(Bonifati, 2012).   
Large deletions account for approximately 50%–60% of the PRKN disease–
causing mutations, only a small number of small deletions or duplications which 
are a result of exon-exon breakpoints have been identified.  Small deletions and 
duplications occur as well in this region in PRKN (Morais et al., 2016).  
The CNV mechanism implicated in PRKN was NAHR, mediated by Alu 
elements. Alu-mediated NAHR seems to be the responsible mechanism for the 
CNVs observed in this study. This mechanism has been previously described in 
PRKN deletions and duplications observed in early onset PD (Jun-Mitsui et al 
2010). In contrast, rearrangements that can be explained by NAHR are relatively 
rare. There is only a limited number of rearrangements (4.3%) in PRKN in 
patients with early onset PD whose junctions show extended homologies (Mitsui 
et al., 2010).  
In this study, the patient with PRKN exon 1 and 2 duplications had AAO of 50 
years with no family history of PD (Supplementary Table 3.1). The exonic 
duplications observed may suggest a loss-of-function and possible reduced 
expression of parkin ubiquitin ligase. CNVs can also regulate the expression of 
target genes through position effects i.e. through the insertion or deletion of 
sequences leading to alterations in distance to regulatory elements (Gamazon 
and Stranger 2015). However, transcriptional analyses will be required to show 
gains, losses and diversification of functions that characterize the effects of 
deletion or duplications identified in CNV in this study 
 
It is noteworthy that compound heterozygous duplications of exons 7 and 9 in 
PRKN have also been reported (Hedrich et al., 2002). 
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 Genomic positions of PRKN exon 1 and 2 [162727771-162443353 GRCh38 
coordinates; reverse strand]. 
 
 
Figure 3.2: Representation of PRKN on genomic and transcript level and 
the functional domains of the parkin protein. The PRKN gene spans 
approximately 1.38 Mb and encodes the protein parkin. It has 12 exons. The 
456-amino acid protein harbors four major functional domains corresponding 
to its function as an E3 ubiquitin ligase. The arrows indicate the locations  for 
PRKN exon 1 and 2 duplications . On transcript level exons are coloured 
alternately (NM_004562.2). (UBL: ubiquitin-like; IBR: in-between-ring) taken 
from Nuytemans et al 2010. Permission from John Wiley and Sons. 
 
The PARK7 gene has a size of 34 kb with seven exons (Figure 3.3). It is among 
the known PD genes. It accounts for 1.2% of single or multiple exon deletions 
and duplications reported in PD patients.  CNVs in PARK7 are not as common 
as point mutations. But, because of the rarity of mutations in PARK7, most 
studies have limited information for PARK7 CNVs in PD. 
In this study, the patient with the PARK7 exon 1 deletion had AAO of 71 years. 
The majority of the Nigerian PD patients recruited for this study have late age-
at-onset PD.  Previous studies from various populations found PARK7 gene to 
harbour CNVs in PD. A study on a Dutch family identified CNVs in PARK7 
gene. A homozygous deletion of 14 kb involving the first five of seven exons 
was found (Bonifati et al. 2003). Further heterozygous CNVs (both deletions and 
duplication) in PARK 7 gene have been described in PD studies. 
 
 The authors identified two carriers of single heterozygous loss-of-function 
PARK7 mutations, including a heterozygous deletion of exons 5 to 7 and an 11-
base pair deletion, removing the invariant donor splice site in intron 5. 
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Interestingly, both PARK7 mutations identified were found in the heterozygous 
state only.  (Djarmati et al., 2004; Guo et al., 2010; Hedrich et al., 2004). Detailed 
mechanisms on how PARK7 contributes to PD have been described in Chapter 
1, however, it remains not fully understood how CNVs in PARK7 develop. 
 
 
      
Genome position of PARK7 exon 1 locations [7961692 –7961735 GCHR 38 
coordinates-reverse strand] 
 
 
Figure 3.3: Representation of PARK7 on genomic and transcript level. On 
transcript level exons are coloured alternately (NM_007262.4). It has 8 Exons 
and locates at chromosome band 1p36.23. The product of this gene belongs to 
the peptidase C56 family of proteins. It acts as a positive regulator of androgen 
receptor-dependent transcription. The arrows indicate the locations where 
PARK7 exon 1 deletion was located. The diagram is taken from Nuytemans et al 
2010. Permission from John Wiley and Sons. 
 
PINK1 gene is 18 kb. PINK1 protein is a putative serine/threonine kinase 
involved in mitochondrial response to cellular and oxidative stress (Figure 3.4).  
Approximately 6.5% of known mutations in familial and sporadic patients carry 
a mutation in PINK1, (Nuytemans et al 2010). 
 
A study by Marongiu et al showed that deletions in PINK1 exons in PD patients 
are pathogenic. The authors identified an Italian PD patient with a deletion of 
the entire PINK1 gene and a splice site mutation in the gene (Marongiu et al., 
2007).  
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Likewise, homozygous and compound heterozygous deletions involving 
different combinations of PINK1 exons 4–8 have been described in both familial 
and sporadic cases in PD patients from Japan, Brazil, Sudan and Iran (La 
Cognata et al 2017). 
The largest heterozygous deletion known so far is 56 kb and includes the entire 
PINK1. Further heterozygous deletions in PINK1 involving exons 1, 3–8 and 
exon 7 have also been described (La Cognata et al 2017). However, while PINK1 
exon dosage variation is rare, and the ones identified were mostly deletions, 
hence, it is simply not common to identify a duplication in PINK1 gene, but it is 
not impossible that PINK1 exon 5 duplication was identified in a patient in this 
study, because exon dosage analyses on PINK1 gene are rare. 
Genomic position of PINK1 exon 5 locations [20645560 –20645723, GCHR 38 
coordinates-reverse strand] 
 
 
Figure 3.4: Representation of PINK1 on genomic and transcript level and 
the functional domains of the PINK1 protein. PINK1 gene is 18 kb and 
encodes a protein called PTEN induced putative kinase 1. PINK1 protein is a 
putative serine/threonine kinase involved in mitochondrial response to cellular 
and oxidative stress. The diagram shows the locations of the duplication at gene 
and transcript levels. On transcript level exons are colored alternately 
(NM_032409.2). Taken from Nuytemans et al 2010 Permission from John Wiley 
and Sons. 
 
Stellenbosch University  https://scholar.sun.ac.za
                                                                                                                                    
111 
 
The roles of the CNVs identified in this study need to be investigated further for 
disease mechanisms and also to identify the specific regions in the DNA 
susceptible to structural rearrangements, such as tandem multiplication and 
duplications that often occur due to ambiguity in alignment of repeat sequences 
(Frith and Khan 2018). CNVs in certain genes like PRKN are frequent because 
of the unstable regions where such genes are located in the genome.  The degree 
of multiplication varies greatly, e.g. duplication (most common) or multiple 
duplications. (Frith and Khan 2018).  
 
3.4   Study limitations 
 
There were several limitations to this study. It is noteworthy to stress that only 
one MLPA probemix (PO51) was used for detecting CNVs in this study. In a 
situation where the CNV electropherogram peaks when compared to the 
reference probe peak did not confirm the presence of CNV, we did not consider 
those CNVs further (e.g. ATP13A2 exon 4 and PRKN exon 4 duplications 
identified in 54 of the 57 patients screened, but the electropherogram peak ratios 
did not confirm the results. It was therefore, suggested that, they might be 
artefacts or a random CNVs or maybe polymorphisms that exist in the population 
screened.  In fact, the presence of polymorphisms in this assay could prevent 
probe ligation, leading to no amplification and wrong identification of CNVs.  
 
It is necessary to mention that the 15 South African and 14 of the 42 Nigerian 
patients used in this study were also included in the tNGS analysis that screened 
the coding regions of these genes for pathogenic variants. However, tNGS is 
limited by its inability to correctly identify CNV especially large deletions or 
duplications. 
In addition, considering that the probemix ligation and amplifications were not 
quantified especially by using qRTPCR, which makes the study less robust. 
However, both the internal reference probe and the choice of electrophoresed 
size markers used, could have detected possible problems related to probe 
ligations and amplification during the analyses.  
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In the panels of the Figure 3.1 (a-d), The variability observed in the reference 
signal can be introduced by a number of factors, including sample treatments, 
since all the samples were not screened at the same time. Differences in reaction 
conditions do not always affect all probes equally, which can lead to changes in 
relative probe signals. For example, there is a relationship between relative probe 
signals and polymerase activity. The relative signal of some probes may decrease 
with reduced polymerase activity, whereas other probes may actually produce 
higher signals. Variability can also be the result of experimental issues such as 
pipetting errors. Evaporation can also lead to variability. It is always 
recommended that the result be validated using other methods. 
 
Moreover, it is important to use an adittional method to verify CNVs identified 
in this study. It is important therefore, to use two different MLPA probemix to 
limit errors relating to false positive results.      
 
In conclusion, this study suggests that SSA PD patients could harbour CNVs. 
The use of the MLPA method to identify CNV was further established in this 
study. The CNVs identified in this study have not been described in the SSA PD 
patients in the literature. Since these are recessive genes, there must be two 
mutations to lead to a disease phenotype. This has not been demonstrated and 
we are not able to conclude if the CNVs are causative.  To identify more CNVs 
in the patients from SSA origin, sample size must be increased. It will also be 
necessary to study family members of the PD patients to ascertain the type of 
mutations, and to determine if there is a founder effect. Finally, it will be 
essential to establish the mechanisms of pathogenicity of these CNV mutations 
in PD. 
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d.  
Figure 3.1: Representative electropherograms from MLPA. Figures a-c show results for three Nigerian PD patients 
(samples 13.039, 13.254 and 13.334) and d shows results for a positive control sample. The figures demonstrate signal 
peaks of the PD-MLPA fragments obtained by using the SALSA P051 probe mix of the commercially available MLPA kit 
followed by analysis using Coffalyser. Net software (v14072.1958, MRC-Holland, Netherlands). Red arrows indicate 
fragments in which CNVs were identified. In sample 13.039 the PARK7-1fragment had a lower peak than expected and is, 
therefore, likely to contain a deletion. In sample 13.254 two peaks with abnormal heights were observed: PINK1-5 and 
PRKN-1 fragments had higher than expected peaks and thus are likely to contain insertions. In sample 13.334, two peaks 
with abnormal heights were observed: PRKN-1 and PRKN-2 fragments had higher than expected peaks and thus are likely 
to contain insertions
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 Table S3.0: Demographics of the 57 PD patients. 
Sample 
code 
Sex Ethnicity/ 
Country 
AAO 
(y) 
AAD 
(y) 
Family 
history 
of PD 
Affected 
family 
member 
Other diseases 
96.87 M Black/SA 37 38 No N/A No 
10.308 F Black/SA 49 77 No N/A No 
10.309 M Black/SA 52 59 No N/A No 
10.313 F Xhosa/SA 43 49 No N/A No 
10.314 F Black/SA 55 57 No N/A No 
11.781 F Black/SA 31 35 No N/A No 
11.830 F Black/SA 57 60 No N/A No 
11.833 M Black/SA 48 50 No N/A No 
11.834 M Black/SA 52 56 No N/A No 
11.835 F Black/SA 52 60 No N/A No 
11.894 M Black/SA 44 49 No N/A No 
11.895 M Black/SA 49 53 No N/A No 
11.962 M Black/SA 53 77 No N/A No 
12.177 M Black/SA 45 55 No N/A No 
12.178 F Black/SA 53 55 No N/A No 
12.975 F Yoruba/N 80 80 No N/A Hypertension  
13.007 M Yoruba/N 52 59 No N/A Hypertension 
13.008 M Yoruba/N 62 66 No N/A Hypertension 
13.036 M Yoruba/N 57 64 No N/A Hypertension 
13.037 M Yoruba/N 79 81 No N/A No 
13.038 M Yoruba/N 36 42 No N/A No 
13.039 F Yoruba/N 71 73 No N/A No 
13.090 M Yoruba/N 59 60 No N/A Hypertension 
13.091 M Yoruba/N 79 80 No N/A No 
13.092 M Yoruba/N 48 59 No N/A No 
13.093 M Yoruba/N 53 64 No N/A No 
13.094 F Yoruba/N 62 64 No N/A No 
13.095 M Yoruba/N 73 81 No N/A No 
13.096 M Yoruba/N 68 71 No N/A No 
13.117 M Yoruba/N 60 64 No N/A No 
13.119 F Yoruba/N 62 63 No N/A No 
13.118 M Yoruba/N 63 64 No N/A Hypertension 
13.147 F Yoruba/N 69 71 No N/A No 
13.167 M Yoruba/N 72 81 No N/A No 
13.168 M Yoruba/N 55 61 No N/A No 
13.185 M Yoruba/N 54 57 No N/A No 
13.186 M Yoruba/N 60 72 No N/A No 
13.202 M Yoruba/N 66 77 No N/A No 
13.219 M Yoruba/N 49 49 No N/A No 
13.220 F Yoruba/N 70 73 No N/A Hypertension 
13.241 M Yoruba/N 84 84 No N/A No 
13.253 F Yoruba/N 71 71 No N/A No 
13.254 M Yoruba/N 77 78 No N/A No 
13.275 M Yoruba/N 69 69 No N/A No 
13.276 F Yoruba/N 66 66 No N/A No 
13.277 M Yoruba/N 77 78 No N/A Hypertension 
13.278 M Yoruba/N 58 60 No N/A Hypertension 
13.310 M Yoruba/N 83 84 Yes Sibling, 
cousin 
No 
13.311 M Yoruba/N 70 74 No N/A No 
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Sample 
code 
Sex Ethnicity/ 
Country 
AAO 
(y) 
AAD 
(y) 
Family 
history 
of PD 
Affected 
family 
member 
Other diseases 
13.321 M Yoruba/N 63 66 No N/A No 
13.322 M Yoruba/N 48 58 No N/A No 
13.323 M Yoruba/N 68 74 No N/A No 
13.324 M Yoruba/N 66 72 No N/A No 
13.325 M Yoruba/N 70 73 No N/A No 
13.334 F Yoruba/N 50 54 No N/A No 
13.335 M Yoruba/N 59 60 No N/A No 
13.369 F Yoruba/N 60 62 No N/A No 
N/A: Not applicable. 
 
 
 
 
,4DR 
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4.1          ABSTRACT 
BACKGROUND: The prevalence of Parkinson's disease (PD) is increasing in 
sub-Saharan Africa, but little is known about the genetics of PD in these 
populations. Due to their unique ancestry and diversity, sub-Saharan African 
populations have the potential to reveal novel insights into the pathobiology of 
PD. 
METHODS: We recruited 33 Black South African and 14 Nigerian PD 
patients, and screened them for mutations in 751 genes using an Ion 
AmpliSeq™ Neurological Diseases panel. We used bcftools to filter variants 
by quality score > 100 and a minimum read depth > 40, used annovar utility 
software for the annotation, removed variants with minor allele frequency 
>0.01 in any of the frequency databases, and selected variants using MetaLR 
and MetaSVM prediction scores. We generated radar plots of these selected 
variants predicted to be deleterious to illustrate the overall pathogenicity 
prediction using 17 different prediction scores. We used ConsensusPathDB to 
generate protein-protein interaction networks, and investigated the effect of 
PINK1 variants on the protein structure by molecular modelling. 
RESULTS: The mean age-at-onset of PD in the South Africans and Nigerians 
was 48 ± 8 and 63 ± 13 years, respectively. Sequence data from all samples 
passed global quality control criteria. We identified 14,655 rare variants with a 
minor allele frequency ≤0.01, of which, 7,934 were intronic, 5,695 exonic, 27 
intergenic, 539 in untranslated regions, and 430 in non-coding RNA. They 
included 3,175 synonymous and 2,448 missense variants. Altogether 60 
variants in 44 genes were considered deleterious and were prioritized based on 
MetaLR and MetaSVM scores for future follow-up studies. Of the 44 proteins 
encoded by these genes, 52% (23) were classified as enzymes. We found seven 
novel variants in three known PD genes ATP13A2, PRKN and PINK1. Protein 
modelling suggested that PINK1 variant S228F, a site for autophosphorylation, 
is near the interaction surface with PRKN.  
 
Stellenbosch University  https://scholar.sun.ac.za
                                                               
                                        125 
 
CONCLUSIONS: We identified variants predicted to be pathogenic in genes 
not previously known to harbour mutations in PD patients from sub-Saharan 
Africa. We also identified novel mutations in known PD genes. Further studies 
are required to validate the findings and ascertain the biological effects of these 
variants. 
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4.2                                        Background 
 
Parkinson's disease (PD) is a debilitating neurodegenerative disorder that 
impairs patients’ motor skills, and speech coordination. It is one of the leading 
causes of disability and mortality among neurological disorders globally (GBD 
2015 Neurological Disorders Collaborator Group, 2017). Currently, there is no 
drug that can prevent, reverse, or halt the progression of the disease. The 
neuropathological hallmark of PD is the progressive loss of predominantly 
dopaminergic neurons of the substantia nigra pars compacta of the midbrain, 
which regulate voluntary movement. PD affects 1–2% of individuals over the 
age of 60 years and ~4% of people over the age of 80 years (de Lau and 
Breteler, 2006a). The diagnosis of PD is largely clinical using criteria such as 
the UK PD Society Brain Bank criteria (UKPDSBBC) to differentiate ageing 
related symptoms from PD (Jankovic, 2008).  
The pathobiology of the disease is yet to be fully elucidated, but environmental 
and genetic factors have been linked to PD etiology (Cannon and Greenamyre, 
2013; Chin-Chan et al., 2015).  PD symptoms usually manifest in the same way 
in all patients, but the prevalence, incidence and risk factors may vary 
according to the geographical region (Pringsheim et al., 2014c). Estimates of 
PD prevalence in sub-Saharan Africa (SSA) vary widely across previous 
studies and range from 10 to 235/100,000 in urban populations (Lekoubou et 
al., 2014b; Williams et al., 2018b). 
Genetics as an etiologic concept in PD has been well-established (Klein and 
Westenberger, 2012; Lill, 2016b). Approximately 5–10% of PD patients have 
a monogenic form of the disease, which is due to highly penetrant, rare 
pathogenic mutations (Lill, 2016b). For sporadic forms of this disorder, the 
genetics is complex as common genetic variants may act in concert with 
environmental factors (Lill, 2016; Polito et al., 2016; Zschiedrich et al., 2009). 
The genetic discoveries have led to important hypotheses about the 
mechanisms underlying PD, which include dysfunction of the ubiquitin–
proteasome system and mitochondrial dysfunction coupled with oxidative 
stress (Jain et al., 2005).  
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The functional role of the common pathogenic PD mutations is currently being 
studied in various cellular and animal models.  
Most of the studies on the established PD genes (SNCA, LRRK2, PRKN, 
PINK1, PARK7 and  ATP13A2) or in the PD-related genes (GBA, CHCHD2, 
EIF4G1, SPG11, SYNJ1, TMEM230, MAPT, FBXO7, VPS13C, VPS35, GRN, 
GIGYF2, HTRA2, DCTN1 and DNAJC6) were performed in European, North 
American, North African Arab or Asian populations (Clarimón and 
Kulisevsky, 2013; Lill, 2016b; Popescu, 2016). Common PD mutations such 
as LRRK2 G2019S, have not been studied extensively in SSA populations. 
Notably, the frequency of LRRK2 G2019S varies widely across different 
geographic regions; 1–2% in European PD patients and much higher in 
Ashkenazi Jews (~20%) and in North-African Arab (41%) PD patients (Bras 
et al., 2008; Lesage et al., 2006). In general, limited studies exist on the genetics 
of PD in the Black African populations (Blanckenberg et al., 2013c).  
It has been suggested that the common PD mutations are rare among South 
African PD patients (Blanckenberg et al., 2014b; Haylett et al., 2012b). 
Similarly, a previous genetic study screened for mutations in LRRK2, PRKN 
and ATXN3 in 57 Nigerian PD patients but did not identify any pathogenic 
mutations (Okubadejo et al., 2008c). African populations have a diverse 
ancestry, and have more private alleles than any other populations, suggesting 
that the genetic etiology of PD in African populations could be unique 
(Gurdasani et al., 2015). 
Next-Generation Sequencing (NGS) provides a way to explore the genetic 
basis of diseases, and has resulted in the discovery of a large number of disease-
associated mutations (Olgiati et al., 2016a). In contrast to whole-genome or 
whole-exome sequencing (Farlow et al., 2016; Steele et al., 2015), targeted 
sequencing panels (Gorostidi et al., 2016) focus the analysis on specific genes 
of interest. Commercially available panels such as the Ion AmpliSeq™ 
Neurological Diseases Panel were designed to screen genes for mutations in 
neurological diseases as well as genes involved in brain function.  
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This panel targets the exons and RNA splice sites of 751 candidate genes 
known to harbour mutations in neurological diseases including PD 
(www.ampliseq.com). In the present study, we used this panel to screen for 
deleterious sequence variants in Black South African and Nigerian Yoruba PD 
patients. We identified putative pathogenic mutations in a number of candidate 
genes in this group of patients. 
 
4.3.       Materials and Methods 
 
4.3.1      Study Participants and Sample Collection 
 
The study group consisted of 33 unrelated Black South African PD patients and 
14 unrelated Nigerian sporadic PD patients. South African patients were 
recruited at the Neurology Clinic of Tygerberg Academic Hospital, Cape 
Town, South Africa, and at the Neurology Clinic of Frere Hospital, East 
London, South Africa. Nigerian PD patients were recruited at the Neurology 
Clinic, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, 
Nigeria. All patients were confirmed to have PD by the neurologists, based on 
the UKPDSBBC diagnostic criteria. All patients provided written informed 
consent to take part in the study. This study was approved by the Health 
Research Ethics Committee of Stellenbosch University (HREC 2002/C059, 
N16/04/041 and S16/08/151), and the Ethics and Research Committee of 
Obafemi Awolowo University Teaching Hospitals (ERC/2015/08/15). 
Demographic information and clinical characteristics of the patients are 
summarized in Table 4.1. Individual data on each study participant are 
available in Table S4.1.  
Information about co-morbidities was collected, and included information on 
high blood pressure and diabetes on the Nigerian patients, and information on 
dementia and arthritis on the Black South African PD patients. 
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Blood samples were collected at the recruitment sites into 
ethylenediaminetetraacetic acid (EDTA) tubes and genomic DNA (gDNA) 
were extracted using the Nucleo Spin Blood XL kit (Macherey-Nagel Duren, 
Germany).  
 
4.3.2 Library Construction and Ion Torrent Sequencing 
 
gDNA was quantified with a Qubit 2.0 Fluorometer using the Qubit dsDNA 
HS assay kit according to the manufacturer’s protocol, MAN0002326 
REVA.0. Quality scores were determined on the LabChip GXII Touch using 
the DNA Extended Range LabChip and the gDNA Reagent Kit according to 
the protocol CLS140166, Rev. C (PerkinElmer, USA). The Ion AmpliSeq™ 
Neurological Diseases panel and the Ion AmpliSeq™ Library Kit 2.0 (Thermo 
Scientific, Waltham, Massachusetts, USA) were used for multiplex PCR 
amplification of 751 genes (APPENDIX V) and library construction prior to 
sequencing on the Ion S5.  
 
In addition to targeting all coding regions, an additional 101 non–coding 
disease–causing loci were targeted, as well as 14 repeat-expansion regions in 
genes AFF2, AR, ATN1, ATXN7, ATXN8OS, ATXN3, CACNA1A, CSTB, 
DMPK, HTT, JPH3, PABPN1, PPP2R2B, and TBP. Among the 751 
neurological genes on the panel, there are 16 genes which have been previously 
reported to contain mutations in PD patients. These genes are: SNCA, LRRK2, 
PRKN, PINK1, PARK7, ATP13A2, EIF4G1, GIGYF2, PLA2G6, FBXO7, 
VPS35, MAPT, HTRA2, SPG11, GRN and DCTN1. 
 
Using two primer pools with a 20 ng input gDNA template, the target regions 
were amplified in 13 cycles, consisting of 15 s at 99°C and 16 min at 60°C, on 
the SimpliAmp Thermal Cycler Kit (Thermo Fisher Scientific, Waltham, MA, 
USA)  using the Ion AmpliSeq™ Neurological Diseases Panel according to the 
manufacturer’s protocol, MAN0006735, REVE.0 (www.ampliseq.com).  
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Following amplification with the two primer pools, the products were 
combined and primer sequences partially digested by the IonShear™ Plus 
Enzyme Mix II. Barcode adapters were used to generate adapter-ligated 
libraries. The libraries were purified with Agencourt™ AMPure™ XP reagent 
and eluted in 50 µl low-Tris-EDTA buffer. 
 
The AmpliSeq™ library was quantified using the Ion Library TaqMan™ 
Quantitation Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to 
the manufacturer’s protocol, MAN0015802 REVA.0. Quantitative PCR 
amplification was performed using the StepOnePlus™ Real-time PCR system 
(Thermo Scientific, Waltham, Massachusetts, USA) (APPENDIX V1). 
Libraries were diluted to 60 pM. The diluted, barcoded libraries were combined 
in equivamolar amounts using the Ion520™ and Ion530™ Chef Kit. In brief, 
25 µl of pooled diluted library were loaded on the IonChef liquid handler using 
reagents, solutions and supplies according to the manufacturer’s protocol, 
MAN0010846, REVD.0. Enriched, template-positive ion sphere particles were 
loaded onto two Ion530™ Chips. Massively parallel sequencing was 
performed on the Ion S5™ System using the Ion S5™ Sequencing Solutions 
and Sequencing Reagent Kits according to the manufacturer’s protocol, 
MAN0010846 REV D.0 (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) at the DNA Sequencing Unit, Central Analytical Facilities of 
Stellenbosch University, Stellenbosch, South Africa. 
 
4.3.3 Quality Control, Annotation and Variant Prioritization of 
Targeted NGS (tNGS) Data  
The flow space calibration, base calling, alignment with the reference genome 
(GRCh38–hg19), coverage analysis and variant calling were performed using 
standard parameters in the Ion Torrent Suite Version 5.4.0. Sequenced variants, 
including insertions and deletions (INDELs), splice site variants, single 
nucleotide variants (SNVs), multiple nucleotide variants (MNVs), as well as 
variants in the 3’ untranslated region (UTR3) and 5’ untranslated region 
(UTR5) were identified.  
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The variant call format (VCF) files produced by the Ion Torrent Software Suite 
(ISS) were filtered using bcftools to ensure that: 
FILTER = PASS (the ISS internal criteria for setting the PASS filter were 
met)  
QUAL > 100 (thequality score exceeded 100)  
FMT/AO ≥ 20 (there were at least 20 read for the alternative allele) 
FMT/DP ≥ 40 (there were at least 40 reads)  
FMT/SAF ≥ 5 (there were at least 5 reads of the alternative allele in the 
forward direction)  
FMT/SAR ≥ 5 (there were at least 5 reads of the alternative allele in the 
reverse direction) 
These criteria ensured that the observation was made in both directions with at 
least five reads in either direction, the overall depth was at least 40 and the 
alternative allele depth was at least 20. 
The VCF files were merged into a single file and processed with the utility 
annovar (annovar.openbioinformatics.org/) to produce an annotation file for 
all the variants that passed the criteria above. We separated the Nigerian and 
South African subsets of our data set. All available annotations were included. 
These included conservation scores, allele frequencies and functional 
predictions (Table S3). Perl (https://www.perl.org/)  was used to extract data 
and analyses were carried out in R (R Core Team, 2018). Variants were 
extracted as homozygous (homo) or heterozygous (hetero) for the alternative 
allele.  
 
The quality scores for all the variants passing the filters were extracted and 
analyzed in R. Using the bam files, bedtools was used to generate statistics on 
the coverage (depth of sequencing) for the regions in the Ampliseq capture 
panel as defined by the manufacturer’s bed file. We read in the quality score 
for each variant in matrix format.  In order to identify novel PD candidate 
genes, we focused on variants that are rare in control populations as defined by 
a minor allele frequency (MAF) threshold of 0.01.  
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Kaviar allele frequency threshold was set to include only variants that had 
MAF ≤ 0.01 or no frequency information. We created global classifications of 
variants and generated a summary of variant types, to encode variants as 
synonymous, missense or frameshift in the variable amino acid class, insertion, 
deletion or substitution in the variable mutation type, as well as single or 
multiple base variants in the variable mutated base). 
 
We merged the variant summary (whether the variant was observed as a 
homozygous or heterozygous), with the annotation. We also computed how 
many individuals shared each variant, in total as well as in the regional 
ethnicities, and displayed the results using Venn diagrams (https://www.r-
graph-gallery.com/14-venn-diagramm). 
 
We searched for previously reported mutations in PD patients catalogued in the 
PDmutDB database (http://www.molgen.vib-ua.be/PDmutDB), from the list of 
variants identified. The PDmutDB (Cruts et al., 2012; Nuytemans et al., 2010) 
contains data on mutations in the following genes: SNCA, LRRK2, PRKN, 
PINK1 and PARK7. We accessed the PDmutDB last on 30 September, 2018, 
and it contained 25 different pathogenic mutations in SNCA2 in 50 different 
families, six different pathogenic mutations in LRRK2 in 940 different families, 
127 different pathogenic mutations in PRKN in 607 different families, 28 
different pathogenic mutations in PINK1 in 65 different families, and six 
different pathogenic mutations in PARK7 in ten different families.  
We used the prediction scores MetaLR and MetaSVM for selecting deleterious 
sequence variants (Table S4.3). MetaLR and MKetaSVM are themselves 
ensembles (composite models) of many other scores (Liu et al., 2016). 
Currently, these two have the best performance on curated data sets (training 
and test) of non-synonymous variants that contain both deleterious (protein-
function altering) and benign variants. We, therefore, used these to prioritize 
the variants in our data.  
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Both metrics were scaled as probabilities [0, 1] with scores close to 1 indicating 
certainty that the variant is deleterious. We used score >0.8 as a cut-off for 
including the variant into our list of “variants predicted to be deleterious” as 
recommended by Liu et al (Liu et al., 2016). For variants in genes known to 
harbour mutations in patients with PD in previous studies (ATP13A2, PARK7, 
LRRK2, PINK1, PRKN, and SNCA), we used a less stringent filtering threshold 
>0.45.  
The rationale for this was that there is a greater prior probability that a variant 
in these genes will have an effect on the disease than in genes not previously 
known to be associated with the PD. We also used 24 other variant scoring 
algorithms. We plotted the correlation matrix of all 26 mutation scoring 
algorithm outputs used in our study. We generated Radar plots 
(http://www.cmap.polytechnique.fr/~lepennec/R/Radar/RadarAndParallelPlot
s.html) for each variant likely to be deleterious to demonstrate the correlation 
among 17 different scoring algorithms. All scores were standardized to 0–1 
scale with score 1 (furthest from the center of the graph) indicating strongest 
evidence that the variant is deleterious. See Supplement for details on the 
scores used in the analyses. 
The BAM files of the tNGS data have been deposited to the European 
Nucleotide Archive (ENA) and can be retrieved with an accession number from 
https://www.ebi.ac.uk/ena/browse/data-retrieval-rest.  
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4.3.4   Sanger Sequencing 
We selected four novel variants for verification to confirm the tNGS results. 
Specific oligonucleotide primers were designed on Ensembl Genome Browser 
(https://www.ensembl.org/) and Primer3 web version 4.0.0 (primer3.ut.ee/) 
(Table S4). We used BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-
blast) to confirm the primer specificity. PCR was performed in a reaction 
mixture containing a final volume of 25 μl on a PCR machine (2720 Thermal 
Cycler, Applied Biosystems, Forster City, California, USA). Clean-up of PCR 
products was done by adding 0.05 ul of 100 units/μl (at 0.62 μM final 
concentration) Shrimp Alkaline Phosphatase and 0.5 μl of 20 units/μl (at 1.25 
μM final concentration) Exonuclease 1 enzymes (New England Biolabs UK 
Ltd). Sequencing of the purified DNA samples was carried out using the 
BigDye® Terminator version 3.1 Cycle Sequencing kit (Applied Biosystems, 
Forster City, California, USA) on an ABI Prism™ 3730 XL automated 
sequencer (Applied Biosystems, Forster City, California, USA), at the DNA 
Sequencing Unit, Central Analytical Facilities of Stellenbosch University. 
4.3.5  High Resolution Melt (HRM) Analysis  
Two novel variants were selected for HRM screening in 150 Black South 
African controls to assess their frequency. DNA samples were amplified using 
the same primers as for Sanger sequencing (Table S4.3) to screen for the 
sequence variants ATP13A2 S960R and PRKN D245E. Briefly, a reaction 
mixture containing 1 μl of 2 μM (at 0.08 μM final concentration) SYTO9 
fluorescence dye (ThermoFisher Life Technology, Waltham, Massachusetts, 
USA) was added, to make a final reaction volume of 25 μl. The samples were 
placed in a Rotor-Gene 6000 Series real-time analyzer HRM machine (Corbett 
Research UK Ltd, Cambridge, United Kingdom) for the real-time PCR and 
HRM. The range of melting temperatures selected was 65–90oC. The melting 
curves were viewed on the Rotor-Gene Q series software 
(https://www.qiagen.com) for the analysis of the normalised and the difference 
graphs. 
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4.3.6 Protein Structures and Modelling for Functional Prediction 
To understand the changes introduced by the variants predicted to be 
deleterious in the protein structure, we selected novel variants identified in this 
study in PINK1, a known PD gene, for this analysis. We extracted protein 
information from the Protein Data Bank (https://www.rcsb.org/) (Kouranov et 
al., 2006). 
 
The human PINK1 structure was aligned to the Pediculus humanus  corporis 
structure reported by Schubert et al (Schubert et al., 2017), using PyMOL 
(pymol.org) Structural alignment was possible because PINK1 is highly 
conserved between phyla. Exceptions to the conservation occur in limited 
regions that form loops. The most divergent regions are the insertion sequence 
1, which is poorly conserved and in P. humanus corporis is about 20 amino 
acids shorter, and in insertion sequence 2, which is weakly conserved, but about 
the same length (Schubert et al., 2017). A previously reported pathogenic 
PINK1 mutation L347P was used as a reference (Schubert et al., 2017).  
We used Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) 
to construct a protein secondary and tertiary structure to extend known crystal 
structure for PINK1. Phyre2 is a suite of tools available on the web to predict 
and analyse protein structure, function and mutations (Kelley et al., 2015). 
We then used Mobyle (http://mobyle.rpbs.univ-paris-diderot.fr/cgi-
bin/portal.py#welcome) to predict stability of β-turn secondary structure in 
PINK1 S228F. This method can predict both the presence and the type of β‐
turns, using propensities and multiple alignments (Fuchs and Alix, 2005). 
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4.3.7   Network Analysis 
We used Ingenuity Pathway Analysis® (IPA) tool version 9.0 (Qiagen’s 
Ingenuity Systems, Redwood City, CA, USA; www.ingenuity.com) to 
determine the functional classes, cellular localization and drug targets of the 44 
genes harboring variants predicted to be deleterious.  
 
To determine the functional connections that exist between the proteins 
encoded by the known PD genes and other genes that we identified to harbor 
putative pathogenic mutations in the PD patients, a network analysis was 
carried out using ConsensusPathDB 33 (11.04.2018) 
(http://cpdb.molgen.mpg.de/CPDB)188-191). The list of 44 genes was 
submitted to the ConsensusPathDB web-based tool for generating an inferred 
network. ConsensusPathDB–human integrates interaction networks in Homo 
sapiens including binary and complex protein–protein, genetic, metabolic, 
signalling, gene regulatory and drug–target interactions, as well as biochemical 
pathways. Currently the data originate from 32 public resources for interactions 
and interactions that have been curated from the literature.  
 
When the ConsensusPathDB  analysis as carried out (4 September, 2018), the 
database contained the following annotations: 170,276 unique physical entities, 
603,543 unique interactions, 17,410 gene regulations, 397,088 protein 
interactions, 1,738 genetic interactions, 23,482 biochemical reactions, 163,825 
drug-target interactions and a total of 5,359 pathways. ConsensusPathDB infers 
a network to include proteins or metabolites that are not in the user-supplied 
input list, but associate two or more nodes (gene/protein/metabolites) on the 
input list with each other. These nodes are termed intermediate nodes and are 
ranked according to the significance of association with the input nodes given 
their overall connectivity in the background network. This is quantified by a z-
score calculated for each intermediate node with the binomial proportion test. 
We used only interactions with “high confidence” evidence as implemented in 
a study by Kamburov et al. (Kamburov et al., 2013).  
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4.4    RESULTS 
4.4.1  Characteristics of Study Participants 
In this study, 33 Black South African and 14 Nigerian PD patients were 
screened for mutations in 751 candidate genes as part of a neurological diseases 
gene panel. The South African patients were of Sotho, Xhosa, Zulu or Ndebele 
origins, and the Nigerian patients were from the Yoruba ethnic group. The age-
at-onset (AAO) of PD in patients varied between the two study groups. The 
estimated mean AAO for the South African PD patients was 48±8 years while 
the mean AAO for the Nigerian patients was 63±13 years (Table 4.1 and Table 
S4.1). Recruitment in South Africa was prioritized so that predominantly PD 
patients with earlier AAO (30–59 years) were recruited. In Nigeria, the PD 
patients recruited were mostly sporadic cases and had later onset of the disease 
(60–85 years).  One Nigerian patient had an AAO of only 36 years, and five 
others were <60 years.  
 
Two of the South African PD patients had a positive family history of the 
disease. PD is known to affect males more often than females. In the South 
African patients, 45% were female, but in the Nigerian patients, only 21% were 
female. Numbers of patients with comorbidities were 2/33 and 8/14 among the 
South African and Nigerian patients, respectively (Table 4.1). 
 
4.4.2   Quality of NGS Data 
The sequencing data on the 47 samples were of good quality. We plotted a 
graph for the target region coverage using the bamfiles generated by the Ion 
Torrent Variant Caller (Figure S4.1). This graph showed that 41 samples were 
above 80% for the fraction of capture target bases at an average read depth of 
40X, three samples had a coverage of 78–79%, and another three samples had 
a coverage of 61–76% (Figure S4.1).  
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The mean and the median scores of the variant calls were standardised and 
plotted as a smooth density histogram. The histograms showed the quality 
versus depth for the variants called in each sample. The two peaks observed in 
the histogram per sample showed adequate overall distribution of quality and 
depth density (Figure S4.2).  
 
We assessed separately the quality of sequence data on the six known PD genes 
ATP13A2, LRRK2, PARK7, PINK1, PRKN, and SNCA. As can be seen in 
Figure S3, there was quite a large variation in the quality scores for the exonic 
regions of these genes. Many regions were below the 100 threshold set for the 
analyses. 
 
4.4.3  Identification of Sequence Variants 
We applied stringent threshold criteria for the filtering and annotation of the 
variants to exclude low quality variants. Altogether 25,917 sequence variants 
passed quality control. We then removed from the list all variants with 
MAF>0.01 in any of the sequencing databases used as reference databases for 
the study (Table S3) and were left with 14,655 rare variants. These rare variants 
could be classified into 7,934 intronic and 5,695 exonic variants (Figure 4.1; 
an interactive html-version of the figure is at https://www.frontiersin.org). 
They included 198 UTR5 and 341 UTR3 variants, as well as 32 frameshift, 
3,175 synonymous and 2,448 missense variants. Altogether 14,057 were SNVs 
and 598 MNVs. There were 261 insertions, 600 deletions and 13,794 
substitutions (Figure 4.1).  
 
From the list of previously described pathogenic mutations in known PD genes 
and linked to PD (LRRK2, PARK7, PINK1, PRKN, and SNCA) and catalogued 
in the PDmutDB database (http://www.molgen.vib-ua.be/PDmutDB/), or 
variants reported in ATP13A2, we did not find any of the known PD mutations 
in the study groups. A subset of the South African samples had been screened 
for mutations in these genes previously by other methods (Haylett et al. 2012).  
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In these previous studies one patient (78_074) was found to have two mutations 
in the PRKN gene: G430D and exon 4 deletion (Haylett et al. 2012). These 
variants did not pass quality control in the current study. Quality score was 50.1 
(only variants with score of >100 were considered), depth was 31 (had to be at 
least 40), number of reads in reverse 19 (had to be at least 20), number of reads 
for the alternative allele: 12 (had to be at least 20); number of reads for in 
forward for the alternative allele: 5 (had to be at least 5), and number of reads 
in reverse for the  alternative allele: 7 (had to be at least 5) 
 
We also assessed how often each variant was found in common between the 
two study groups. The shared variants in the study groups included 5899  
substitutions, 189 deletions and 110 insertions (Figure 4.2).  
 
4.4.4  Pathogenicity Prediction of Variants 
To determine which variants were likely to be pathogenic and contribute to the 
PD pathobiology in the study groups, we present data on 26 different scoring 
systems (Table S4.3 and Figure S4.4). For the final selection of variants 
predicted to be deleterious, we used MetaLR and MetaSVM as these two have 
shown the best performance on curated data sets (Liu et al., 2016).  
 
We focused on identifying homozygous and heterozygous rare (MAF ≤ 0.01) 
or novel (not seen in any of the databases listed in Table S3) exonic variants 
predicted to be pathogenic, to identify novel genes that could have an 
association with the PD pathobiology. The goal was to minimize the number 
of false positives by applying stringent filtering criteria. We realize that this 
would lead to false negatives, but in a study to identify novel genes for disease 
pathobiology, it is better to apply stringent threshold. Altogether, 58 exonic, 
heterozygous missense variants and two exonic homozygous rare (MAF ≤0.01) 
missense variants were predicted to be deleterious (Table 4.2 and Table 4.3), 
in 44 genes. 
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In Figure 3 we present the radar plots demonstrating 17 different pathogenicity 
scores for each of these 60 variants. The deleteriousness scores were 
standardised for uniformity before making the radar plots. The observations of 
the variants identified in the known PD genes PRKN and PINK1, and in the 
ARSA, ATP2A1, CP, DST, FLNA, GNE, PC, PSEN2, RYR1, SAMHD1, 
SLC12A6, and TMEM67 genes indicated limited concordance between the 
deleteriousness prediction tools.  
  
The 60 variants predicted to be deleterious based on MetaLR and MetaSVM 
scores included seven novel heterozygous missense variants in three known PD 
genes: ATP13A2 (S960R), PRKN (P153R and D245E) and PINK1 (S73L, 
S228F, S284Y and P305A) (Table 4.2). Most (53/60) of the sequence variants 
predicted to be deleterious were not in any of the known PD genes and included  
41 genes not previously associated with PD genetics (Table 4.2). 
 
The ATP13A2 (S960R) substitution was among the variants that passed the 
threshold of >0.8 for deleteriousness using MetaLR and MetaSVM scores. 
However, because the known PD genes already have adequate supporting 
evidence for their role in the pathobiology of PD, it is therefore, plausible to 
identify candidates with a lower deleteriousness score (i.e., because of prior 
evidence, the chances of false positives is lower at the same threshold). Hence, 
we relaxed the MetaLR and MetaSVM deleteriousness threshold to >0.45 to 
allow six additional deleterious variants in PRKN (P153R and D245E) and 
PINK1 (S73L, S228F, S284Y and P305A) to be included in the list of variants 
predicted to be deleterious (Figure S4.5, Table 4.2, and Table 4.3). 
 
Altogether, 21% (7/33) of the South African patients and 29% (4/14) of the 
Nigerian PD patients did not have any deleterious variants in the 751 genes 
studied here (Table 3).  
Some patients had more than one deleterious variant (Table 4.3). They included 
22 (67%) South African and six (43%) Nigerian patients. Twelve (36%) South 
African and five (36%) Nigerian PD patients had two pathogenic variants, of 
which compound heterozygosity occurred in four SA PD patients and as well 
two homozygotes identified in the South African PD patients (Table 4.3). 
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Ten (30%) South Africans had 3-5 variants predicted to be deleterious, which 
probably means that some of these variants are not associated with PD. Only 
one Nigerian patient had three variants predicted to be deleterious, and no 
Nigerian patient had more than three variants predicted to be deleterious. 
 
Thirteen variants were found in more than one study patient (Table 4.2, Table 
4.3). One variant (SCN4A E81Q) was found in four patients, two of whom were 
South African and two Nigerian. This variant, therefore, had an estimated MAF 
of 0.043 among Black SSA PD patients. Three variants (GALC T445S, GNE 
D203E, and PINK1 P305A) were found in three South African patients (Table 
2 and Table 3) yielding an estimated MAF of 0.045 among Black South African 
PD patients. RYR1 P1632S was found in two South African and one Nigerian 
patient. Altogether eight variants (CAPN3 R441Q, CLN6 S257G, NDUFAF5 
G294A, PC R732G, PRNK D245E, PSEN1 V191A, RYR1 D2943N, and RYR1 
H3642Q) were found in two study patients yielding an estimated MAF of 0.021 
among Black SSA PD patients. 
 
4.4.5   Follow-up Studies 
Four novel variants (PRKN D245E, ATP13A2 S960R, PINK1 S228F and 
PINK1 P305A) were selected for verification using Sanger sequencing. As 
shown in Figure S6, all four were confirmed.  
 
The frequencies of two of these variants (PRKN D245E and ATP13A2 S960R) 
were assessed in 150 controls of Black South African ancestry using HRM. 
The HRM normalised and the difference graphs showed that the variants were 
present only in the two PD patients analysed by tNGS and Sanger sequencing, 
and were not found in any of the controls (Figure S4.7). The estimated 
frequency among Black South Africans controls was, therefore, < 0.0033.       
 
Functional classification of the 44 genes revealed that 23 (52%) of them were 
enzymes (Table S4.5). Other functional classes included transporter, ion 
channel and transmembrane receptor. The cellular localization was in the 
Stellenbosch University  https://scholar.sun.ac.za
                                                               
                                        142 
 
cytoplasm for 26, nucleus for six, plasma membrane for eight, and extracellular 
for four of the proteins encoded by the 44 genes. Altogether 43 of 44 genes 
(97.7%) were mapped to 66 distinct proteins in ConsensusPathDB (Figure 
S4.7). Interactions were shown between the 44 proteins, on which 20 proteins 
were intermediate nodes and 24 proteins are seed nodes involved in the control 
of biological processes. The ConsensusPathDB analyses also revealed 
interactions between the three known PD genes (ATP13A2, PRKN and PINK1) 
and some of the 41 other genes not previously associated with PD. The PRKN 
protein appeared to be at the center of several interactions, suggesting that 
autophagy and mitochondrial dysfunction, as well as, oxidative stress could be 
plausible mechanisms of PD pathobiology for the 41 novel genes connected to 
PRKN gene (Figure S4.7). Also, PINK1 protein demonstrated interaction with 
PRKN in this analysis. We highlighted signs and symptoms of the neurological 
diseases that are associated with the 41 non-PD genes and their potential 
phenotypic overlap with PD (Table S4.6). 
The variants S228F, S284Y and P305A identified in PINK1, which is an 
established PD gene, were subjected to protein modelling to predict the effects 
of these variants on the function of the PINK1 protein. For this analysis the 
human PINK1 was aligned to the Pediculus humanus corporis structure 
reported by Schubert et al (Schubert et al., 2017). In the models the PINK1 
mutation S228F (red) is seen in the interface between parkin (blue and green) 
and ubiquitin (beige) in the complex (Figure 4.4).  PINK1 S228 is also highly 
conserved across different species and is a known site for autophosphorylation, 
which is important for the kinase activity (Rasool et al., 2018; Schubert et al., 
2017). The PINK1 mutation S284Y (yellow) is seen on the surface of PINK1 
but not at a binding interface. Although, it is the carboxy-terminal residue in a 
beta sheet (β4) and tyrosine is not frequently found in the carboxy-terminal 
position of a beta sheet, it is unlikely to have a large destabilizing effect. 
 PINK1 P305A (orange) mutation is in a loop not directly interacting with 
ubiquitin (Figure 4.4).  
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It is located in an insertion sequence 3 (Schubert et al., 2017), which comprises 
27 amino acids that in many species contains 5 or 6 prolines. P305 is conserved 
among the eight species aligned by Schubert et al. (Schubert et al., 2017). The 
conservation among species suggests that it might be required for efficient 
folding of PINK1. Substitution of alanine for proline is likely to make the loop 
at the top of the molecule (Figure 4.4) more flexible and possibly less ordered. 
Not observed in the current study, but shown as a reference in Figure 4.4 is a 
previously identified PINK1 mutation L347P (magenta), which has been 
shown to disrupt an α-helix in the core of the carboxyl-terminal lobe of PINK1 
destabilizing the structure (Schubert et al., 2017). This mutation has been 
reported in three different studies (Doostzadeh et al., 2007; Hatano et al., 2004; 
Rogaeva et al., 2004), including in a study on a patient diagnosed with juvenile 
parkinsonism, which was inherited in an autosomal recessive manner (Hatano 
et al., 2004). 
 
4.5   DISCUSSION 
In this study, we recruited 47 Black South African and Nigerian PD patients 
and screened them for rare pathogenic mutations in 751 genes involved in 
neurological diseases. The study groups represented SSA population 
understudied in PD genetics. Altogether 60 potentially deleterious sequence 
variants with MAF ≤ 0.01 in 44 different genes were identified. 
 
4.5.1 tNGS of 47 Black African PD Patients Identifies Novel Variants 
in Three PD Genes   
To date, 34 genes have been directly implicated in the etiology of PD (Jansen 
et al., 2017; Michelle K Lin and Farrer, 2014; Quadri et al., 2018). Six of these 
genes have been consistently and robustly associated with PD pathology 
(ATP13A2, LRRK2, PARK7, PINK1, PRKN, and SNCA). However, most PD 
patients do not harbor mutations in these genes. 
The 751-gene array used in the current study contains only 16 of the 34 known 
PD genes, but it does have all six genes (ATP13A2, LRRK2, PARK7, PINK1, 
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PRKN, and SNCA) with the strongest prior evidence of being involved in PD 
pathobiology.  
The panel covers 100% of the exonic regions of these six genes, but the quality 
of the sequence data obtained on them was variable. We identified pathogenic 
sequence variants in only three (ATP13A2, PRKN and PINK1) of these 16 
genes in the SSA study patients.  
Previous studies found mutations in these genes in patients with an early onset 
PD (Morais et al., 2016). A study by Sironi et al (Sironi et al., 2008) analysed 
the PRKN gene in 146 unrelated early AAO PD patients and identified twelve 
cases (8.2%) with homozygous or compound heterozygous point mutations 
and/or exon rearrangements. In our study, the AAO varied between different 
patients with the same variants. The PRKN D245E variant was found in two 
Black South African male PD patients, one of whom had an AAO of 49, and 
the other 35 years, whereas P153R, the second PKRN variant predicted to be 
deleterious, was identified in a single Nigerian male patient who was diagnosed 
at the age of 36 years. The South African male PD patient with the ATP13A2 
S960R variant had AAO of 39 years. The three South African patients (two 
female and one male patient) with the PINK1 P305A variant had AAO of 30, 
53 and 55 years. Patients with three different PINK1 variants (S73L, S228F 
and S284Y) were all 53 years when diagnosed with PD. Since the recruitment 
in South Africa targeted younger patients, it is difficult to make any 
generalizations of the AAO and type of variant. 
The protein structure and modelling analysis of the PINK1 S228F found in the 
53-year old Nigerian patient suggested that the variant is functionally 
important. The S228F mutation occurs at the interface between PINK1 and 
ubiquitin (Figure 4.4). Substitution of serine with phenylalanine changes both 
the physical size of the side chain as well as its properties, changing from polar 
to hydrophobic.  
The size alone has the potential to sterically hinder the binding, and the change 
in hydrophobicity will likely change the rates of association and dissociation 
should the S228F not sterically hinder the binding.  
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More importantly, a recent study (Rasool et al., 2018) demonstrated that 
autophosphorylation of S228 is required for ubiquitin binding. Together, these 
observations make it highly probable that S228F causes, or contributes to, PD 
in this patient. 
We did not identify any of the previously reported mutations in SNCA, LRRK2, 
PARK7, PINK1 or PRKN associated with PD and catalogued in the PDmutDB 
database (https://www.molgen.vib-ua.be/PDMutDB/database) in the SSA 
patients. There are two possible explanations for this. One is that as seen in 
previous genetic studies on SSA PD patients, common mutations such as 
LRRK2 G2019S are a rare cause of PD in these populations (Blanckenberg et 
al., 2013). The other possible explanation is that the variants in these genes did 
not pass our strict quality control. 
 
4.5.2 The Majority of variants predicted to be deleterious are in genes 
not previously associated with PD pathobiology 
Out of the 60 missense variants predicted to be deleterious in the current study, 
53 were in 41 genes not previously known to harbour mutations in PD patients.  
More than half of the 44 genes with deleterious variants identified in this study 
encode enzymes. Previous studies have pointed to neuroinflammation and 
immune dysfunction as important mediators in PD development (Poewe et al., 
2017). Enzymes are key regulators in neuro-inflammation processes and could 
also be associated with other enzyme-dependent-biomedical pathways. 
Inheritance pattern for mutations in genes encoding enzymes is usually 
autosomal recessive. Hence, these genes serve as important candidate genes in 
further studies to understand PD pathobiology.  
 
The novel PD genes with deleterious variants identified in this study have 
important physiological functions (http://www.uniprot.org). Many of them are 
part of the basement membrane and have been implicated in a wide variety of 
biological processes including cell adhesion, differentiation, migration, 
signalling, neurite outgrowth and metastasis.  
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Some of them are part of calcium channels responsible for muscle fibres and 
nerve impulses and the regulation of other genes. Below we highlight some of 
the deleterious variants found in these 41 genes. 
 
We identified a hemizygous deleterious variant in AR in one 55-year old male 
Black South African PD patient (Table S4.1, Table 4.2 and Table 4.3). AR is 
located on the X chromosome. AR protein functions as a steroid-hormone 
activated transcription factor and also stimulates transcription of androgen-
responsive genes. Mutations in this gene have been attributed to many forms 
of cancer, and recently mutations in AR were associated with spinal and bulbar 
muscular atrophy (Lieberman, 2018). The same patient also had a deleterious 
variant in the GNE gene. 
 
We identified two different deleterious variants in FLNA (A666V and G1698S) 
in the Black South African PD patients (Table 4.2 and Table 4.3).  A 37-year 
old man was homozygous for the A666V variant, whereas a 52-year old woman 
was heterozygous for the G1698S variant (Table S1 and Table 3). The male 
patient also had a deleterious variant in ALDH7A1, and the female patient had 
two other deleterious RYR1 variants. FLNA gene encodes a protein named 
filamin A, which binds to many other proteins in the cell to carry out various 
functions, including the attachment of cells to one another, cell movement, 
determination of cell shape, and cell survival. It is involved in skeletal muscle 
and brain development. 
 
We also identified four deleterious variants in the RYR1 gene (Table 4.2 and 
Table 4.3), which encodes a protein involved in the formation of calcium 
channels. Physiologically, calcium regulates the dopamine release during 
exocytosis, suggesting that this protein could have a potential role in 
PDpathobiology. Two of the RYR1 variants (H3642Q and P1632S) were 
present in two PD patients. 
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We found a heterozygous deleterious variant SCN4A E81Q in four patients, 
two of whom were South African and two Nigerian. The sodium channel genes 
are highly conserved with few amino acid substitutions among some 65 
mammalian proteins (Zakon, 2012). A number of pathogenic mutations which 
give rise to a variety of muscle disorders including various myotonias and 
periodic paralyses, have been characterized in SCN4A (Platt and Griggs, 2009). 
Almost all of the consequential mutations occur in the transmembrane helices 
of the pore loops. Only two mutations have been characterized in the N-
terminal cytoplasmic domain. One of these, P72L, showed very little functional 
effect, and was thought to be a modifier. The other, R104H, caused complete 
loss of function when in recessive form (sodium channel is composed of two 
mutated subunits). The E81Q mutation identified in the current study in four 
PD patients scored as deleterious by prediction algorithms. It is difficult to add 
further interpretation to the predicted consequence of an E81Q substitution. It 
is possible that decreased functionality of the sodium channel could aggravate 
tremor caused by, and characteristics of PD. 
 
The AARS gene catalyses the attachment of alanine to tRNA. The Y535F 
mutation was found in AARS in one female Nigerian PD patient, who was 
diagnosed with PD at the age of 80 (Table S4.1, Table 4.2 and Table 4.3).  
 
We also found a deleterious variant (G5585S) in the TTN gene in one female 
South African PD patient who developed PD at the age of 31 years (Table S4.1, 
Table 4.2 and Table 4.3). The same patient had two other deleterious variants, 
one in NDUFS2 and the other in SAMHD1. TTN encodes the protein called 
titin, which plays an important role in muscle movement. Mutations in this gene 
have been linked to severe limb girdle muscular dystrophies (Harris et al., 
2017).  
The role for the POLG gene in PD is still debatable. A study published in 2008 
identified two mutations in 31 unrelated patients with autosomal recessive 
parkinsonism (Wong et al., 2008).  
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Moreover, it is interesting that in our study a heterozygous deleterious variant 
in POLG was found in one Nigerian patient, who also had a deleterious variant 
in the CAPN3 gene (Table 2 and Table 3). The patient had an AAO of PD at 
71 (Table S1) and had a history of exposure to environmental toxins that could 
damage the mitochondria, and potentially make him more susceptible for 
developing PD.  
4.5.3   Study Limitations 
Our study has several limitations. First, the sample size was small making it 
difficult to estimate the actual contribution of genetic factors to PD in the SSA 
populations. The belief that PD is caused by witchcraft and does not have a 
genetic link among Black SSA populations (Mokaya et al., 2017), may have 
contributed to difficulty in recruiting more patients for the study. More 
awareness of PD is needed in this region, which can be achieved by organizing 
educational programs and PD support groups.  
 
Second, we used a commercially available targeted gene panel for sequencing 
and were able to analyse primarily the protein-coding regions of the 751 genes 
of the panel. It is possible that intronic variants could produce aberrant RNA 
splicing of exons and cause premature decay of mRNA, resulting in no protein 
synthesis (Aneichyk et al., 2018; Cartegni et al., 2002). Furthermore, 18 of the 
34 previously identified PD genes were not on the panel. 
 
Third, the Ion Torrent sequencing platform used in the study has difficulty in 
detecting the length of homopolymer stretches with precision. We observed 
this in the annotation where INDELs appeared as one or more codons at a time. 
Also, tNGS might not be able to correctly detect large deletions that span entire 
exons and other structural changes. It is important to mention that 15 of the 33 
South African and all of the 14 Nigerian patients used in this study were also 
included in the MLPA analysis. The results showed that three Nigerian PD 
patients had four CNVs in three known PD genes (PINK, PRKN and PARK7). 
The role of heterozygous and homozygous structural changes in PD is well-
established (La Cognata et al., 2017), and future studies in this SSA sample 
should take this into consideration.  
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It is important therefore, to screen the Black South African PD patients with 
early AAO for copy number variations especially in the PINK1 and PRKN 
genes as copy number variations in these genes have been linked to PD 
(Pankratz et al., 2011).     
Fourth, annotation of sequence variants in terms of effect on the protein 
remains problematic, as demonstrated by the discrepancy between predictions 
from different algorithms. We chose to use the MetaLR and MetaSVM 
algorithms that currently appear to perform best, but also present results from 
26 different scoring algorithms.  
Fifth, due to the small sample sizes, we were not able to carry out a replication 
study for the variants identified among the SSA PD patients. As numerous 
previous genetic studies have shown (Elbaz et al., 2006), replication is an 
essential next step for our study. This will, however, require long-term 
recruitment efforts to achieve a larger sample size.  
Sixth, variants identified in our study as potentially deleterious might not be 
involved in PD pathobiology. It is plausible that some of the patients had other 
clinical conditions, in addition to PD. It is, therefore, possible that the 
discovered deleterious variants may contribute to that other disease. On the 
other hand, it is also possible that having only one mutant allele was not 
sufficient to manifest as a disease since many of the genes encode for enzymes. 
Most (58/60) of the deleterious variants were found in a heterozygous state in 
the study patients and these patients could be carriers of rare, non-PD diseases. 
Previous studies have shown that each human being has approximately “110-
120 predicted highly deleterious alleles” in his/her genome (Henn et al., 2016). 
Only extensive follow-up studies, which are beyond the scope of this study, 
will be able to address this limitation. 
Seventh, we did not carry out any functional follow-up studies. We 
acknowledge that identification and prioritization of PD candidate genes 
requires  additional work,  including functional cell-based assays (Jansen et al., 
2017) and use of animal models to characterize mutations and understand their 
true significance in PD.  Other groups have used induced pluripotent stem cell 
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(iPSC) models to assess the functional significance of sequence changes in 
neuronal cell lines (Djelloul et al., 2015; Holmqvist et al., 2016; Russ et al., 
2018). 
In conclusion, the use of tNGS to screen for pathogenic mutations in the 
understudied SSA populations for PD genetics in this study provided a list of 
novel candidate genes. Further studies are required to ascertain their roles in 
PD among SSA patients.  
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4.10    Tables and Figures 
 
         Table 4.1: Characteristics of the 47 PD patients 
Characteristic 
Black South African 
N = 33 
Nigerian 
N = 14 
Sex, males, n (%) 18 (54) 11 (78) 
Average age-at-onset ± 
SD (range), years 
48 ± 8 (30-59) 63 ± 13 (36-80) 
Average age at 
recruitment ± SD 
(range), years 
55 ± 11 (35-78) 67 ± 11 (42-81) 
Positive family history 
for PD, n (%) 
2 (6) 0 
History of trauma/head 
injury, n (%) 
 4 (29) 
Co-morbidities,a n (%) 2 (6) 8 (57) 
aCo-morbidities on which information was collected on the Nigerian patients included high 
blood pressure and diabetes, whereas information on dementia and arthritis was collected 
on the Black South African PD patients. 
See Table S4.1 for additional individual clinical information on the patients. 
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     Table 4.2. Variants predicted to be deleterious identified using MetaLR and MetaSVM 
Chr Start Symbol  Ref  Alt  AAfrom  AAPos  AAto  Sanger 
sequencing 
verification1 
 HRM 
screening1 
Known 
PD 
gene 
FreqNGR  FreqSA  FreqAll  
16  70296316  AARS  T  A  Y  535  F     1  0  1  
22  40755001  ADSL  G  T  A  206  S     0  1  1  
5  125919688  ALDH7A1  C  T  R  110  Q     0  1  1  
X  66863156  AR  A  T  T  559  S     0  1  1  
22  51063778  ARSA  T  C  N  442  S     0  1  1  
22  51065288  ARSA  G  T  P  220  T     1  0  1  
1  17313614  ATP13A2  T  G  S  960  R  Yes Yes Yes 0  1  1  
16  28912085  ATP2A1  G  A  D  525  N     0  1  1  
11  62458888  BSCL2  A  G  L  290  P     1  0  1  
15  42693950  CAPN3  G  A  R  441  Q     1  1  2  
10  50828566  CHAT  T  G  M  84  R     0  1  1  
1  154544030  CHRNB2  C  T  P  244  L     1  0  1  
15  68500645  CLN6  T  C  S  257  G     1  1  2  
21  47544826  COL6A2  G  A  G  588  S     0  1  1  
2  238258801  COL6A3  G  A  R  1683  C     0  1  1  
3  148899821  CP  T  C  E  842  G     1  0  1  
19  10893647  DNM2  G  T  V  234  L     0  1  1  
6  56765318  DST  A  C  S  106  R     1  0  1  
6  56765371  DST  C  T  A  89  T     0  1  1  
X  153583294  FLNA  C  T  G  1698  S     0  1  1  
X  153592919  FLNA  G  A  A  666  V     0  1  1  
14  88414158  GALC  G  C  T  445  S     0  3  3  
9  36236974  GNE  A  C  D  203  E     0  3  3  
17  10443936  MYH2  T  C  D  328  G     0  1  1  
17  10314218  MYH8  A  C  L  488  R     0  1  1  
12  4763994  NDUFA9  G  A  R  75  H     1  0  1  
20  13797783  NDUFAF5  G  C  G  294  A     0  2  2  
1  161182208  NDUFS2  C  G  P  352  A     0  1  1  
11  66618540  PC  G  C  R  732  G     0  2  2  
1  20960259  PINK1  C  T  S  73  L    Yes 0  1  1  
1  20966392  PINK1  C  T  S  228  F  Yes  Yes 1  0  1  
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1  20971057  PINK1  C  A  S  284  Y    Yes 0  1  1  
1  20971119  PINK1  C  G  P  305  A  Yes  Yes 0  3  3  
15  89868793  POLG  G  A  H  613  Y    Yes 1  0  1  
3  64133345  PRICKLE2  T  G  Q  274  P     0  1  1  
6  161781223  PRKN  A  C  D  245  E  Yes Yes Yes 0  2  2  
6  162622239  PRKN  G  C  P  153  R    Yes 1  0  1  
14  73659375  PSEN1  T  C  V  191  A     0  2  2  
1  227073297  PSEN2  G  A  V  139  M     0  1  1  
1  227079048  PSEN2  A  G  Y  319  C     0  1  1  
19  12921137  RNASEH2A  C  T  R  186  W     0  1  1  
19  38974116  RYR1  C  T  P  1632  S     1  2  3  
19  38998362  RYR1  G  A  D  2943  N     0  2  2  
19  39019242  RYR1  C  G  H  3642  Q     0  2  2  
19  39025421  RYR1  C  T  A  3769  V     0  1  1  
20  35533822  SAMHD1  T  G  N  452  T     0  1  1  
17  62019123  SCN4A  C  T  V  1507  I     0  1  1  
17  62036686  SCN4A  C  A  S  653  I     0  1  1  
17  62049961  SCN4A  C  G  E  81  Q     2  2  4  
4  52895854  SGCB  T  C  N  140  S     0  1  1  
15  34534333  SLC12A6  C  A  G  696  V     0  1  1  
15  34542869  SLC12A6  A  C  I  503  M     0  1  1  
6  152809602  SYNE1  A  G  W  333  R     0  1  1  
20  2376062  TGM6  T  A  L  135  H     0  1  1  
11  61160781  TMEM216  A  G  E  38  G     1  0  1  
8  94827551  TMEM67  G  A  S  928  N     0  1  1  
16  2130346  TSC2  G  T  G  949  V     0  1  1  
16  2134230  TSC2  C  T  S  1092  L     0  1  1  
16  2138318  TSC2  C  T  R  1507  C     1  0  1  
2  179590564  TTN  C  T  G  5585  S     0  1  1  
Start refers to GRCh38 coordinates. Chr, chromosome; Ref, reference allele based on GRCh38; Alt, alternative (variant) allele found in this study; 
 Symbol, Gene Symbol available at the Gene database at NCBI (https://www.ncbi.nlm.nih.gov/); AAfrom, amino acid in reference sequence; AAPos,  
amino acid position; AAto, amino acid in variant sequence; CountNGR, number of variant alleles in the Nigerian sample; CountRSA, number of variant 
 alleles in the South African sample; CountAll, number of variant alleles in the entire study sample. 
1Four variants were selected for Sanger sequencing and two variants for HRM analysis. 
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Table 4.3: Variants predicted to be deleterious identified in study patients. 
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 s10_308 0.81             het                                  het      het        
 s10_309 0.79                                                             
 s10_310 0.84                           het            het                      
 s10_313 0.85                      het   het                                    
 s10_314 0.83                                                             
 s11_781 0.79                            het                  het              het 
 s11_830 0.88               het                                              
 s11_833 0.83          het                                                   
 s11_834 0.88                                                             
 s11_835 0.91                     het                      het het                 
 s11_894 0.80                                                             
 s11_895 0.83  het               het      het             het           het              
 s11_910 0.87                                                             
 s11_962 0.85           het                      het       het                     
 s12_170 0.76                                                             
 s12_171 0.87       het                               het                       
 s12_172 0.78                           het              het  het het                 
 s12_176 0.72                  het     het                         het             
 s12_177 0.80                                                             
 s12_178 0.80                              het  het                             
 s12_179 0.78                                                 het     het  het     
 s12_180 0.85                              het                               
 s12_486 0.82                                    het                het         
 s43_059 0.85                      het       het                              het  
 s52_023 0.92                        het                                 het    
 s55_052 0.89                                          het   het                
 s55_065 0.86                      het                             het          
 s60_039 0.85      hom                 het                                      
 s61_081 0.85              het                        het                       
 s78_074 0.87                                                  het           
 s84_052 0.85        het                                     het                
 s94_069 0.83    het                         het het     het                          
 s96_087 0.88   het                 hom                                         
Nigeria                                                             
 s12_975 0.88 het                         het                                   
 s13_007 0.86                                               het              
 s13_008 0.61                                                             
 s13_090 0.86                                               het              
 s13_036 0.87                                             het                
 s13_037 0.84             het                                             het   
 s13_038 0.80         het                            het                        
 s13_039 0.86          het                        het                           
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 s13_091 0.85                                                             
 s13_092 0.87            het    het   het                                          
 s13_093 0.83                               het                        het      
 s13_094 0.86                                                             
 s13_095 0.86                                                             
 s13_096 0.83     het                                                        
Subject, sample code; Coverage, tNGS data coverage for the listed sample; other column headers indicate gene and variant for which data are provided. Hemi, patient 
was hemizygous for the variant; het, patient was heterozygous for the variant; hom, patient was homozygous for the variant. SA, South African; NGR, Nigerian. See 
Table S1 for additional clinical information on the patients. 
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Figure 4.1: Sunburst diagram showing the functional classes of 14,655 
rare (MAF≤0.01) sequence variants identified in 33 Black South 
African and 14 Nigerian PD patients. An interactive HTML-version of 
the figure is available at Frontiers website          
. 
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  Figure 4.2: Venn diagram showing the distributions of the shared variants 
 (substitution, insertion and deletions) between South African (SA) and Nigerian 
NGR) PD patients. The number of deletion, insertion and substitution variants 
shared between the Nigerian and South African PD patients in this study is 
shown using Venn diagram. Of which, 5899 substitutions, 189 deletions and 110 
insertions were shared. 
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Figure 4.3. Radar plots of 60 selected missense variants. Plots are 
identified by symbol and amino acid change and illustrate 17 scores for each 
variant considered deleterious. All scores were standardized to 0–1 scale with 
score 1 (furthest from the center of the graph) indicating strongest evidence 
that the variant is deleterious. See Supplement for details on the scores used 
in the analyses. 
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FIGURE 3 (continued) 
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FIGURE 3 (continued) 
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Figure 4.3 (continued) 
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FIGURE 4.4. Stereoscopic crystal structure models of PINK1 and its 
substrate ubiquitin demonstrating the potential effects of sequence 
variants S228F, S284Y, and P305A on the function of PINK1 protein. 
Crystal structure of PINK1 bound to ubiquitin showing position of sequence 
variants in PINK1 as well as the position of serine 65 in ubiquitin. Structures 
are represented in ribbon format. Ubiquitin is shown in gold. PINK1 is shown 
in light green as the crystal structure derived from the human louse (Schubert 
et al. 2017) with the predicted structure of the human PINK1 overlayed in 
light blue. PINK1 sequence variants shown are L347P (orange) located 
centrally in the helical domain of the C-lobe; S228F (red) in the centre, S284Y 
(yellow) near the top, and P305A (green) at the top. The ubiquitin S65 is show 
in CPK atom colors. In addition, the catalytic spine (C-spine) is shown in 
faded grey and the regulatory spine is shown in faded purple. The ATP 
necessary for phosphorylating S65 has to be coordinated between two 
hydrophobic amino acids of the C-spine. The approximate position of the 
plane of ATP coordination (red arrow) is indicated by the dashed red line.
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Table S4.1. Clinical information on the 47 PD patients and their deleterious sequence variants 
Sample 
code 
 Sex Ethnicity/Country AAO 
(y) 
AAD 
(y) 
Family 
history of PD 
s43_59  M Black/SA 51 61 Yes  
s52_23  M Black/SA 50 57  
s55_52  M Black/SA 42 49  
s55_65  M Black/SA 40 42  
s60_39  M Black/SA 55 56  
s61_81  M Black/SA 55 57  
s78_74  F Black/SA 56 63  
s84_52  F Black/SA 57 61  
s94_69  F Black/SA 30 36 Yes  
s96_87  M Black/SA 37 38  
s10_308  F Black/SA 49 77  
s10_309  M Black/SA 52 59  
s10_310  M Black/SA 45 48  
s10_313  F Black/SA 43 49  
s10_314  F Black/SA 55 57  
s11_781  F Black/SA 31 35  
s11_830  F Black/SA 57 60  
s11_833  M Black/SA 48 50  
s11_834  M Black/SA 52 56  
s11_835  F Black/SA 52 60  
s11_894  M Black/SA 44 49  
s11_895  M Black/SA 49 53  
s11_910  F Black/SA 59 62  
s11_962  M Black/SA 53 77  
s12_170  M Black/SA 52 62  
s12_171  M Black/SA 39 78  
s12_172  F Black/SA 55 56  
s12_176  F Black/SA 51 55  
s12_177  M Black/SA 45 55  
s12_178  F Black/SA 53 55  
s12_179  F Black/SA 30 35  
s12_180  M Black/SA 55 55  
s12_486  M Black/SA 35 49  
s12_975  F Yoruba/N 80 80  
s13_007  M Yoruba/N 52 59  
s13_008  M Yoruba/N 62 66  
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s13_036  M Yoruba/N 57 64  
s13_037  M Yoruba/N 79 81  
s13_038  M Yoruba/N 36 42  
s13_039  F Yoruba/N 71 73  
s13_090  M Yoruba/N 59 60  
s13_091  M Yoruba/N 79 80  
s13_092  M Yoruba/N 48 59  
s13_093  M Yoruba/N 53 64  
s13_094  F Yoruba/N 62 64  
s13_095  M Yoruba/N 73 81  
s13_096  M Yoruba/N 68 71  
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   Table S4.2: Conservation scores, allele frequencies and functional prediction tools used in the annotation of sequence variants 
Annovar Name Description Source 
RefSeq Annotation 
 
 
Gene.refGene RefGene gene Symbol https://www.ncbi.nlm.nih.gov/refseq 
GeneDetail.refGene Variant in HGNC Notation per transcript https://www.ncbi.nlm.nih.gov/refseq 
ExonicFunc.refGene Type of mutation (synonymous, 
frameshift, etc.) 
https://www.ncbi.nlm.nih.gov/refseq 
AAChange.refGene Variant at protein level in HGNC 
Notation 
https://www.ncbi.nlm.nih.gov/refseq 
cytoband Cytological Bands http://www.software.broadinstitute.org/software/igv/cytoband 
genomicSuperDups Known Large Duplications http://varianttools.sourceforge.net/Annotation/GenomicSuperD
ups 
SNP databases 
 
 
snp142 SNP name in dbSNP v142 http://www.ncbi.nlm.nih.gov/snp 
avsnp142 SNP name http://www.ncbi.nlm.nih.gov/snp 
Frequencies 
 
 
X1000g2015aug_all 1000 Genomes Frequencies All http://www.internationalgenome.org/category/population 
X1000g2015aug_afr 1000 Genomes Frequencies African http://www.internationalgenome.org/category/population 
X1000g2015aug_eas 1000 Genomes Frequencies East 
Asian 
http://www.internationalgenome.org/category/population 
X1000g2015aug_amr 1000 Genomes Frequencies 
American 
http://www.internationalgenome.org/category/population 
Kaviar_AF Kaviar Frequencies http://www.db.systemsbiology.net/kaviar 
Kaviar_AC Kaviar Variant Count http://www.db.systemsbiology.net/kaviar 
Kaviar_AN Kaviar Total Allele Count http://www.db.systemsbiology.net/kaviar 
cg69 Cancer Genome Frequencies http://www.completegenomics.com/public-data/69-genomes/ 
gnomAD_genome_ALL Genome Aggregation Database 
(gnomAD) Genome Frequencies All 
http://gnomad.broadinstitute.org/ 
gnomAD_genome_AFR gnomAD Genome Frequencies 
African 
http://gnomad.broadinstitute.org/ 
gnomAD_genome_AMR gnomAD Genome Frequencies 
American 
http://gnomad.broadinstitute.org/ 
gnomAD_genome_ASJ gnomAD Genome Frequencies 
Ashkenazi Jewish 
http://gnomad.broadinstitute.org/ 
gnomAD_genome_EAS gnomAD Genome Frequencies East 
Asian 
http://gnomad.broadinstitute.org/ 
gnomAD_genome_FIN gnomAD Genome Frequencies 
Finnish 
http://gnomad.broadinstitute.org/ 
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Annovar Name Description Source 
gnomAD_genome_NFE gnomAD Genome Frequencies Non-
Finnish European 
http://gnomad.broadinstitute.org/ 
gnomAD_genome_OTH gnomAD Genome Frequencies Other http://gnomad.broadinstitute.org/ 
esp6500siv2_all esp 6500 Frequencies All http://www.evs.gs.washington.edu 
esp6500siv2_aa esp 6500 Frequencies African 
American 
http://www.evs.gs.washington.edu 
esp6500siv2_ea esp 6500 Frequencies European 
American 
http://www.evs.gs.washington.edu 
gnomAD_exome_ALL gnomAD Exome Frequencies All (as 
above) 
http://gnomad.broadinstitute.org/ 
gnomAD_exome_AFR gnomAD Exome Frequencies http://gnomad.broadinstitute.org/ 
gnomAD_exome_AMR gnomAD Exome Frequencies http://gnomad.broadinstitute.org/ 
gnomAD_exome_ASJ gnomAD Exome Frequencies http://gnomad.broadinstitute.org/ 
gnomAD_exome_EAS gnomAD Exome Frequencies http://gnomad.broadinstitute.org/ 
gnomAD_exome_FIN gnomAD Exome Frequencies http://gnomad.broadinstitute.org// 
gnomAD_exome_NFE gnomAD Exome Frequencies http://gnomad.broadinstitute.org/ 
gnomAD_exome_OTH gnomAD Exome Frequencies http://gnomad.broadinstitute.org/ 
gnomAD_exome_SAS gnomAD Exome Frequencies South 
Asian 
http://gnomad.broadinstitute.org/ 
ExAC_ALL ExAC Frequencies All http://exac.broadinstitute.org/ 
ExAC_AFR ExAC Frequencies African http://exac.broadinstitute.org/ 
ExAC_AMR ExAC Frequencies American http://exac.broadinstitute.org/ 
ExAC_EAS ExAC Frequencies East Asian http://exac.broadinstitute.org/ 
ExAC_FIN ExAC Frequencies Finnish http://exac.broadinstitute.org/ 
ExAC_NFE ExAC Frequencies Non-Finnish 
European 
http://exac.broadinstitute.org/ 
ExAC_OTH ExAC Frequencies Other http://exac.broadinstitute.org/ 
ExAC_SAS ExAC Frequencies South Asian http://exac.broadinstitute.org/ 
Functional Annotation 
 
 
cosmic70 Cosmic database https://cancer.sanger.ac.uk/cosmic/ 
CLINSIG Clinical significance in ClinVar  www.openbioinformatics.org/annovar 
CLNDBN Variant disease name www.openbioinformatics.org/annovar 
CLNACC Variant Accession and Versions www.openbioinformatics.org/annovar 
CLNDSDB Variant disease database name www.openbioinformatics.org/annovar 
CLNDSDBID Variant disease database ID www.openbioinformatics.org/annovar 
ICGC_Id International cancer genome 
consortium ID 
www.openbioinformatics.org/annovar 
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Annovar Name Description Source 
ICGC_Occurrence International cancer genome 
consortium occurrence 
www.openbioinformatics.org/annovar 
nci60 60 human cancer cell lines www.openbioinformatics.org/annovar 
Prediction Scores 
 
 
CADD13_RawScore Combined annotation dependent 
depletion score 
https://cadd.gs.washington.edu/ 
CADD13_PHRED Combined annotation dependent 
depletion prediction 
https://cadd.gs.washington.edu/ 
SIFT_score sorting intolerant from tolerant score http://sift.bii.a-star.edu.sg/ 
SIFT_pred sorting intolerant from tolerant 
prediction 
http://sift.bii.a-star.edu.sg/ 
Polyphen2_HDIV_score Pholyphen2 score based on HDIV. http://genetics.bwh.harvard.edu/pph2/ 
Polyphen2_HDIV_pred Pholyphen2 prediction based on 
HDIV 
http://genetics.bwh.harvard.edu/pph2/ 
Polyphen2_HVAR_score Polyphen2 score based on HVAR. http://genetics.bwh.harvard.edu/pph2/ 
Polyphen2_HVAR_pred Polyphen2 prediction based on 
HVAR. 
http://genetics.bwh.harvard.edu/pph2/ 
LRT_score LRT score http://www.doclogica.com/  
LRT_pred LRT prediction http://www.doclogica.com/ 
MutationTaster_score MutationTaster score www.mutationtaster.org 
MutationTaster_pred MutationTaster prediction. www.mutationtaster.org 
MutationAssessor_score MutationAssessor score http://mutationassessor.org/r3/ 
MutationAssessor_pred MutationAssessor prediction http://mutationassessor.org/r3/ 
FATHMM_score FATHMM score http://www.fathmm.biocompute.org.uk 
FATHMM_pred FATHMM prediction http://www.fathmm.biocompute.org.uk 
PROVEAN_score PROVEAN score http://provean.jcvi.org/index.php 
PROVEAN_pred PROVEAN prediction http://provean.jcvi.org/index.php 
VEST3_score VEST V3 score https://omictools.com/vest-tool 
CADD_raw CADD raw score. https://cadd.gs.washington.edu/info 
CADD_phred CADD phred-like score https://cadd.gs.washington.edu/info 
DANN_score DANN score. https://omictools.com/dann-tool 
fathmm.MKL_coding_score fathmm-MKL score for one coding 
variant 
http://www.fathmm.biocompute.org.uk/fathmmMKL.htm 
fathmm.MKL_coding_pred fathmm-MKL prediction for one 
coding variant 
http://www.fathmm.biocompute.org.uk/fathmmMKL.htm 
MetaSVM_score MetaSVM score. www.openbioinformatics.org/annovar 
MetaSVM_pred MetaSVM prediction www.openbioinformatics.org/annovar 
MetaLR_score MetaLR score www.openbioinformatics.org/annovar 
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Annovar Name Description Source 
MetaLR_pred MetaLR prediction www.openbioinformatics.org/annovar 
Eigen Eigen  https://eigen.tuxfamily.org/dox/ 
Dann Dann score https://omictools.com/dann-tool 
FATHMM_noncoding FATHMM score for one noncoding 
variant 
http://www.fathmm.biocompute.org.uk 
FATHMM_coding FATHMM score for one noncoding 
variant 
http://www.fathmm.biocompute.org.uk 
GWAVA_region_score GWAVA region score https://www.sanger.ac.uk/sanger/StatGen_Gwava 
GWAVA_tss_score GWAVA score https://www.sanger.ac.uk/sanger/StatGen_Gwava 
GWAVA_unmatched_score GWAVA unmatched score https://www.sanger.ac.uk/sanger/StatGen_Gwava 
Conservation Scores 
 
 
integrated_fitCons_score Fitness Consequences https://compgen.cshl.edu/fitCons/ 
integrated_confidence_value 
 
 
GERP++_RS GERP++ Genomic Evolutionary Rate 
Profiling 
https://mendel.stanford.edu/SidowLab/downloads/gerp 
phyloP7way_vertebrate PhyloP score for 7 vertebrate species 
(Phylogenetic Hidden Markov 
Model) 
www.openbioinformatics.org/annovar 
phyloP20way_mammalian PhyloP score for 20 mammalian 
species 
www.openbioinformatics.org/annovar 
phastCons7way_vertebrate PhastCons score for 7 vertebrate 
species 
www.openbioinformatics.org/annovar 
phastCons20way_mammalia
n 
PhastCons score for 20 mammalian 
species 
www.openbioinformatics.org/annovar 
SiPhy_29way_logOdds SiPhy score for biased substitutions 
(SIte-specific PHYlogenetic) 
www.openbioinformatics.org/annovar 
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Table S4.3: Primers used in Sanger sequencing  
Gene Variant Primer Primer sequence Annealing 
temperature 
(oC) 
Product 
size 
(bp) 
ATP13A2 c.3010A>C S001F* 5'-GGCAGATCAACACCAACCTG-3' 55 248 
S002R* 5'-CAGTCAGCTCCCTACTCACC-3' 
PRKN c.1182T>G S011F* 5'-TCTTTGTTTCCCCAGGCCTA-3' 60 300 
   S012R* 5'-GCTCAGCACAGACTCACCAT-3' 
PINK1 c.88G>C    S017F 5'-AAGTTTGTTGTGACCGGCG-3' 55 278 
   S018R 5'-GAGACGGTTAGGGAGCCC-3' 
PINK1 c.683C>T    S021F 5'-AGGCAGGGCTTACAAGGAAC-3' 55 220 
   S022R 5'-TGCTCTCAAAGAAGTCCCAGT-3' 
*These primers were also used in HRM (for results, see Figure S4.6)
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Table S4.4: Information on the 44 selected genes with variants predicted to be deleterious based on the Ingenuity Pathway Analysis 
Gene Description Location Family Drugs 
AARS alanyl-tRNA synthetase Cytoplasm Enzyme 
 
ADSL adenylosuccinate lyase Cytoplasm Enzyme 
 
ALDH7A1 aldehyde dehydrogenase 7 
family member A1 
Cytoplasm Enzyme 
 
AR androgen receptor Nucleus ligand-
dependent 
nuclear 
receptor 
estradiol valerate/testosterone enanthate, estradiol 
cypionate/testosterone cypionate, BMS-641988, 
cyproterone acetate/ethinyl estradiol, enzalutamide, 
galeterone, ostarine, 1-testosterone, flutamide/goserelin, 
nandrolone phenpropionate, androgen receptor 
antagonist, apalutamide, darolutamide, AZD3514, APC-
100, EPI-506, bicalutamide/leuprolide, 
bicalutamide/goserelin, dexamethasone/enzalutamide, 
SHR3680, LY2452473, enzalutamide/exemestane, 
drospirenone/ethinyl estradiol, nilutamide, TRC253, 
bicalutamide, SXL01, proxalutamide, hydroxyflutamide, 
testolone, flutamide, nandrolone decanoate, testosterone 
cypionate, cyproterone acetate, nandrolone, 
drospirenone, medroxyprogesterone acetate, 
oxandrolone, danazol, dihydrotestosterone, 
fluoxymesterone, stanozolol, spironolactone, 
methyltestosterone, testosterone, oxymetholone, 7alpha-
hydroxytestosterone, testosterone propionate, 
testosterone enanthate 
ARSA arylsulfatase A Cytoplasm Enzyme 
 
ATP13A2 ATPase 13A2 Cytoplasm Transporter 
 
ATP2A1 ATPase 
sarcoplasmic/endoplasmic 
reticulum Ca2+ 
transporting 1 
Cytoplasm Transporter 
 
BSCL2 BSCL2, seipin lipid 
droplet biogenesis 
associated 
Cytoplasm Other 
 
CAPN3 calpain 3 Cytoplasm Peptidase 
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CHAT choline O-
acetyltransferase 
Nucleus Enzyme 
 
CHRNB2 cholinergic receptor 
nicotinic beta 2 subunit 
Plasma 
Membrane 
transmembrane 
receptor 
varenicline, ABT-089, ABT 418, isoflurane, 
mecamylamine, succinylcholine, rocuronium, 
doxacurium, amobarbital, mivacurium, pipecuronium, 
rapacuronium, metocurine, atracurium, cisatracurium, 
acetylcholine, nicotine, D-tubocurarine, arecoline, 
lobeline, enflurane, pancuronium, vecuronium 
CLN6 CLN6, transmembrane 
ER protein 
Cytoplasm Other 
 
COL6A2 collagen type VI alpha 2 
chain 
Extracellular 
Space 
Other collagenase clostridium histolyticum 
COL6A3 collagen type VI alpha 3 
chain 
Extracellular 
Space 
Other collagenase clostridium histolyticum 
CP ceruloplasmin Extracellular 
Space 
Enzyme 
 
DNM2 dynamin 2 Plasma 
Membrane 
Enzyme 
 
DST dystonin Plasma 
Membrane 
Other 
 
FLNA filamin A Cytoplasm Other 
 
GALC galactosylceramidase Cytoplasm Enzyme 
 
GNE glucosamine (UDP-N-
acetyl)-2-epimerase/N-
acetylmannosamine 
kinase 
Cytoplasm Kinase 
 
MYH2 myosin heavy chain 2 Cytoplasm Enzyme 
 
MYH8 myosin heavy chain 8 Cytoplasm Enzyme 
 
NDUFA9 NADH:ubiquinone 
oxidoreductase subunit 
A9 
Cytoplasm Enzyme 
 
NDUFAF5 NADH:ubiquinone 
oxidoreductase complex 
assembly factor 5 
Cytoplasm Other 
 
NDUFS2 NADH:ubiquinone 
oxidoreductase core 
subunit S2 
Cytoplasm Enzyme 
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PC pyruvate carboxylase Cytoplasm Enzyme 
 
PINK1 PTEN induced putative 
kinase 1 
Cytoplasm Kinase 
 
POLG DNA polymerase gamma, 
catalytic subunit 
Cytoplasm Enzyme lamivudine/nelfinavir/stavudine, lamivudine/stavudine, 
lamivudine/nevirapine/stavudine, stavudine, vidarabine, 
zalcitabine 
PRICKLE2 prickle planar cell 
polarity protein 2 
Nucleus Other 
 
PRKN parkin RBR E3 ubiquitin 
protein ligase 
Cytoplasm Enzyme 
 
PSEN1 presenilin 1 Plasma 
Membrane 
Peptidase Tarenflurbil 
PSEN2 presenilin 2 Cytoplasm Peptidase Tarenflurbil 
RNASEH2A ribonuclease H2 subunit 
A 
Nucleus Enzyme 
 
RYR1 ryanodine receptor 1 Cytoplasm ion channel Dantrolene 
SAMHD1 SAM and HD domain 
containing 
deoxynucleoside 
triphosphate 
triphosphohydrolase 1 
Nucleus Enzyme 
 
SCN4A sodium voltage-gated 
channel alpha subunit 4 
Plasma 
Membrane 
ion channel diclofenac/omeprazole, diclofenac/misoprostol, 
diclofenac, flecainide, riluzole, zonisamide 
SGCB sarcoglycan beta Plasma 
Membrane 
Other 
 
SLC12A6 solute carrier family 12 
member 6 
Plasma 
Membrane 
Transporter 
 
SYNE1 spectrin repeat containing 
nuclear envelope protein 
1 
Nucleus Other 
 
TGM6 transglutaminase 6 Cytoplasm Enzyme 
 
TMEM216 transmembrane protein 
216 
Extracellular 
Space 
Other 
 
TMEM67 transmembrane protein 67 Plasma 
Membrane 
Other 
 
TSC2 TSC complex subunit 2 Cytoplasm Other 
 
TTN titin Cytoplasm Kinase 
 
Source:  QIAGEN 2000-2018 (www.qiagenbioinformatics.com). All rights reserved. 
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Table S4.5. Signs and symptoms of genetic diseases associated with the 44 selected genes harbouring 
variants predicted to be deleterious, and their overlap with cardinal PD signs and symptoms 
Gene 
Symbol 
Disease OMIM# Signs & symptoms Possible clinical overlap with 
PD 
AARS Charcot-Marie-Tooth 
disease, axonal, type 2N 
613287 Distal muscle weakness and 
atrophy; mild sensory loss 
Distal muscle weakness 
AARS Epileptic 
encephalopathy, early 
infantile, 29 
616339 Seizure  
ADSL Adenylosuccinase 
deficiency 
103050 Psychomotor retardation; 
aggressive behaviour; 
epileptic seizures 
 
ALDH7A1 Epilepsy, pyridoxine-
dependent 
266100 Seizures  
AR Androgen insensitivity 300068 Anxiety; reduced masculinity  
AR Breast cancer 312300 Pain; red or swollen lymph 
nodes 
 
AR Hypospadias 1, X-linked 300633 Abnormal male reproductive 
system 
 
AR Spinal and bulbar 
muscular atrophy of 
Kennedy 
313200 Muscle wasting in the arms 
and legs resulting in cramping; 
leg muscle weakness and fall 
Leg muscle weakness and fall 
AR Prostate cancer 176807 Difficulty with urination Difficulty with urination 
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ARSA Metachromatic 
leukodystrophy 
250100 Abnormal muscle movement; 
decreased muscle tone; 
difficulty walking; frequent 
falls 
Abnormal muscle movement; 
difficulty walking; frequent 
falls 
ATP13A2 Kufor-Rakeb syndrome 606693 Bradykinesia; rigidity; tremors Bradykinesia;  rigidity; 
tremors 
ATP13A2 Spastic paraplegia, 78, 
autosomal recessive 
617225 Weakness in the legs; 
increased muscle tone and 
stiffness (spasticity); urinary 
problems; lack of sensation in 
the feet 
Weakness in the legs; 
increased muscle tone and 
stiffness (spasticity); urinary 
problems 
ATP2A1 Brody myopathy 601003 Muscle cramping and 
stiffening 
Muscle cramping and 
stiffening 
BSCL2 Encephalopathy, 
progressive, with or 
without lipodystrophy 
615924 Problems with coordination; 
rhythmic muscle contractions; 
muscle spasm; fainting or 
fatigue 
Rhythmic muscle 
contractions; 
muscle spasm 
BSCL2 Lipodystrophy, 
congenital generalized, 
type 2 
269700 Fat accumulation around the 
neck and jaw 
 
BSCL2 Neuropathy, distal 
hereditary motor, type 
VA 
600794 Difficulty walking; muscle 
weakness; problems with 
coordination; loss of muscle 
Difficulty walking; muscle 
weakness 
BSCL2 Silver spastic paraplegia 
syndrome 
270685 Weakness in the legs; 
increased muscle tone and 
stiffness; urinary problems; 
lack of sensation in the feet 
Weakness in the legs; 
increased muscle tone and 
stiffness 
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CAPN3 Muscular dystrophy, 
limb-girdle 
618129 
(AD); 
253600 
(AR) 
Abnormality walking; 
muscle weakness; loss of 
muscle 
Abnormality walking; muscle 
weakness 
CHAT Myasthenic syndrome, 
congenital, 6, 
presynaptic 
254210 Muscle weakness; trouble 
walking; tingling sensation in 
the hands or feet 
Muscle weakness; trouble 
walking 
CHRNB2 Epilepsy, nocturnal 
frontal lobe, 3 
605375 Rhythmic muscle 
contractions; muscle spasms; 
seizures, amnesia 
Rhythmic muscle 
contractions; muscle spasms 
 
CLN6 Ceroid lipofuscinosis, 
neuronal, 6 
601780 Abnormal retinal vasculature; 
mental deterioration; 
intellectual disability 
 
CLN6 Ceroid lipofuscinosis, 
neuronal, Kufs type, 
adult onset 
204300 Difficulties with muscle 
coordination; involuntary 
movements such as tremors 
and dysarthria. 
Difficulties with muscle 
coordination; involuntary 
movements such as tremor 
COL6A2 Myosclerosis, congenital 255600 Muscle weakness; poor motor 
control; inability to sit or stand 
without support 
Muscle weakness; poor motor 
control 
COL6A2 Bethlehem myopathy 1 158810 Muscle weakness; joint 
stiffness (contractures) in 
fingers, wrists, elbows, and 
ankles 
Muscle weakness; joint 
stiffness 
COL6A2 Ullrich congenital 
muscular dystrophy 1 
254090 Muscle weakness; difficulty 
walking; contractures (neck); 
joint looseness 
Muscle weakness 
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COL6A3 Bethlem myopathy 1 158810 Muscle weakness; joint 
stiffness (contractures) in 
fingers, wrists, elbows, and 
ankles 
Muscle weakness; joint 
stiffness 
COL6A3 Dystonia 27 616411 Difficulty with jaw movement, 
swallowing or speech; pain 
and fatigue due to constant 
contraction of muscles 
Difficulty with jaw 
movement, swallowing or 
speech; pain and fatigue due 
to constant contraction of 
muscles 
COL6A3 Ullrich congenital 
muscular dystrophy 1 
254090 Muscle weakness; difficulty 
walking; contractures 
Muscle weakness 
CP Cerebellar ataxia 604290 Impaired coordination in the 
arms and legs; frequent 
stumbling; unsteady gait; 
motor disability; slurred 
speech; vocal changes; 
headaches 
Unsteady gait; motor 
disability; slurred speech 
 
CP Hemosiderosis, systemic, 
due to 
aceruloplasminemia 
604290 Fatigue; severe exercise 
limitation 
 
CP Hypoceruloplasminemia, 
hereditary 
604290 Tremors; chorea; ataxia; 
eyelid twitching;  grimacing 
Tremors; ataxia 
DNM2 Centronuclear myopathy 
1 
160150 Muscle weakness Muscle weakness 
DNM2 Charcot-Marie-Tooth 
disease, axonal type 2M 
606482 Distal muscle weakness and 
atrophy; mild sensory loss 
Distal muscle weakness 
DNM2 Charcot-Marie-Tooth 
disease, dominant 
intermediate B 
606482 Distal muscle weakness and 
atrophy; mild sensory loss 
Distal muscle weakness 
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DNM2 Lethal congenital 
contracture syndrome 5 
615368 Akinesia; micrognathia; 
pulmonary hypoplasia; 
pterygia; multiple joint 
contractures 
Akinesia 
DST Neuropathy, hereditary 
sensory and autonomic, 
type VI 
614653 Cramping; difficulty walking; 
muscle weakness; problems 
with coordination, or loss of 
muscle 
Difficulty walking; muscle 
weakness 
DST Epidermolysis bullosa 
simplex, autosomal 
recessive 2 
615425 Blisters inside the mouth and 
throat; thickened skin on the 
palms and soles of the feet; 
scalp blistering, scarring and 
hair loss 
 
FLNA FG syndrome 2 300321 Mild to severe hypotonia; 
constipation; a distinctive face 
 
FLNA Cardiac valvular 
dysplasia, X-linked 
314400 Chest pain; shortness of 
breath; light-headedness 
 
FLNA Congenital short bowel 
syndrome 
300048 Diarrhea; poor appetite; 
fatigue; vomiting 
Diarrhea 
 
FLNA Frontometaphyseal 
dysplasia 1 
305620 Hearing loss Hearing loss 
FLNA Heterotopia, 
periventricular, 1 
300049 Mild intellectual disability 
including difficulties with 
reading and spelling 
Difficulties with spelling 
FLNA Intestinal 
pseudoobstruction, 
neuronal 
300048 Nausea; vomiting; abdominal 
bloating or swelling; 
constipation 
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FLNA Melnick-Needles 
syndrome 
309350 Short stature; skeletal 
abnormalities; characteristic 
facial features 
 
FLNA Otopalatodigital 
syndrome, type I 
311300 Hearing loss; chest 
deformities; abnormal fingers 
and toes 
Hearing loss 
FLNA Otopalatodigital 
syndrome, type II 
304120 Hearing loss Hearing loss 
FLNA Terminal osseous 
dysplasia 
300244 Brachydactyly; 
camptodactyly; clinodactyly, 
severe limb deformities; joint 
contractures 
 
GALC Krabbe disease 245200 Changing muscle tone and 
rigidity; hearing loss that leads 
to deafness; failure to thrive; 
feeding difficulties; irritability 
and sensitivity to loud sounds; 
severe seizures (may begin at 
a very early age); unexplained 
fever; vision loss 
Changing muscle tone and 
rigidity; vision loss 
GNE Nonaka myopathy 605820 Muscle weakness and 
degeneration 
Muscle weakness and 
degeneration 
GNE Sialuria 269921 Failure to thrive; slightly 
prolonged neonatal jaundice; 
hepatomegaly; microcytic 
anemia 
 
MYH2 Proximal myopathy and 
ophthalmoplegia 
605637 Difficulty swallowing; general 
muscle weakness 
Difficulty swallowing; general 
muscle weakness 
MYH8 Carney complex variant 608837 Weight gain; high blood 
pressure; diabetes; easy 
bruising 
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MYH8 Trismus- 
pseudocamptodactyly 
syndrome 
158300 Inability to open mouth wide; 
shortened muscles, including 
hamstrings and calf muscles 
 
NDUFA9 Leigh syndrome due to 
mitochondrial complex I 
deficiency 
256000 Generalized weakness; lack of 
muscle tone; lactic acidosis 
Generalized weakness; lack of 
muscle tone 
NDUFAF5 
 
Mitochondrial complex I 
deficiency, nuclear type 
16 
616238 Hypotonia;  myalgia; exercise 
intolerance 
Hypotonia 
NDUFS2 Mitochondrial complex I 
deficiency 
252010 Hypotonia;  myalgia; exercise 
intolerance 
 
PC Pyruvate carboxylase 
deficiency 
266150 Abdominal pain; vomiting; 
tiredness; muscle weakness 
Muscle weakness 
PINK1 Parkinson disease 6, 
early onset 
605909 Stiff muscles; difficulty 
standing; difficulty walking; 
difficulty with bodily 
movements; involuntary 
movements; muscle rigidity; 
problems with coordination; 
rhythmic muscle contractions; 
slow bodily movement; slow 
shuffling gait 
Stiff muscles; difficulty 
standing; difficulty walking; 
difficulty with bodily 
movements; involuntary 
movements; muscle rigidity; 
problems with coordination; 
rhythmic muscle contractions; 
slow bodily movement; slow 
shuffling gait 
POLG Mitochondrial DNA 
depletion syndrome 4A 
(Alpers type) 
203700 Hypotonia; lactic acidosis, 
failure to thrive; tubulopathy; 
microcephaly;  psychomotor 
delay; sensorineural hearing 
loss 
Hearing loss 
POLG Mitochondrial DNA 
depletion syndrome 4B 
(MNGIE type) 
613662 Hypotonia; lactic acidosis, 
failure to thrive; tubulopathy; 
microcephaly;  psychomotor 
delay; sensorineural hearing 
loss 
Hearing loss 
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POLG Mitochondrial recessive 
ataxia syndrome 
(includes SANDO and 
SCAE) 
607459 Hypotonia; lactic acidosis, 
failure to thrive; tubulopathy; 
microcephaly;  psychomotor 
delay; sensorineural hearing 
loss 
Hearing loss 
POLG Progressive external 
ophthalmoplegia, 
autosomal dominant 1 
157640 Drooping eyelids (ptosis) and 
paralysis of the eye muscles 
ophthalmoplegia 
Ptosis 
POLG Progressive external 
ophthalmoplegia, 
autosomal recessive 1 
258450 Drooping eyelids (ptosis) and 
paralysis of the eye muscles 
ophthalmoplegia. 
Ptosis 
PRICKLE2 N/A N/A N/A  
PRKN Parkinson disease, 
juvenile, type 2 
600116 Stiff muscles; difficulty 
standing; difficulty walking; 
difficulty with bodily 
movements; involuntary 
movements; muscle rigidity; 
problems with coordination; 
rhythmic muscle contractions; 
slow bodily movement; slow 
shuffling gait 
Stiff muscles; difficulty 
standing; difficulty walking; 
difficulty with bodily 
movements; involuntary 
movements; muscle rigidity; 
problems with coordination; 
rhythmic muscle contractions; 
slow bodily movement; slow 
shuffling gait 
PRKN Adenocarcinoma of lung, 
somatic 
211980 Shortness of breath, persistent 
cough, coughing up blood. 
unexplained weight loss. 
chest pain 
 
 
PRKN Adenocarcinoma, 
ovarian, somatic 
167000 Abdominal or pelvic pain, 
increased abdominal size. 
excessive fatigue or lethargy, 
needing to urinate often or 
urgently, appetite loss. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
                                                               
                                        182 
 
PRKN Leprosy 607572 Blister, loss of colour, rashes, 
ulcers, or redness 
 
PSEN1 Acne inversa, familial, 3 613737 Lumps; rash; ulcers  
PSEN1 Alzheimer disease, type 
3 
607822 Mental decline, difficulty 
thinking and understanding, 
confusion, delusion, 
disorientation, forgetfulness, 
and apathy. 
Apathy, delusion and 
forgetfulness 
PSEN1 Alzheimer disease, type 
3, with spastic 
paraparesis and unusual 
plaques 
607822 Mental decline, difficulty 
thinking and understanding, 
confusion, delusion, 
disorientation, forgetfulness, 
and apathy. 
 
Weakness in the legs. 
Muscle stiffness and lack of 
sensation in the feet. 
 
Apathy, delusion and 
forgetfulness. 
 
Weakness in the legs. 
Muscle stiffness and lack of 
sensation in the feet 
PSEN1 Pick disease 172700 Mood changes, 
compulsive, behaviour, 
depression. 
 
Mood changes. 
PSEN1 Alzheimer disease type 3 
with spastic paraparesis 
and apraxia 
607822 Memory loss; behavioural and 
personality change; 
progressive loss of language 
ability; gait disturbances; 
seizures 
Gait disturbances 
PSEN1 Cardiomyopathy, dilated, 
1U 
613694 Arrhythmia;  dyspnea; fatigue; 
syncope; swelling of the legs 
and feet 
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PSEN1 Dementia, 
frontotemporal 
600274 Loss of empathy and other 
interpersonal skills; lack of 
judgment and inhibition; 
apathy; repetitive compulsive 
behaviour 
Apathy 
PSEN2 Alzheimer disease-4 606889 Mental decline, difficulty 
thinking and understanding, 
confusion, delusion, 
disorientation, forgetfulness, 
and apathy. 
Apathy, delusion and 
forgetfulness 
PSEN2 Cardiomyopathy, dilated, 
iV 
613697 Shortness of breath, 
swelling of legs, 
fatigue, 
weight gain, fainting, 
palpitations, 
dizziness or light headedness 
and blood clots in the dilated 
left ventricle 
 
 
RNASEH2
A 
Aicardi-Goutières 
syndrome 4 
610333 Microcephaly; early 
progressive encephalopathy; 
lack of motor and social skills; 
feeding difficulties; 
irritability; vomiting; 
spasticity 
Lack of motor and social skills 
 
RYR1 Central core disease 117000 Muscle weakness Muscle weakness 
RYR1 King-Denborough 
syndrome 
145600 Progressive weakness; short 
stature; kyphoscoliosis; pectus 
carinatum or excavatum; 
facial and skeletal deformities; 
susceptibility to malignant 
hyperthermia 
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RYR1 Minicore myopathy with 
external ophthalmoplegia 
255320 Severe muscle weakness; 
generalized myopathy; high-
arched palate; respiratory 
insufficiency 
 
RYR1 Neuromuscular disease, 
congenital, with uniform 
type 1 fiber 
117000 Muscles weakness; fatigue; 
mild proximal weakness 
Muscles weakness 
RYR1 Malignant hyperthermia 
susceptibility 1 
145600 Rapid heart rate, rapid 
breathing, acidosis, muscle 
rigidity, and breakdown of 
muscle tissue 
Muscle rigidity 
SAMHD1 Chilblain lupus 2 614415 Rash mainly on acral surfaces  
most exposed to cold 
 
SAMHD1 Aicardi-Goutieres 
syndrome 5 
612952 Microcephaly; early 
progressive encephalopathy 
 
SCN4A Hyperkalemic periodic 
paralysis, type 2 
170500 Muscle stiffness and pain; 
irregular heartbeat. 
Muscle stiffness 
SCN4A Hypokalemic periodic 
paralysis, type 2 
613345 Extreme muscle weakness 
beginning in childhood or 
adolescence 
Extreme muscle weakness 
SCN4A Myasthenic syndrome, 
congenital, 16 
614198 Weak muscles; trouble 
walking; tingling sensation in 
hands or feet; eyelid drooping; 
fatigue; dry mouth. 
 
SCN4A Myotonia congenita, 
atypical, acetazolamide-
responsive 
608390 Muscle weakness in legs, 
hands, neck and face; stiffness 
and tightness of muscles 
Stiffness and tightness of 
muscles 
SCN4A Paramyotonia congenita 168300 Muscle stiffness and weakness Muscle stiffness and weakness 
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SGCB Muscular dystrophy, 
limb-girdle, autosomal 
recessive 4 
604286 Gait abnormality Gait abnormality 
SLC12A6 Agenesis of the corpus 
callosum with peripheral 
neuropathy 
218000 Peripheral neuropathy  
SYNE1 Emery-Dreifuss 
muscular dystrophy 4, 
autosomal dominant 
612998 Head and neck muscle 
weakness; muscle atrophy 
 
SYNE1 Spinocerebellar ataxia, 
autosomal recessive 8 
610743 Ataxia; uncoordinated walk; 
poor hand-eye coordination; 
dysarthria; involuntary eye 
movement; vision problems;  
difficulty processing, learning, 
and remembering information 
Ataxia; uncoordinated walk;  
poor hand-eye coordination; 
dysarthria; involuntary eye 
movement; vision problems 
 
TGM6 Spinocerebellar ataxia 35 613908 Limb ataxia; gait ataxia; 
hyperreflexia; dysarthria; hand 
tremor; saccadic pursuit 
Limb ataxia; gait ataxia 
TMEM216 Joubert syndrome 2 608091 Hypotonia; abnormal 
breathing patterns; abnormal 
eye movements; ataxia; 
distinctive facial features; 
intellectual disability 
Hypotonia 
TMEM216 Meckel syndrome 2 603194 Eye abnormalities including 
microphthalmia; under-
development of the nerves of 
the eyes 
 
TMEM67 COACH syndrome 216360 Mental retardation; liver 
fibrosis; ataxia; abnormal eye 
movements 
Abnormal eye movements 
TMEM67 Joubert syndrome 6 610688 Ataxia; abnormal eye and 
tongue movements; low 
muscle tone 
Low muscle tone leading to 
movement disorder 
TMEM67 Meckel syndrome 3 607361 Eye abnormalities  
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TMEM67 Nephronophthisis 11 613550 Polyuria; polydipsia; fatigue  
TMEM67 Barder-Biedl syndrome 
14, modifier of 
615991 Progressive retinal 
degeneration, postaxial 
polydactyly, obesity, learning 
difficulties, and renal tract and 
genital anomalies 
 
TSC2 Focal cortical dysplasia, 
type II, somatic 
607341 Seizure  
TSC2 Lymphangioleiomyomat
osis, somatic 
606690 Shortness of breath, especially 
during physical activity 
 
TSC2 Tuberous sclerosis-2 613254 Behavioural changes, such as 
temper tantrums, anxiety, or 
sleep problems; nausea; 
headache; autism; 
developmental delays 
 
TTN Cardiomyopathy, dilated, 
1G 
604145 Arrhythmia; dyspnea; swelling 
of the legs and feet; fatique 
 
TTN Cardiomyopathy, 
familial hypertrophic, 9 
613765 Chest pain; dyspnea especially 
with physical exertion; 
palpitations; light-headedness; 
dizziness; fainting 
 
TTN Muscular dystrophy, 
limb-girdle, autosomal 
recessive 10 
608807 Progressive weakness of 
muscles of the pelvic girdle, 
legs, arms and shoulders 
Progressive weakness of 
muscles of the pelvic girdle, 
legs, arms and shoulders 
TTN Myopathy, proximal, 
with early respiratory 
muscle involvement 
603689 Distal leg weakness; nocturnal 
respiratory symptoms due to 
respiratory muscle weakness 
Distal leg weakness 
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TTN Salih myopathy 611705 Facial muscle weakness; 
scoliosis; delayed motor 
development 
 
TTN Tibial muscular 
dystrophy, tardive 
600334 Muscle weakness Muscle weakness 
Information was collected from OMIM at www.omim.org/. 
*Since data on the PRICKLE2 gene in OMIM are limited, we carried out a literature search. 
PRICKLE2 missense mutations were found to segregate with Autism Spectrum Disorders 
(ASDs) in a study by Sower and colleagues (PMID: 23711981). They identified two different 
heterozygous missense variants in the PRICKLE2 gene (E8Q and V153I) in two unrelated 
families. The variants were not found in 192 controls and have low frequencies in databases. 
Similarly, the frequent association of ASDs with epilepsy suggests a shared underlying genetic 
susceptibility; several genes, when mutated, can contribute to both disorders, including 
PRICKLE2 (PMIDs: 24938409 22037766). The PRICKLE2 protein functions in the non-
canonical WNT signalling pathway, which regulates intracellular calcium release and Planar 
cell polarity in dopaminergic neurons (PMID: 24431302). PRICKLE2 gene is expressed mainly 
in the adult brain where it is associated with the postsynaptic density (PMID: 21324980).  In 
addition, Tao and colleagues found missense mutations (R104Q, R144H, Y472H, R148H; 
V153I V605F) in both male and female patients with myoclonic seizures, epilepsy, generalized 
electroencephalography pattern, and ataxia (PMID: 21276947). They also identified a 
heterozygous deletion of the PRICKLE2gene in a male patient with developmental delay, 
epilepsy, and autistic disorder. In a GWAS, SNPs in PRICKLE2 gene were shown to affect the 
vitamin B6, vitamin B12, folate, and homocysteine concentrations (PMID:19303062). 
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d.  
 
Figure S4.1. Target region coverage for the 47 samples. Sets 1-4(a-d) represent the 
samples binned into sets of up to12 samples each. Most (42/47) of the samples show 
coverage of 80% of the target region at a depth of 40x. Sample codes are shown in the 
insert. 
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d.  
 
Figure S4.2: Graphs representing quality–density. (QD) scores of all variants identified in 
each sample in this study. Sample code is shown above each graph. The graphs were generated 
by ggplot2 facet_grid. QD represents the variant quality score by the unfiltered heterozygous 
reference depth. QD annotation normalizes the variant quality in order to make it possible to 
compare variants with different alternative allele read depths based on quality. The plots show 
two peaks where the majority of variants were found.
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FIGURE S4.3:  Coverage depth of known PD genes. The coverage of six 
known PD genes ATP13A2, LRRK2, PINK1, PRKN, and SNC using the Ion 
AmpliSeq™ Neurological Diseases Panel and Ion Torrent sequencing platform 
is presented. The y-axis scale is 50, 100, 150, 200 and 25
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Figure S4.4: Correlation between prediction and conservation scores. 
We plotted the correlation matrix of 26 mutation scoring algorithm outputs 
for the 60 variants predicted to be deleterious identified in this study using 
variant scores obtained from tNGS data. MetaLR and MetaSVM were 
well-correlated and were used to predict the deleteriousness of sequence 
variants. See Figure 3 for comparison of 17 different scores for each of the 
60 deleterious variants. 
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Figure S4.5: Density plot of the metaLR and metaSVM scores for the 
60 selected variants. Variants based on score alone contributed to the 
peak above 0.8, whereas variants in known PD genes had scores > 0.45. 
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a. PRKN c.1182T>G (heterozygous missense D245E (NM_103988)) in a male Black South African 
PD patient. AAO of PD was 35 years. 
 
 
 
 
b. ATP13A2 c.3010A>C (heterozygous missense S960R (NM_001141974)) in a male Black South 
African PD patient. AAO of PD was 39 years. 
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c. PINK1 c.683C>T (heterozygous missense S228F (NM_032409)) in a male Nigerian PD patient. 
AAO of PD was 53 years. 
 
 
 
 
 
d. PINK1 c.913C>G (heterozygous missense P305A (NM_032409)) in a female Black South 
African PD patient. AAO of PD was 30 years. 
 
Figure S4.6: Sanger sequencing results for selected variants. 
Chromatograms (a-d) demonstrating the variants identified in the tNGS. Blue 
arrows, locations of sequence variants. 
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C.  
 
D.  
 
Figure S4.7:  HRM screening for two variants in150 Black South African 
controls. Symbols: dark blue arrow, the mutant allele; red arrow, a group of 
control samples. Screening for PRKN D245E (A, B), and ATP13A2 S960R 
(C, D). Normalised graphs (A, C) and difference graphs (B, D) for the 
genotypes. The HRM melting temperature was 80-95oC for PRKN D245E and 
75-95oC for ATP13A2 S960R.
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FIGURE S4.8: ConsensusPathDB network analysis of the 44 genes with variants predicted to be 
deleterious. We observed protein-protein interactions, on which 20 proteins were intermediate nodes and 24 
proteins were seed nodes of biological processes. Produced using ConsensusPathDB 
http://cpdb.molgen.mpg.de/CPDB/cySVis 
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                                CHAPTER FIVE 
 
    GENERAL DISCUSSION 
 
In the Chapters one and two, the rationale for studying the genetics of PD in 
the Black South African and Nigerian PD patients were described. Important 
issues were highlighted, such as the notable differences that exist in the 
haplotypes of the people who are from SSA. The differences have important 
ramifications for the disease pathophysiology and responses to treatments. 
Universally, the signs and symptoms of PD are the same in different parts of 
the world, including the majors signs observed in the PD patients in SSA. 
However, misdiagnosis, and the lack of neurologists in the rural communities 
to diagnose PD are some of the major challenges facing the investigators 
performing prevalence and incidence studies of PD in SSA.  
Furthermore, these Chapters explained that genetic and environmental factors 
are profoundly involved in PD pathophysiology. Similarly, the reasons for 
implementing a tNGS technique for screening large numbers of genes involved 
in neurological diseases were stated. tNGS allows for a custom-design panel to 
screen genes of interest accurately and fast. SSA populations are greatly 
admixed and could harbour unique mutations in PD, hence by screening for 
pathogenic mutations in the PD patients in the unique SSA patients novel 
pathogenic mutations could be identified.  
The present study lays the foundation for future studies on genetics of PD in 
SSA. There is not yet an ideal platform to screen for pathogenic mutations in 
patients, because each approach has advantages and disadvantages. A number 
of known PD genes that have been previously studied and associated with PD 
were highlighted and the mechanisms of PD pathology were discussed. 
Overall, a total of 15 Black SA and 42 Nigerian were studied for CNV in PD 
genes using the MLPA technique.  
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Similarly, 33 Black SA and 14 Nigerian PD patients were studied for putative 
pathogenic mutations in candidate genes using a tNGS technique. Mutations 
found in PD patients from other geographic regions were not identified in this 
study, supporting the hypothesis that SSA PD patients may harbour novel 
mutations. 
5.1  The Collaboration to Study the Genetics of PD in South Africa 
and Nigeria 
The rationale for screening as many PD patients as possible for pathogenic 
mutations is strongly supported by literature (Lin and Farrer, 2014). Screening 
for disease mutations in a particular population, also provides an opportunity 
to identify novel mutations that might be unique to the people affected with the 
disease. 
 
One of the challenges of PD studies in SSA is that sample sizes are relatively 
small. It therefore, requires a joint effort to recruit a large number of patients 
and ethnically matched controls in SSA. To address this matter, a research 
collaboration was established with the PD research group at Stellenbosch 
University located in Cape Town, South Africa, the Neurology Units of the 
Obafemi Awolowo University, Ile-Ife, in Nigeria, and the Mayo Clinic at 
Jacksonville, Florida, United States. The goal was to carry out cutting-edge 
research on the genetics of PD in SSA. This was the first time a research 
collaboration was established between South Africa and Nigeria to study the 
genetics of PD in Black PD patients.  
 
The collaboration received funding from the Fogarty International Centre, 
National Institutes of Health (NIH) Bethesda, MD, USA. Bringing together the 
potentially large numbers of Black PD patients recruited from Nigeria, the most 
populous country in SSA, and in South Africa, where studies on the genetics 
of PD are in progress, provided an excellent starting point for this collaboration.  
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The Mayo Clinic's Udall Center of Excellence in PD, in Florida, USA has been 
continuously funded by the NIH since 1999 attesting to their research 
excellence. This provided the ideal basis for innovative and multidisciplinary 
research on PD for this study. The funding covered two years. Ethics 
applications were submitted to both the Nigerian and the South African Ethics 
Committees. Patients were recruited, blood samples were collected for 
genomic DNA isolation and tNGS for studying pathogenic mutations in the PD 
patients was implemented. 
 
The knowledge of genetic involvement in PD is still very limited in SSA. A 
previous study conducted to assess the knowledge, attitude and interest in 
genetic testing for mutations in PD in the Caucasians showed that the majority 
of participants thought it was likely they inherited a PD gene and showed that 
they were interested in genetic screening for PD (Falcone et al 2011).  
 
Also, a study that provided insights into how people in SSA population 
perceive PD showed that the knowledge on PD was relatively high. However, 
many people opted not to provide a blood sample for genetic screening. The 
participants thought that PD was caused mostly by stress, certain foods or 
drinks, mental illness or other disorders. Some participants identified 
witchcraft as a cause of PD (Mokaya et al 2017). These beliefs are the major 
reasons why genetic studies on PD are not common in SSA. There is need for 
more awareness on PD genetics in these populations to ascertain the 
contributions of genetic mutations as one of the contributing factors of PD.   
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5.1.1   Sample shipment 
 
PD patients were recruited from Nigeria between the time period of 10 March 
2017 to 20 July 2018. Material transfer agreement certificate issued by the 
Department of Health Republic of South Africa allowed the transfer of 
biological samples between the two countries. The recruiters informed the 
shipping company and completed the paper documentation needed to arrange 
for the sample pick-up and the shipping of the samples to South Africa.  
Due to the sensitivity of the shipment, DHL Medical Express was contracted 
to take care of the shipment. They handle ambient, controlled at room 
temperature, and chilled or frozen shipments, with capabilities in place for 
monitoring these during transit. Ambient boxes were delivered to the Genetic 
Laboratory at Stellenbosch University and they included the packaging 
instructions inside the boxes. These boxes keep biological substances at a 
steady temperature during transit.  
It usually took an approximately two weeks to transfer blood samples from the 
Nigerian recruitment sites to the Stellenbosch University Campus where the 
genetic studies were carried out. We recorded damage to blood sample tubes, 
which occurred in only one occasion and led to poor quality genomic DNA. 
The ethics approvals to commence this study took three months. Participant 
information and informed consent forms used for research involving genetic 
studies, and the environmental exposure to hazard questionnaire form were 
completed by the patients. This information was catalogued and used for the 
patients’ demographics in this study.   
The tNGS was carried out at the DNA Sequencing Unit, Central Analytical 
Facilities of Stellenbosch University in Stellenbosch, South Africa. Analyses 
were performed in collaboration with the Bioinformatics Unit, Division of 
Molecular Biology and Human Genetics, Stellenbosch University. Patients and 
controls were also recruited in South Africa where there is an on-going 
recruitment for genetic studies on PD.  
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5.1.2          Pilot Study to Check Feasibility 
To check the performance of the Ampliseq 751genes Neurological Diseases 
panel, a pilot study involving the screening of eight PD patients including 
Caucasians, and Black South Africans was done. The study revealed that the 
Ion Ampliseq Neurological panel is a timeous and cost-effective method for 
screening of sequence variants in DNA extracted from both blood and saliva 
samples. Also, the preliminary analysis showed that the Black individuals 
seemed to have more sequence variations than the White South Africans in the 
genes studied. The pilot study also served as an internal control, as one sample 
was included in every run to determine the technical variability between 
different runs (unpublished data).  
The patients' demographic and clinical information such as the AAO, AAR, 
family history of PD, sex, other disorders, prominent signs and symptoms and 
history of exposure to environmental toxins were collected. This information 
was entered on a study-specific REDCap database for easy accessibility.  
 
5.2                           Overall Study Outcomes 
 
The review of previous genetic studies on PD patients in SSA suggested that 
genetic screening for pathogenic mutations in PD in these populations is still 
relatively new as limited information exists. It is therefore difficult to actually 
quantify the genetic risks for PD in SSA PD patients. Herein, the present study 
screened for mutations in the genes that are not previously linked to PD, and 
also included 17 of the known PD genes. The aim was to identify putative genes 
related to PD pathogenesis in SSA.  
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The patients’ demographic data showed that they have lived in their individual 
environments for a long period. Almost all the South African patients were 
diagnosed with early-onset PD. Early onset PD has implication in PD genetics. 
Nigerian patients, however, were late-onset PD, with some of them having a 
long history of exposure to different environmental toxins, such as herbicides. 
Environmental toxins could influence the development of PD (Nicolopoulou-
Stamati et al., 2016). Similarly, people that are exposed to pesticides and other 
toxic chemicals could develop PD (Nicolopoulou-Stamati et al., 2016). 
Increasing age is the greatest risk factor for the development of PD. The 
number of neurons reduces in old people (Dickson, 2012). The reduction in the 
dopaminergic neurons activities often lead to the onset of PD symptoms (Chu 
and Kordower, 2007).  
 
This study found four putative pathogenic CNVs in sporadic PD patients and 
concentrated on the 60 missense variants predicted to be deleterious identified 
in 44 genes including ATP13A2, PRKN and PINK1 genes in the patients 
(Figure 5.1). Deleterious missense variant is known to change protein 
structure, solubility and dynamics and may affect the overall function of a gene.  
In silico pathogenicity prediction tools mostly based their predictions on these 
principles by calculating the degree of conservation within species of the 
mutated site and its effect on RNA splicing and protein structure. 
 
It is noteworthy to stress that sporadic PD cases were focused on in this study 
because sporadic forms of PD are seen predominantly, showing non-Mendelian 
inheritance pattern and lack of a definite family history (Kalinderi et al. 2016; 
Verstraeten et al. 2015). 
 
Studies have described how different heterozygous missense, insertion, 
compound heterozygous, frame shift and duplication mutations in PINK1 and 
PRKN in the monogenic PD patients, occurred virtually at every site on these 
genes (Pickrell and Youle, 2015).  It was intriguing however that previously 
reported mutations in PD genes were not identified in the current study.  
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These findings corroborate the previous genetic studies in SSA PD patients and 
indicated that common mutations like LRRK2 G2019S are a rare cause of PD 
in these populations (Blanckenberg et al., 2013c). Previous genetic studies in 
SSA individuals with PD identified a duplication of exon 2 and a deletion of 
exon 9; and an heterozygous G430D mutation in the PRKN gene in Black South 
African patients, while an heterozygous deletions of exon 2 and exon 4 in 
PRKN gene were identified in Zambians with PD (Keyser et al., 2010c; 
Yonova-Doing et al., 2012). The above-mentioned variants were not identified 
in this study. The variants predicted to be deleterious identified in this study in 
the 44 genes have not been reported in PD patients before. Although, PRKN, 
PINK1 and ATP13A2 genes have been studied in the European, North 
American and North African population and found to harbour other pathogenic 
mutations (Singleton et al., 2013). Hence, new genes are to be studied in order 
to uncover the genetic architecture that impacts disease susceptibility in PD 
sporadic cases. 
 
The availability of high-throughput genetic analysis techniques is increasing 
the information available for PD genetics. NGS technique has been effective to 
discover new candidate genes. The NGS requires selecting variants with high-
quality calls to identify variants predicted to be deleterious which can be used 
for functional studies to verify the roles of the genes in PD (Jansen et al., 2017). 
The known PD genes belong to biological pathways involved in autophagy, 
apoptosis or mitochondrial function (Poewe et al., 2017).  
 
tNGS and other methods used in the present study to screen for mutations in 
the Black South African and Nigerian PD patients are established and reliable 
(Quail et al., 2012). A recent study that used the Ion torrent tNGS sequencing 
platform to screen for mutations in PD genes in the Spanish population, 
confirmed this platform to be effective (Gorostidi et al., 2016).  
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For variant identifications and annotation, certain metrics are critical for variant 
interpretation. Recently, a joint consensus recommendation by the Association 
for Molecular Pathology, American Society of Clinical Oncology and College 
of American Pathologists was published, and provided standards and 
guidelines for variant identification and annotation (Li et al., 2017). The criteria 
includes supporting reads (depth of coverage) and variant allele frequency, and 
using up-to-date bioinformatics pipelines. It also includes identifying the 
genomic locations of the variants, to determine if it is coding or non-coding (Li 
et al., 2017; Li and Wang, 2017). These criteria were considered in the variant 
evaluation processes in our study. 
 
The quality of the BAM files collected in this study was good and was 
important for the additional information retrieved for each variant presented 
for annotations. Variant annotation is crucial to accurate interpretation of 
somatic sequence variants. The most applicable QC criteria applied to any NGS 
data are not restricted (Utturkar et al., 2015), usually, a minimum coverage 
required to call a base accurately at any position is (≥ 20X read depth) (Craig 
et al., 2008). Because NGS platforms are likely to make errors, it is therefore, 
important to use stringent criteria for variant annotations, to have confidence 
in the sequencing data and the variants selected. In our study, we used stringent 
threshold to discover high confidence variants and assessed the pathogenicity 
with 26 different scoring algorithms.  
 
Identified variants might not be sufficient to produce PD symptoms in some 
people, but could increase their risk for developing PD. The interactions 
between genetic variants, in conjunction with environmental factors could lead 
to the development of PD. The identification of these factors provides 
information on pathogenic pathways that may be therapeutic targets (Cannon 
and Greenamyre, 2013). Determination of the pathogenicity or clinical impact 
of variants in PD remains a monumental task. 
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tNGS analyses identified variants predicted to be deleterious in three known 
PD genes and 41 other genes in the SSA PD patients’ part of the current study. 
Also, the MLPA assay identified four putative pathogenic CNVs in three 
known PD genes (PARK 7, PRKN and PINK1).  
 
Interestingly, the 41 non-PD genes with variants predicted to be deleterious 
found in the Black South African and Nigerian PD patients encode important 
proteins. The proteins share biological pathways that have connections to the 
pathophysiology of neurological disorders including PD. In the present study, 
pathogenicity of the variants identified were determined by their 
deleteriousness scores.  
 
Variants identified in PINK1 and PRKN genes were further studied using 
protein modelling and the protein structures indicated that (PRKN D234E,, 
PINK1 S228F and PINK1 P305A) variants have strong implications for PD 
pathogenesis because their positions are in a domain that regulate autophagy, 
supporting the fact that these genes are prominent disease-causing genes.    
 
Studies have shown that PINK1/PARKIN pathway facilitates mitophagy by 
altering mitochondrial trafficking (Wang et al. 2011). The PINK1/PARKIN 
pathway affects mitochondrial functions and trafficking by proteasomal 
degradation of specific mitochondrial outer membrane proteins. It also targets 
the entire mitochondria for autophagic degradation by selective recruitment of 
adaptor proteins to other mitochondrial outer membrane substrates (Narendra 
et al. 2012).   
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Parkin at serine 65 and/or PINK1 at threonine 257 have been used for 
examining activity of PINK1-Parkin signalling pathway in vivo (Kondapalli et 
al., 2012). Although, PINK1 directly phosphorylates Parkin at S65 domain to 
stimulate Parkin E3 ligase activity and recruitment to mitochondria 
(Kondapalli et al., 2012; Shiba-Fukushima et al., 2012),  mutation at S65 
Parkin prevents phosphorylation by PINK1. The Parkin mutation S65A did not 
influence Parkin translocation to mitochondria, despite a lack of 
phosphorylation in S65A, Parkin still translocates to mitochondria in a PINK1 
kinase-dependent process, indicating that other cytosolic PINK1 substrates are 
involved in Parkin activation (Kane et al., 2014), suggesting that, there are 
other mutations in PINK1 and Parkin mitochondrial quality control processes 
in PD pathogenesis. 
                    Figure 5.1: Overview of the study outcomes 
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MLPA study (samples from 15 South African and 
42 Nigerian patients) identified three putative 
pathogenic CNVs in PD genes (PINK1,PRKN 
and PARK7)
tNGS (samples from 33 South African and 14 
Nigerian patients)  study identified 60 variants 
predicted to be deleterious based on in silico tests, 
on which seven were found in known PD genes 
(ATP13A2, PRKN and PINK1).
ConsensusPathDB pathway analysis revealed that 
these 44 genes show functional interactions  
The accuracy of tNGS was confirmed by using 
Sanger sequencing to verify four novel variants 
in the known PD. Allele frequencies of two 
selected novel variants were confirmed using 
HRM. 
Protein modelling  discovered potential 
deleterious effects of sequence variants S228F, 
S284Y, and P305A on the function of PINK1 
protein.
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Growing evidence is supporting mutations in ATP13A2 gene to be deleterious 
and disease-causing in PD patients. The previously reported mutations in 
ATP13A2 gene in PD are described in Chapter 1. ATP13A2 is located inside 
the lysosomal membrane and its proper function is essential to the lysosomal 
membrane stability. Variant predicted to be deleterious in this gene could 
impair lysosomal membrane stability which in turns affects the process of 
mitophagy degradation. In the present study, the deleterious variant S960R 
identified in the ATP13A2 gene in one of the PD patients suggests that SSA 
patients with PD may be susceptible to mutations in this gene, which may 
increase their risk for developing the disease.  
 
As hypothesized in this study, novel variants predicted to be deleterious were 
identified in PD genes and other genes that have not been previously associated 
with PD. Especially the frequently identified mutations in PD in Europe, North 
America, North Africa and Asia were not found in these patients. The 
Consensus PathDB analysis revealed biological networks that exist between 
the 44 genes that share mechanisms of pathology like autophagy, mitochondrial 
dysfunction, neuroinflammation, oxidative stress and cellular/receptor 
damage.  
 
No variant predicted to be deleterious however was identified in SNCA gene. 
SCNA has a crucial role in PD pathology, SNCA gene mutations produced 
deleterious effects in dopaminergic neurons by reducing the affinity of α-
synuclein for lipids, thus increasing the tendency of the protein to form 
oligomers through a concentration-dependent pattern and continuous 
accumulations of toxic α-synuclein fibrils (the major component of Lewy 
bodies) (Winner et al. 2011). Lewy body exist in Nigerian PD patients as it 
described in Chapter 2 of this study. Previous studies on PD genetics in SSA 
also showed that mutations in this gene are rare. Nonetheless, more patients are 
to be screened for mutations including CNVs in SNCA gene before drawing 
final conclusion.  
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5.3 Study Limitations and Future Follow-up Studies 
 
Major limitations to this study were discussed extensively in the Chapters 3, 
and 4. In addition to those limitations, a total of 18 genes with associations with 
PD and reported in literature, were not on the Ampliseq 751-gene panel. Some 
genes like the APOE gene which are often studied in PD-dementia patients 
were not on the panel used. Similarly, the coiled-coil-helix-coiled-coil-helix 
domain 2 (CHCHD2) gene.  Whole genome analysis in a Japanese family with 
AD PD (Funayama et al. 2015) found a heterozygous mutation. CHCHD2 
should, therefore, also be considered a candidate gene for PD.  
 
Therefore, using a whole exome sequencing to screen for mutation in the SSA 
PD patients in the future will allow to screen all genes in the human genome. 
Whole genome sequencing will provide the opportunity to identify copy 
number variations which are difficult to identify in a targeted gene panel. Also, 
putative pathogenic non-coding variants could be revealed with a whole 
genome sequencing approach.     
 
 
Mutations in vacuolar protein sorting 13C (VPS13C) have association with the 
development of autosomal recessive early-onset forms of PD. It has been 
proven that VPS13C encodes a member of a family of VPS13 (Velayos-Baeza 
et al. 2004) and VPS13C is located on the outer mitochondrial membrane.  
 
The Ubiquitin C-terminal hydrolase L1 (UCHL1) gene is among the genes first 
implicated in PD. The mutations in this gene have not yet been fully proven to 
cause PD. The presence of Lewy bodies and the function of UCHL1 in the 
proteasome pathway suggest that UCHL1 could be a compelling PD candidate.  
 
Sequence analyses also confirmed GIGYF2 gene as a PD gene in 12 unrelated 
familial PD patients from Italy and France, the study revealed seven different 
heterozygous mutations in the GIGYF2 gene. 
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The CAG repeat expansions within the coding region of Ataxin-2 (ATXN2) 
were gene identified in a dominantly inherited familial forms of PD (Gwinn–
Hardy et al. 2000; Payami et al. 2003), and the clinical examinations suggest 
that cerebellar ataxia is a predominant symptom among PD patients.  
 
Mutations in the DNAJC6 gene in juvenile-onset atypical parkinsonism with 
autosomal recessive inheritance have been reported. (Edvardson et al. 2012; 
Koroglu et al. 2013). Similarly, mutations in DNAJC13 gene have been 
reported in patients with a dominant form of PD characterized by α-synuclein 
positive Lewy bodies.  
 
The SYNJ1 gene is among the newly identified PD genes. The SYNJ1 gene 
encodes synaptojanin-1, a presynaptic phosphoinositide phosphatase protein 
which has a role in the regulation of synaptic vesicle endocytosis, important in 
the recycling of proteins. It has a similar role to synaptojanin-1in endocytosis 
and parkin (Quadri et al. 2013; Krebs et al. 2013; Olgiati et al. 2014).  
 
Mutations identified in the aforementioned genes require further studies to 
understand their true significance in PD. Likewise in this study the other 41 
novel genes with variants predicted to be deleterious in PD will require 
extensive further studies as discussed in Chapter 4.  
 
5.4   Conclusions 
 
 
In conclusion, the genetic analyses described here, which included MLPA and 
the advanced bioinformatics tools led to the identification of novel pathogenic 
mutations in the Black South African and Nigerian PD patients. Mutations 
were found in known PD genes and in genes not previously known to harbour 
mutations in PD patients. Further studies are required to ascertain the biological 
functions of these mutations. Moreover, their role in PD pathobiology needs to 
be validated. The results could advance the discovery and the development of 
improved treatment approaches and drug interventions for PD. 
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APPENDIX I: List of variants or mutations in genes identified in PD 
Gene Mutation Family member 
with PD 
Reference 
PINK1 Gly32Arg 1Asian Choi JM, Neurogenetics 9: 263-9, 2008 
PINK1 Lys24fs and 
Cys549fs 
4 Caucasians  Ibáñez P, Brain 129: 686-94, 2006 
PINK1 Leu67Phe 1 Caucasian Marongiu R, Hum Mutat 29: 565, 2008 
Ferraris A, Mov Disord 24: 2350-7, 2009 
PINK1 Arg68Pro 1 Caucasian Valente EM, Ann Neurol 56: 336-41, 2004 
Marongiu R, Hum Mutat 29: 565, 2008 
PINK1 Gln129Stop 5 Caucasians and 4 
Tunisians 
Ishihara-Paul L, Neurology 71: 896-902, 
2008 
PINK1 Thr145Met 2 Caucasians and 1 
Tunisian 
Ishihara-Paul L, Neurology 71: 896-902, 
2008 
PINK1 Arg152Trp 3 Tunisians Ishihara-Paul L, Neurology 71: 896-902, 
2008 
PINK1 Glu240Lys 2 Caucasians and 1 
Asian 
Rogaeva E, Arch Neurol 61: 1898-904, 
2004. 
Ibáñez P, Brain 129: 686-94, 2006 
PINK1 Arg246Stop 4 Asians and 2 
Jewish 
Hatano Y, Ann Neurol 56: 424-7, 2004 
Tan EK, Mov Disord 21: 789-93, 2006 
Ephraty L, Mov Disord 22: 566-9, 2007 
PINK1 Tyr258Stop 3 Indian South 
Africa and I Asian 
Tan EK, Mov Disord 21: 789-93, 2006 
Keyser RJ, Neurogenetics Epub: , 2009 
PINK1 Leu268Val 2 Asians Tan EK, Clin Genet 68: 468-70, 2005 
Marongiu R, Hum Mutat 29: 565, 2008 
PINK1 Arg276Gln 5 Asians Marongiu R, Hum Mutat 29: 565, 2008 
Biswas A, Parkinsonism Relat Disord 
Epub: , 2009 
PINK1 Asp297fs 2 Asians Kumazawa R, Arch Neurol 65: 802-8, 
2008 
Savettieri G, Parkinsonism Relat Disord 
14: 509-12, 2008 
PINK1 Ala383Thr 5 Tunisia and 2 
Caucasians 
Ibáñez P, Brain 129: 686-94, 2006 
Abou-Sleiman PM, Ann Neurol 60: 414-9, 
2006 
Marongiu R, Hum Mutat 29: 565, 2008 
PINK1 Gly411Ser 2 Tunisians and 5 
Caucasians 
Zadikoff C, Mov Disord 21: 875-9, 2006 
Abou-Sleiman PM, Ann Neurol 60: 414-9, 
2006 
Toft M, J Neurol Neurosurg Psychiatry 
78: 82-4, 2007 
Mellick GD, Parkinsonism Relat Disord 
15: 105-9, 2009 
Brooks J, J Med Genet 46: 375-81, 2009 
PINK1 Trp437Stop 5 Caucasians Valente EM, Science 304: 1158-60, 2004 
Bonifati V, Neurology 65: 87-95, 2005 
Criscuolo C, Mov Disord 21: 1265-7, 2009 
PINK1 Gln456Stop 22 (Caucasian and 
Tunisians) 
Bonifati V, Neurology 65: 87-95, 2005 
Ibáñez P, Brain 129: 686-94, 2006 
Hedrich K, Arch Neurol 63: 833-8, 2006 
Zadikoff C, Mov Disord 21: 875-9, 2006 
Abou-Sleiman PM, Ann Neurol 60: 414-9, 
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2006 
Marongiu R, Hum Mutat 29: 565, 2008 
PINK1 Glu476Lys 12 (Tunisians, 
Jordanian and 
Caucasians 
Valente EM, Ann Neurol 56: 336-41, 2004 
Rogaeva E, Arch Neurol 61: 1898-904, 
2004 
Bonifati V, Neurology 65: 87-95, 2005 
Abou-Sleiman PM, Ann Neurol 60: 414-9, 
2006 
Marongiu R, Hum Mutat 29: 565, 2008 
Myhre R, BMC Neurol 8: , 2008 
LRRK2 Ala211Val 3 Caucasian Xiromerisiou G, Eur J Neurol 14: 7-11, 
2007 
Nuytemans K, Hum Mutat Epub: , 2009 
LRRK2 Glu334Lys 2 Caucasians Nichols WC, Neurology 69: 1737-44, 2007 
Lesage S, J Med Genet Epub: , 2009 
LRRK2 Arg793Met 6 Caucasians Zimprich A, Neuron 44: 601-7, 2004 
Farrer M, Neurology 65: 738-40, 2005 
Berg D, Brain 128: 3000-11, 2005 
Toft M, Acta Neurol Scand Suppl 187: 72-
5, 2007 
Chen-Plotkin AS, Neurology 70: 521-7, 
2008 
Covy JP, Mov Disord 24: 32-9, 2009 
LRRK2 Leu1114 4 Caucasians Zimprich A, Neuron 44: 601-7, 2004 
Farrer M, Neurology 65: 738-40, 2005 
Berg D, Brain 128: 3000-11, 2005 
LRRK2 Arg1325Gln 3 Caucasians Nuytemans K, Eur J Hum Genet 16: 471-
9, 2008 
Lesage S, J Med Genet Epub: , 2009 
LRRK2 Thr1410Met 7 Caucasians Lesage S, J Med Genet Epub: , 2009 
Abdalla-Carvalho CB, Eur J Neurol Epub: 
, 2010 
LRRK2 Arg1441Gly 126 Caucasians, 
Latin Americans, 
Jewish and Asian 
Paisán-Ruíz C, Neuron 44: 595-600, 2004 
Mata IF, Neurosci Lett 382: 309-11, 2005 
Mata IF, Neurogenetics 6: 171-7, 2005 
Gaig C, Arch Neurol 63: 377-82, 2006 
Simón-Sánchez J, Mov Disord 21: 1954-9, 
2006 
Dächsel JC, Neurosci Lett 410: 80-4, 2006 
Deng H, J Neurol Sci 251: 102-6., 2006 
González-Fernández MC, Parkinsonism 
Relat Disord 13: 509-15, 2007 
Gómez-Esteban JC, Neurosurgery 62: 
857-62, 2008 
Gao L, Eur J Neurol Epub: , 2009 
Gorostidi A, Neurogenetics 10: 157-9, 
2009 
Mata IF, Parkinsonism Relat Disord 15: 
370-3, 2009 
Martí-Massó JF, Mov Disord 24: 1998-
2001, 2009 
LRRK2 Arg1441Cys 28 Caucasians, 
Americans, Asianss 
Zimprich A, Neuron 44: 601-7, 2004 
Zabetian CP, Neurology 65: 741-4, 2005 
Goldwurm S, J Med Genet 42: e65, 2005 
Mata IF, Neurogenetics 6: 171-7, 2005 
Di Fonzo A, Eur J Hum Genet 14: 322-31, 
2006 
Gaig C, Arch Neurol 63: 377-82, 2006 
Tan EK, Mov Disord 21: 997-1001, 2006 
Hedrich K, Mov Disord 21: 1506-10, 2006 
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Pankratz N, Mov Disord 21: 2257-60, 
2006 
Gosal D, Mov Disord 22: 291-2, 2007 
Nuytemans K, Eur J Hum Genet 16: 471-
9, 2008 
Haugarvoll K, Neurology 70: 1456-60, 
2008 
Pchelina SN, Eur J Neurol 15: 692-6, 2008 
Latourelle JC, BMC Med 6: , 2008 
Floris G, Parkinsonism Relat Disord 15: 
277-80, 2009 
Shojaee S, Mov Disord 24: 1023-7, 2009 
LRRK2 Arg1441His 8 Caucasians Zabetian CP, Neurology 65: 741-4, 2005 
Mata IF, Neurogenetics 6: 171-7, 2005 
Spanaki C, Neurology 67: 1518-9, 2006 
Huang Y, Mov Disord 22: 982-9, 2007 
Ferreira JJ, Mov Disord 22: 1194-201, 
2007 
Lin CH, J Biomed Sci 15: 661-7, 2008 
Lesage S, J Med Genet Epub: , 2009 
LRRK2 Gly2019Ser 772 (Ashkenazi 
Jewish, Arab 
Berber (Tunisia), 
Caucasian and 
Latin Americans) 
Numerous references, strongly known 
LRRK2 Ile2020Thr 3 Caucasians Zimprich A, Neuron 44: 601-7, 2004 
Berg D, Brain 128: 3000-11, 2005 
Ohta E, Neurosci Lett 417: 21-3, 2007 
PRKN Gln34Arg 8 Asians and Indian 
South Africa 
Chaudhary S, Parkinsonism Relat Disord 
12: 239-45, 2006 
Biswas A, Parkinsonism Relat Disord 12: 
420-6, 2006 
Myhre R, BMC Neurol 8: , 2008 
Bardien S, Parkinsonism Relat Disord 15: 
116-21, 2009 
PRKN Arg42Pro 11 Caucasian Terreni L, Neurology 56: 463-6, 2001 
Hedrich K, Neurology 58: 1239-46, 2002 
Bertoli-Avella AM, Mov Disord 20: 424-
31, 2005 
Clark LN, Arch Neurol 63: 548-52, 2006 
Pellecchia MT, Mov Disord 22: 559-63, 
2007 
Wang Y, Arch Neurol 65: 467-74, 2008 
Sironi F, Parkinsonism Relat Disord 14: 
326-33, 2008 
Macedo MG, Mov Disord 24: 196-203, 
2009 
PRKN Asn52fs 31 Caucasians Abbas N, Hum Mol Genet 8: 567-74, 1999 
Hedrich K, Neurology 58: 1239-46, 2002 
Hoenicka J, Arch Neurol 59: 966-70, 2002 
Nichols WC, J Med Genet 39: 489-92, 
2002 
Muñoz E, J Neurol Neurosurg Psychiatry 
73: 582-4, 2002 
Rawal N, Neurology 60: 1378-81, 2003 
Hedrich K, Mov Disord 19: 1146-57, 2004 
Sun M, Arch Neurol 63: 826-32, 2006 
Dächsel JC, Neurosci Lett 410: 80-4, 2006 
Lesage S, J Med Genet 45: 43-6, 2008 
Bras J, BMC Neurol 8: , 2008 
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Lohmann E, Neurology 72: 110-6, 2009 
Nuytemans K, Hum Mutat Epub: , 2009 
Camargos ST, Mov Disord 24: 662-6, 
2009 
Brooks J, J Med Genet 46: 375-81, 2009 
Pankratz N, Neurology 73: 279-86, 2009 
PRKN Ala82Glu 8 Caucasians  Hedrich K, Hum Mol Genet 10: 1649-56, 
2001 
Varrone A, Neurology 63: 2097-103, 2004 
Kay DM, Ann Neurol 61: 47-54, 2007 
Lesage S, J Med Genet 45: 43-6, 2008 
Håkansson A, Parkinsonism Relat Disord 
14: 520-2, 2008 
Sironi F, Parkinsonism Relat Disord 14: 
326-33, 2008 
Nuytemans K, Hum Mutat Epub: , 2009 
Brooks J, J Med Genet 46: 375-81, 2009 
Pankratz N, Neurology 73: 279-86, 2009 
PRKN Pro113fs 25 Caucasians Farrer M, Ann Neurol 50: 293-300, 2001 
Hedrich K, Neurology 58: 1239-46, 2002 
Nichols WC, J Med Genet 39: 489-92, 
2002 
Foroud T, Neurology 60: 796-801, 2003 
Chen R, Parkinsonism Relat Disord 9: 
309-12, 2003 
Scherfler C, Brain 127: 1332-42, 2004 
Wiley J, Mov Disord 19: 677-81, 2004 
Poorkaj P, Am J Med Genet A 129A: 44-
50, 2004 
Hedrich K, Mov Disord 19: 1146-57, 2004 
Poorkaj P, BMC Neurol 5: , 2005 
Clark LN, Arch Neurol 63: 548-52, 2006 
Sun M, Arch Neurol 63: 826-32, 2006 
Wang Y, Arch Neurol 65: 467-74, 2008 
Brooks J, J Med Genet 46: 375-81, 2009 
Pankratz N, Neurology 73: 279-86, 2009 
Sammler EM, Mov Disord 24: 2442-3, 
2009 
PRKN Lys211Asn 8 Caucasians van de Warrenburg BP, Neurology 56: 
555-7, 2001 
Kann M, Ann Neurol 51: 621-5, 2002 
Nichols WC, J Med Genet 39: 489-92, 
2002 
Foroud T, Neurology 60: 796-801, 2003 
Klein C, Eur J Hum Genet 13: 1086-93, 
2005 
Hertz JM, Eur J Neurol 13: 385-90, 2006 
Aguiar P de C, Mov Disord 23: 1228-33, 
2008 
Barsottini OG, Arq Neuropsiquiatr 67: 7-
11, 2009 
Pankratz N, Neurology 73: 279-86, 2009 
PRKN Cys441Arg 10 Asians Shyu WC, Parkinsonism Relat Disord 11: 
173-80, 2005 
Chan DK, J Neural Transm 115: 715-9, 
2008 
Guo JF, Mov Disord 23: 2074-9, 2008 
Lohmann E, Neurology 72: 110-6, 2009 
Lee MJ, Mov Disord 24: 104-8, 2009 
Stellenbosch University  https://scholar.sun.ac.za
                                                               
                                        252 
 
PRKN Pro437Leu 27 Caucasians Hedrich K, Neurology 58: 1239-46, 2002 
Nichols WC, J Med Genet 39: 489-92, 
2002 
Foroud T, Neurology 60: 796-801, 2003 
Rawal N, Neurology 60: 1378-81, 2003 
Djarmati A, Hum Mutat 23: , 2004 
Poorkaj P, Am J Med Genet A 129A: 44-
50, 2004 
Hertz JM, Eur J Neurol 13: 385-90, 2006 
Sun M, Arch Neurol 63: 826-32, 2006 
Kay DM, Ann Neurol 61: 47-54, 2007 
Nuytemans K, Hum Mutat Epub: , 2009 
Brooks J, J Med Genet 46: 375-81, 2009 
Pankratz N, Neurology 73: 279-86, 2009 
Brooks JA, Neurobiol Aging Epub: , 2009 
PRKN Gly430Asp 8 Asians and 
Caucasians) 
Hedrich K, Neurology 58: 1239-46, 2002 
Scherfler C, Brain 127: 1332-42, 2004 
Shyu WC, Parkinsonism Relat Disord 11: 
173-80, 2005 
Sun M, Arch Neurol 63: 826-32, 2006 
Mellick GD, Parkinsonism Relat Disord 
15: 105-9, 2009 
Pankratz N, Neurology 73: 279-86, 2009 
PRKN Cys431Phe 13 (Asians and 
Caucasians) 
Maruyama M, Ann Neurol 48: 245-50, 
2000 
Brooks J, J Med Genet 46: 375-81, 2009 
PARK7 ex1-5del 3 Caucasians Bonifati V, Science 299: 256-9, 2003 
PARK7 Ala179Thr 2 Caucasians Macedo MG, Mov Disord 24: 196-203, 
2009 
Nuytemans K, Hum Mutat Epub: , 2009 
SNCA tripSNCA [F-
I] 
12 Caucasians        Farrer M, Ann Neurol 55: 174-9, 2004 
Fuchs J, Neurology 68: 916-22, 2007 
Puschmann A, Parkinsonism Relat Disord 
15: 390-2, 2009 
Puschmann A, Parkinsonism Relat Disord 
15: 390-2, 2009 
SNCA tripSNCA [S] 13 Caucasians Waters CH, Ann Neurol 35: 59-64, 1994 
Muenter MD, Ann Neurol 43: 768-81, 
1998 
Gwinn-Hardy K, Acta Neuropathol 99: 
663-72, 2000 
Singleton AB, Science 302: 841, 2003 
Farrer M, Ann Neurol 55: 174-9, 2004 
SNCA dupSNCA [A] 8 Nishioka K, Ann Neurol 59: 298-309, 2006 
Nishioka K, Mov Disord Epub: , 2009 
SNCA Ala53Thr 22 families Polymeropoulos MH, Science 276: 2045-7, 
1997 
Papadimitriou A, Neurology 52: 651-4, 
1999 
Athanassiadou A, Am J Hum Genet 65: 
555-8, 1999 
Scott WK, Neurogenetics 2: 191-2, 1999 
Spira PJ, Ann Neurol 49: 313-9, 2001 
Michell AW, J Neurol Neurosurg 
Psychiatry 76: 596-7, 2005 
Ki CS, Clin Genet 71: 471-3, 2007 
Choi JM, Neurogenetics 9: 263-9, 2008 
Puschmann A, Parkinsonism Relat Disord 
Epub: , 2009 
Stellenbosch University  https://scholar.sun.ac.za
                                                               
                                        253 
 
SNCA Ala30Pro 3 Caucasians Krüger R, Nat Genet 18: 106-8, 1998 
Seidel K, Ann Neurol 67: 684-9, 2010 
ATP13A2 Leu1059Arg 
and 
L1085WfsX10
88 
2 Caucasians, many 
cases in Asians  
Park et al, Human mutation 2011. 
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APPENDIX II: List of medications that have been approved to treat Parkinson’s diseases as of    May 2018. 
Mechanism of 
action 
Generic name Trade 
name® 
Common side effects 
DOPA 
Decarboxylase 
inhibitor/DA 
precursor 
Carbidopa/Levodopa Sinemet Nausea, dizziness, orthostatic hypotension, 
anxiety, dyskinesia, confusion, 
hallucinations, somnolence Carbidopa/Levodopa 
(controlled release) 
Sinemet CR 
Carbidopa/Levodopa 
(orally 
disintegrating) 
Parcopa 
Carbidopa/Levodopa 
(extended release 
capsules) 
Rytary 
Carbidopa/Levodopa 
(enteral suspension) 
Duopa 
COMT 
inhibitor, 
inhibits 
breakdown of 
levodopa 
Entacapone Comtan Same as carbidopa/ levodopa. In addition: 
diarrhea, discoloration of body fluids. 
Tasmar can cause elevated liver function 
enzymes. 
Tolcapone Tasmar 
DOPA 
decarboxylase 
inhibitor/DA 
precursor/ 
COMT 
Inhibitor 
Carbidopa/Levodopa 
Entacopone 
Stalevo Same as carbidopa/ levodopa and 
COMT inhibitor 
DA agonist Pramipexole Mirapex Nausea, dizziness, orthostatic hypotension, 
swelling of ankles, dyskinesia, 
hallucinations, confusion, somnolence, sleep 
attacks, impulse control disorders 
Neupro can lead to a skin reaction at the 
patch site 
Pramipexole 
(extended release) 
Mirapex ER 
Ropinirole Requip 
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Ropinirole 
(extended release) 
Requip XL 
Apomorphine  (injection) Apokyn 
Rotigotine 
(transdermal patch) 
Neupro 
Mechanism of action Generic name Trade name® Common 
side effects 
MAO-B inhibitor, inhibits Selegiline Eldepryl Selegiline can 
cause breakdown of dopamine insomnia 
Selegiline 
(orally disintegrating) 
Zelapar 
Dizziness, 
nausea, gastrointestinal 
upset, Rasagiline Azilect dy kinesia, 
hallucinations, 
Safinamide Xadago 
confusion,  
headache 
Note possible 
drug interactions 
Safinamide 
exerts its effects through 
other mechanisms of 
action as well 
Mixed mechanisms, including 
NMDA antagonism 
Amantadine Symmetrel Hallucinations, 
leg swelling, 
dizziness, 
mottled skin 
(livedo 
reticularis), 
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Amantadine 
(extended release) 
Gocovri confusion, dry 
mouth 
and eyes, 
constipation, 
dizziness, 
orthostatic 
hypotension,  
somnolence 
Anticholinergic Trihexyphenidyl Artane Dry mouth 
and eyes, 
constipation, 
urinary 
retention, 
memory 
impairment, 
confusion, 
depression, 
hallucinations 
Benztropine Cogentin 
This table contained information from the American Parkinson Disease Association ( www.apdaparkinson.org). 
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       APPENDIX III: Description of tools used in variant characterization in this study. 
Annotations Database Prediction 
Algorithm/Conserv
ation Score 
Description Method Categorical 
Prediction 
Author(s) 
SIFT_pred  
SIFT_score 
SIFT Sort intolerated 
from tolerated 
P (An amino acid at a 
position is tolerated | The 
most frequent amino 
acid being tolerated) 
D: Deleterious 
(SIFT<=0.05); 
T: tolerated 
(SIFT>0.05) 
Pauline Ng, Fred Hutchinson  
Cancer Research Center, Seattle, 
Washington 
Polyphen2_HDIV_pred  
Polyphen2_HDIV_score 
Polyphen v2 Polymorphism 
phenotyping v2 
Probabilistic Classifier 
Training sets: HumDiv 
D: Probably 
damaging: 
>=0.957,  
P: possibly 
damaging 
0.453<=pp2_hdiv<
=0.956  
B: benign 
pp2_hdiv<=0.452 
 
Ivan Adzhubei 
Havard Medical School  
Polyphen2_HVAR_pred 
Polyphen2_HVAR_scor
e 
Polyphen v2 Polymorphism 
phenotyping v2 
Machine learning 
Training sets: HumVar 
D: Probably 
damaging >=0.957  
P: possibly 
damaging 
0.453<=pp2_hdiv<
=0.956  
B: benign: 
pp2_hdiv<=0.452 
Shamil Sunyaev 
Havard Medical School 
LRT_pred  
LRT_score 
LRT Likelihood Ratio 
Test 
LRT of H0: each codon 
evolves neutrally vs H1: 
the codon evolves under 
negative selection 
D: Deleterious  
N: Neutral 
U: Unknown 
Lower scores are 
more deleterious 
Sung Chung & Justin Fay, Washington 
University 
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Annotations Database Prediction 
Algorithm/Conserv
ation Score 
Description Method Categorical 
Prediction 
Author(s) 
MutationTaster_pred  
MutationTaster_score 
MutationTaster Bayes Classifier A: 
disease_causing_automat
ic  
D:disease_causing  
N:polymorphism 
[probably harmless];  
P:polymorphism_automa
tic[known to be harmless 
higher values are more 
deleterious 
 
Markus Schuelke, 
the Charité –Universitätsmedizin, 
Berlin 
MutationAssessor_pred  
MutationAssessor_score 
MutationAssessor Entropy of 
multiple sequence 
alignments 
  
H/M means functional 
and L/N means non-
functional higher values 
are more deleterious 
H: high;  
M: medium;  
L: low;  
N: neutral 
Reva Boris 
Computation Biology Center Memorial 
Sloan Kettering Cancer Center, New 
York 
FATHMM_pred  
FATHMM_score 
FATHMM Hidden Markov 
Model (HMM) 
Functional analysis 
through HMM 
D: Deleterious  
T: Tolerated 
<lower values are 
more deleterious 
Shihab Hashem, 
University of Bristol, UK 
PROVEAN_pred  
PROVEAN_score 
 
Protein Variation 
Effect Analyzer 
Clustering of homologus 
sequences 
D: Deleterious  
N: Neutral 
Higher values are 
more deleterious 
Choi Y J. Craig Venter Institute 
VEST3_score VEST V3 Variant effect 
scoring tool 
Random forest classifier Higher values are 
more deleterious 
Rachel Karchin, John Hopkins 
University 
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Annotations Database Prediction 
Algorithm/Conserv
ation Score 
Description Method Categorical 
Prediction 
Author(s) 
CADD_raw 
CADD_phred 
Combined annotation 
dependent depletion 
Linear kernel 
Support Vector 
Machine 
Higher values are more 
deleterious 
 
Jay Shendure, Xiaohui Xie, University 
of California – Irvine 
DANN_score DANN Deleterious 
Annotation of 
genetic variants 
using Neural 
Networks 
Neural network Higher values are 
more deleterious 
Jay Shendure & Xiaohui Xie 
University of California – Irvine 
fathmm-
MKL_coding_pred 
FATHMM-MKL predicting the 
effects of both 
coding and non-
coding variants 
using nucleotide-
based HMMs 
Classifier based on 
multiple kernel learning 
D: Deleterious 
Score >= 0.5 
T: Tolerated 
Score < 0.5 
Shihab Hashem 
University of Bristol, UK 
MetaSVM_pred  
MetaSVM_score 
MetaSVM Support vector 
machine 
 D: Deleterious; T: 
Tolerated; 
Higher scores are 
more deleterious 
Coco Dong 
University of South Carolina 
Biostatistics Department, 
South Carolina 
 
MetaLR_pred  
MetaLR_score 
MetaLR Logistic 
regression 
 D: Deleterious;  
T: Tolerated;  
Higher scores are 
more deleterious 
Coco Dong  
University of South Carolina 
Biostatistics Department, South 
Carolina 
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Annotations Database Prediction 
Algorithm/Conserv
ation Score 
Description Method Categorical 
Prediction 
Author(s) 
integrated_fitCons_score  
integrated_confidence_v
alue 
FitCons Fitness 
consequences of 
functional 
annotation 
Integrate functional 
assays like ChIP-Seq 
with conservation 
measure of transcription 
factor binding sites 
Higher scores are 
more deleterious 
Christodoulidou  A Briza 
Cold Spring Harbor Laboratory 
GERP++_RS 
GERP++_NR 
Genome 
Evolutionary Rate 
Profiling ++ 
Maximum 
likelihood 
estimation 
procedure 
Higher scores are more 
deleterious 
 
Eugne Davydov 
Stanford University, CS Department 
phyloP7way_vertebrate PhyloP Phylogenetic p-
values 
Phylogentic p-values 
calculated from a LRT, 
score-based test, GERP 
test uses data on 7 
species 
Higher scores are 
more deleterious 
Adam Siepel, University of California 
Santa Cruz (UCSC), Santa Cruz, 
California 
phyloP20way_mammali
an 
PhyloP Phylogentic p-
values 
Phylogenetic (phylo-
HMM). Uses data on 20 
species 
Higher scores are 
more deleterious 
Adam Siepel, University of California 
Santa Cruz (UCSC), Santa Cruz, 
California 
phastCons7way_vertebra
te 
phastCons A phylogenetic 
hidden Markov 
model (phylo-
HMM) Use 7 
species 
Higher scores are more 
deleterious 
 
Adam Siepel, University of California 
Santa Cruz (UCSC), Santa Cruz, 
California 
phastCons20way_mamm
alian 
phastCons Phylogenetic 
(phylo-HMM). 
Uses data on 20 
species 
Higher scores are more 
deleterious 
 
Adam Siepel, University of California 
Santa Cruz (UCSC), Santa Cruz, 
California 
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Annotations Database Prediction 
Algorithm/Conserv
ation Score 
Description Method Categorical 
Prediction 
Author(s) 
SiPhy_29_way SiPhy Probablistic 
framework, 
HMM. Uses data 
on 29 species. 
Higher scores are more 
deleterious 
 
Manual Garber 
Broad Institute of MIT & Harvard, 
Boston 
dbNSFP Information assessed on: https://brb.nci.nih.gov/seqtools/colexpanno.html#annotableANNOVAR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
                                                               
                                        262 
 
APPENDIX IV: List of articles published articles identified and used in the review on PD studies in Nigeria. 
Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
1 Owolabi Gastrointestinal 
complications in 
newly 
diagnosed 
Parkinson's 
disease: A case-
control study. 
2014 35 227-231 Trop 
Gastroente
rol 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
2.6E+07 
 
2 Ojagbemi Relationship 
between 
cognitive 
dysfunction and 
behavioural 
symptoms in 
Nigerian 
patients with 
Parkinson's 
disease no 
dementia. 
2013 3 293-300 J 
Parkinsons 
Dis 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
2.4E+07 
 
3 Ojagbemi Neuropsychiatri
c symptoms in 
Nigerian 
patients with 
Parkinson's 
disease. 
2013 128 9 to 16 Acta 
Neurol 
Scand 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
2.3E+07 
 
4 Femi Clinical profile 
of parkinsonian 
disorders in 
tropics: 
Experience at 
Kano, 
northwestern 
Nigeria 
2012 3 237-241 J Neurosci 
Rural 
Pract 
Research 
article 
Prevalence and 
Symptoms and 
signs 
Yes Yes Text 
and 
Tables 
1,2 
3505306 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
5 Ojo Plasma 
homocysteine 
level and its 
relationship to 
clinical profile 
in Parkinson's 
disease patients 
at the Lagos 
University 
Teaching 
Hospital. 
2011 30 319-324 West Afr J 
Med 
Research 
article 
Biochemical/path
ology 
Yes Yes Text 
and 
Table 2 
2.3E+07 
 
6 Okubadejo Clinical profile 
of parkinsonism 
and Parkinson's 
disease in 
Lagos, 
Southwestern 
Nigeria. 
2010 10 1 BMC 
Neurol 
Research 
article 
Prevalence  Yes Yes Text 
and 
Table 1 
2806862 
 
7 Okubadejo Analysis of 
Nigerians with 
apparently 
sporadic 
Parkinson 
disease for 
mutations in 
LRRK2, PRKN 
and ATXN3. 
2008 3 e3421 PLoS One Research 
article 
Genetics Yes Yes Text 
and 
Table 3 
2559870 
 
8 Akinyemi Cognitive 
dysfunction in 
Nigerians with 
Parkinson's 
disease. 
2008 23 1378-
1383 
Mov 
Disord 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
1.9E+07 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
9 Okubadejo Parkinson's 
disease in 
Africa: A 
systematic 
review of 
epidemiologic 
and genetic 
studies. 
2006 21 2150-
2156 
Mov 
Disord 
Review Review Yes Yes Text 1.7E+07 
 
10 Okubadejo Longitudinal 
study of 
mortality 
predictors in 
Parkinson's 
disease in 
Nigerians. 
2005 34 365-369 Afr J Med 
Med Sci 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 1.7E+07 
 
11 Muthane Melanized 
nigral neuronal 
numbers in 
Nigerian and 
British 
individuals. 
2006 21 1239-
1241 
Mov 
Disord 
Research 
article 
Biochemical/path
ology findings 
Yes Yes Text  1.7E+07 
 
12 Okubadejo Frequency and 
predictors of 
autonomic 
dysfunction in 
Parkinson's 
disease: a study 
of African 
patients in 
Lagos, Nigeria. 
2004 11 45-49 Niger 
Postgrad 
Med J.  
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
1.5E+07 
 
13 Igbokwe Xenobiotic 
metabolism in 
1993 70 807-809 East Afr 
Med J 
Research 
article 
Environmental 
risk factors 
Yes Yes Text 8026358 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
idiopathic 
Parkinson's 
disease in 
Nigerian 
Africans. 
14 Schoenberg Comparison of 
the prevalence 
of Parkinson's 
disease in Black 
populations in 
the rural United 
States and in 
rural Nigeria: 
door-to-door 
community 
studies. 
1988 38 645-646 Neurology Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
3352927 
 
15 Schoenberg Environmental 
risk factors for 
Parkinson's 
disease: the 
epidemiologic 
evidence. 
1987 14 407-413 Can J 
Neurol Sci 
Review Review Yes Yes Text 3315146 
 
16 Osuntokun Parkinsonism in 
the Nigerian 
African: a 
prospective 
study of 217 
patients. 
1979 56 597-607 East Afr 
Med J 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 1 
520239 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
17 Osuntokun The pattern of 
neurological 
illness in 
tropical Africa. 
Experience at 
Ibadan, Nigeria. 
1971 12 417-442 J Neurol 
Sci 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
4324654 
 
18 Schoenberg Descriptive 
epidemiology of 
Parkinson's 
disease: disease 
distribution and 
hypothesis 
formulation 
1987 45 277-83 Adv 
Neurol 
Review Review Yes No No 3493626 No data 
on 
Nigeria
n PD. 
19 Osuntokun Neurological 
disorder in 
Nigerian 
Africans:  a 
community-
based study 
1987 75 13-21 Acta 
Neurol 
Scand 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
3033973 
 
20 Owolabi Progressive 
supranuclear 
palsy 
misdiagnosed as 
Parkinson's 
disease: A case 
report and 
review of 
literature 
2016 3 S44-S47 Annals of 
Medical 
and Health 
Sciences 
Research 
Research 
article 
Other disease with 
similar symptoms 
Yes Yes Text 3853608 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
21 Okubadejo An analysis of 
genetic studies 
of Parkinson's 
disease in 
Africa 
2008 14 177-182 Parkinsoni
sm and 
Related 
Disorder 
Review Review Yes Yes Text 1.8E+07 
 
22 Akinyemi Epidemiology 
of parkinsonism 
and Parkinson's 
disease in Sub-
Saharan Africa: 
Nigerian profile 
2012 3 233-234 Journal of 
Neuroscie
nces in 
Rural 
Practice 
Review Review Yes Yes Text 2.3E+07 
 
23 Owolabi Pattern of 
neurological 
admissions in 
tropics: 
Experience at 
Kano, 
Northwestern 
Nigeria 
2010 13 167-170 Annals of 
Indian 
Academy 
of 
Neurology 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
2.1E+07 
 
24 Ojo Frequency of 
cognitive 
impairment and 
depression in 
Parkinson's 
disease: A 
preliminary 
case-control 
study 
2012 53 65-70 Nigerian 
Medical 
Journal 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
3530250 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
25 Owolabi Pulmonary 
function tests in 
patients with 
Parkinson's 
disease: A case-
control study 
2016 19 66-70 Nigerian 
Journal of 
Clinical 
Practice 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
2.7E+07 
 
26 Ekenze  Profile of 
neurological 
admissions at 
the University 
of Nigeria 
Teaching 
Hospital Enugu 
2010 19 419-422 Nigerian J 
Med 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
2.2E+07 
 
27 Ogunrin Trace metals in 
patients with 
Parkinson's 
disease: a multi-
center case-
control study of 
nigerian patients 
2013 1 31-38 J Neurol 
Epi 
Research 
article 
Environmental 
risk factors 
Yes Yes Text N/A 
 
28 Olaitan Depression 
among patients 
with Parkinson's 
disease in 
Nigerian tertiary 
hospital 
2013 13 96-103 Nigerian 
Health  J 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
N/A 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
29 Olaitan Non-motor 
features in 
Parkinson's 
disease patients 
attending 
neurology clinic 
at a 
tertiaryinstitutio
n in Nigeria: A 
preliminary 
report 
2014 14 114-118 Nigerian 
Health  J 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
N/A 
 
30 Temitope Falls and their 
associated risks 
in Parkinson's 
disease patients 
in Nigeria 
2016 9 160-165 J Mov 
Disord 
Research 
article 
Symptoms and 
signs 
Yes Yes Text 
and 
Table 2 
5035939 
 
31 Ben-Shlomo  Incidental Lewy 
body disease. 
1994 344 1503 Lancet Letter to 
editor 
No study Yes No No N/A No data. 
32 Jendroska Incidental Lewy 
body disease in 
Black Africans. 
1994 344 882-883 Lancet Research 
article 
Biochemical/path
ology 
Yes Yes Text N/A 
 
33 Odeku Cranial 
meningiomas in 
the Nigerian 
African. 
1973 4 275-287 Afr J Med 
Sci 
Reserch 
article 
Other disease with 
similar symptoms 
Yes Yes Text 4749181 
 
34 Osuntokun Neuropsychiatri
c manifestations 
of typhoid fever 
in 959 patients. 
1972 27 7 to 13 Arch 
Neurol 
Research 
article 
Other disease with 
similar symptoms 
Yes Yes Text 4340378 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
35 Dada The Nigerian 
neurological 
profile. 
1970 31 746-755 Dis Nerv 
Syst 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
4992399 
 
36 Osuntokun Non-embolic 
ischaemic 
cerebrovascular 
disease in 
Nigerians. 
1969 9 361-388 J Neurol 
Sci 
Reserch 
article 
Other disease with 
similar symptoms 
Yes Yes Text 5345116 
 
37 Oguniyi Treatment of 
parkinsonian 
syndromes in 
developing 
countries. 
1997 26 1 to 2 Afr J Med 
Med Sc 
Review Review Yes Yes Text 1.1E+07 
 
38 Adebayo Neuropsychiatri
c and 
Parkinsonian 
manifestations 
of dementia: A 
case report in a 
Nigerian 
woman 
2013 12 46-48 Annal of 
African 
medicine 
Research 
article 
Other disease with 
similar symptoms 
Yes Yes Text 2.3E+07 
 
39 Solomon Parkinsonism 
caused by 
adverse drug 
reactions: a case 
series 
2011 5 105 Journal of 
medical 
case 
reports 
Research 
article 
Other disease with 
similar symptoms 
Yes Yes Text N/A 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
40 Talabi A 3-year review 
of neurologic 
admissions in 
University 
College 
Hospital Ibadan, 
Nigeria. 
2003 22 150-1 West Afr J 
Med 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
1.5E+07 
 
41 Chapp-
Jumbo 
Neurologic 
admissions in 
the Niger Delta 
area of Nigeria - 
a ten year 
review 
2004 23 14-20 African 
Journal of 
Neurol sci 
Research 
article 
Prevalence Yes Yes Text 
and 
Table 1 
N/A 
 
42 Tucci Study of the 
genetic 
variability in a 
Parkinson's 
Disease gene: 
EIF4G1 
2012 518 19-22 Neuroscie
nce letters 
Research 
article 
Genetics Yes Yes Text 
and 
Table 3 
3769807 
 
43 Salawu Current 
management of 
Parkinson's 
disease 
2010 9 55-61 Annal of 
African 
medicine 
Review Review Yes Yes Text 2.1E+07 
 
44 Lekoubou Epidemiology 
of 
neurodegenerati
on diseases in 
sub-Saharan 
Africa: a 
systematic 
review 
2014 14 Not in 
print 
BMC 
Public 
health 
Review Review Yes Yes Text 4094534 
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Coun
t 
First 
Author 
Title Year Vol Pages Journal Article type Area of study on 
PD  
Full text 
obtained 
(Yes/No) 
Used for 
Review 
(Yes/No) 
Used in PMID Reason 
for 
exclusio
n 
45 Okubadejo Prevalence of 
essential tremor 
in urban Lagos, 
Nigeria: a door-
to-door 
community-
based study 
2012 12 Not in 
print 
BMC 
Neurol 
Research 
article 
Other disease with 
similar symptoms 
Yes Yes Text 2.3E+07 
 
 
 
 
 
 
 
 
 
 
   APPENDIX V: Information on the Ampliseq 751 genes neurological diseases panel 
 
The link to this table is provided below:   
https://www.ampliseq.com/tmpl/view.action?tmplDesignId=62969292#/?listAction=tmplCoverageSummaryList&t
mplDesignId=62969292&wrapperId=ajaxTableWrapper 
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                           B.  
APPENDIX VI: Plotted graph representing library quantification during 
amplification using RT-PCR. Standard curve (A) shows the standardized graph 
normalized with internal controls; and (B) multicomponent plot showing library 
enrichments during amplification.  
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